

(19) **DANMARK**

(10) **DK/EP 3423103 T3**



(12)

Oversættelse af europæisk patentskrift

Patent- og
Varemærkestyrelsen

-
- (51) Int.Cl.: **A 61 K 47/56 (2017.01)** **A 61 K 47/60 (2017.01)** **A 61 P 1/02 (2006.01)**
A 61 P 5/18 (2006.01) **A 61 P 7/04 (2006.01)** **A 61 P 17/14 (2006.01)**
A 61 P 19/02 (2006.01) **A 61 P 19/10 (2006.01)** **A 61 P 29/00 (2006.01)**
C 07 K 14/575 (2006.01)
- (45) Oversættelsen bekendtgjort den: **2024-09-30**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2024-09-11**
- (86) Europæisk ansøgning nr.: **17707559.5**
- (86) Europæisk indleveringsdag: **2017-02-28**
- (87) Den europæiske ansøgnings publiceringsdag: **2019-01-09**
- (86) International ansøgning nr.: **EP2017054550**
- (87) Internationalt publikationsnr.: **WO2017148883**
- (30) Prioritet: **2016-03-01 EP 16158048** **2016-07-13 EP 16179294**
2016-09-29 EP 16191484 **2017-02-13 EP 17155839**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **ASCENDIS PHARMA BONE DISEASES A/S, Tuborg Boulevard 12, 2900 Hellerup, Danmark**
- (72) Opfinder: **SPROGØE, Kennett, 2900 Hellerup, Danmark**
CLEEMANN, Felix, , 69120 Heidelberg, Tyskland
MAITRO, Guillaume, , 69120 Heidelberg, Tyskland
KRUSCH, Mathias, , 69120 Heidelberg, Tyskland
Wegge, Thomas, , 69120 Heidelberg, Tyskland
Zettler, Joachim, , 69120 Heidelberg, Tyskland
- (74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**
- (54) Benævnelse: **PTH-pro-drug**
- (56) Fremdragne publikationer:
WO-A2-2005/027978
WO-A2-2005/099768
WO-A2-2009/095479
WO-A2-2014/033540
SMITH ROBERT M. ET AL: "The pH-Rate Profile for the Hydrolysis of a Peptide Bond", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 120, no. 35, 1 September 1998 (1998-09-01), pages 8910 - 8913, XP055929186, ISSN: 0002-7863, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/ja9804565> DOI: 10.1021/ja9804565
ARRIGHI I ET AL: "Bone healing induced by local delivery of an engineered parathyroid hormone prodrug", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 30, no. 9, 1 March 2009 (2009-03-

Fortsættes ...

01), pages 1763 - 1771, XP025928044, ISSN: 0142-9612, [retrieved on 20090104], DOI: 10.1016/J.BIOMATERIALS.2008.12.023

NA D H ET AL: "Capillary electrophoretic characterization of PEGylated human parathyroid hormone with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry", ANALYTICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 331, no. 2, 15 August 2004 (2004-08-15), pages 322 - 328, XP004521373, ISSN: 0003-2697, DOI: 10.1016/J.AB.2004.04.036

REJNMARK L ED - KARSENTY GERARD ET AL: "PTH replacement therapy of hypoparathyroidism", BONE, vol. 50, 1 May 2012 (2012-05-01), XP028922570, ISSN: 8756-3282, DOI: 10.1016/J.BONE.2012.02.041

PAUL M. LEVINE ET AL: "Intrinsic bioconjugation for site-specific protein PEGylation at N-terminal serine", CHEMICAL COMMUNICATIONS - CHEMCOM., vol. 50, no. 52, 1 January 2014 (2014-01-01), pages 6909, XP055305086, ISSN: 1359-7345, DOI: 10.1039/c4cc01928h

FILPULA ET AL: "Releasable PEGylation of proteins with customized linkers", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 60, no. 1, 30 November 2007 (2007-11-30), pages 29 - 49, XP022370570, ISSN: 0169-409X, DOI: 10.1016/J.ADDR.2007.02.001

DESCRIPTION

Description

[0001] The present invention relates to PTH prodrugs, pharmaceutical compositions comprising such PTH prodrugs and their uses.

[0002] Hypoparathyroidism is a rare endocrine disease with low serum calcium and inappropriately low (insufficient) circulating parathyroid hormone levels, most often in adults secondary to thyroid surgery. Standard treatment includes activated vitamin D analogues and calcium supplementation, which increases calcium and phosphorus absorption and serum levels at the expense of abnormally increased urinary calcium excretion. Hypoparathyroidism is the only major endocrine condition today, where the hormonal insufficiency in general is not treated by substitution of the missing hormone (PTH).

[0003] The prevalence of hypoparathyroidism has recently been systematically studied in Denmark, where a total of more than 2000 patients were identified giving a prevalence of ~24/100 000 inhabitants, among whom only a minority (2/100 000) had hypoparathyroidism due to non-surgical causes. These estimates are in agreement with recent data from the USA, showing a prevalence of the same magnitude for patients with chronic hypoparathyroidism.

[0004] Endogenous PTH is synthesized and secreted by the parathyroid glands and is the principal endocrine hormone regulating systemic calcium and phosphorus homeostasis. Physiological actions of PTH include releasing calcium and phosphorus from bone, retaining calcium but not phosphorus in the kidney by increasing renal tubular reabsorption of calcium but decreasing renal tubular reabsorption of phosphate, and stimulating the renal production of active vitamin D ($1,25(\text{OH})_2\text{vitamin D}_3$) which in turn enhances intestinal calcium and phosphorus absorption. Without the renal actions of PTH to conserve calcium and excrete phosphorus, conventional therapy with vitamin D analogs and calcium supplementation may lead to renal insufficiency or failure due to progressive nephrocalcinosis, as well as ectopic calcifications (in the basal ganglia, the lens of the eye, and the vascular system) due to a chronically increased calcium x phosphorus product, which precipitates out as calcium phosphate crystals when this product is maintained elevated for long periods.

[0005] Recently Natpara[®], PTH(1-84) was approved by the FDA for the treatment of hypoparathyroidism. Historically Forteo[®] PTH(1-34) has also been used as once, twice or thrice daily injections for hypoparathyroidism, despite not being approved for this indication.

[0006] When PTH is delivered intermittently, such as by current daily or multiple daily injections of PTH(1-84) or PTH(1-34) it acts on bone as an anabolic agent by preferentially activating

osteoblasts over osteoclasts. This anabolic effect of intermittent PTH exposure contrasts with the net bone catabolism that can occur with continuous exposure to PTH. The anabolic potential of intermittent administration of PTH agonists has successfully been utilized for the treatment of osteoporosis, where bone turnover is usually high and bone mineral density (BMD) is low, whereas the converse is the case for hypoparathyroidism.

[0007] A major complication of hypoparathyroidism is hypercalciuria, due to the lack of PTH dependent calcium reabsorption in the distal renal tubules. Hypercalciuria is associated with an increased risk of nephrocalcinosis, nephrolithiasis and kidney failure. According to the FDAs review of Natpara, daily injections of PTH failed to provide adequate control of urinary calcium excretion, due to the short half-life of this PTH agonist in the body.

[0008] Furthermore, unphysiological levels of PTH may be associated with hypercalcemia and hypocalcemia. Treatment with Natpara did not improve the incidence of these complications compared to placebo. This can in part be explained by the unfavorable PK of Natpara. For example, administration of the currently approved doses of Natpara results in greatly supraphysiological levels of PTH with a C_{max} of 300 pg/ml, which returns to baseline at 12 hours. As a result patients are over treated in the initial phase following administration and under treated in the phase leading up to subsequent dosing.

[0009] Hypocalcemia is associated with numerous symptoms, some of which can be life threatening, including: tetany, paresthesias, impaired cognition, loss of consciousness with convulsions (grand mal seizures), impaired kidney function, heart arrhythmias and fainting and even heart failure.

[0010] As such, there is a high unmet need for a more physiological PTH therapy, providing a sustained exposure to PTH that enables alleviation of symptoms relating to hypocalcemia, hypercalciuria and hyperphosphatemia, without causing hypercalcemia.

[0011] PTH replacement therapy would be more physiologic if delivered by continuous infusion, such as using an insulin pump. This has for example been demonstrated by Winer et al. (J Pediatr, 2014, 165(3), 556-563), where pump delivery simultaneously normalized bone turnover markers and urine and serum mineral levels, whereas intermittent injection delivery did not.

[0012] The normal PTH range is 15-50 pg/ml, and it is important to appreciate that intermittent PTH agonist administration does not constitute physiological replacement therapy. PTH polypeptides have inherently short circulating half-lives because of rapid hepatic metabolism. The rapid clearance of the drug from the body prevents sufficient drug coverage throughout the dosing interval, despite initial supraphysiological drug levels.

[0013] Several approaches have been applied to create longer acting version of PTH, including encapsulation of PTH in PLGA microparticles and permanent conjugation of the PTH molecule to either synthetic or peptidic polymers. Kostenuik et al. (J Bone Miner Res, 2007,

22(10), 1534-1547), described a PTH-Fc fusion protein with a longer half-life than PTH(1-34) and studies were conducted in osteopenic ovariectomized rats and mice to determine whether intermittent (one to two per week) injections of PTH-Fc would increase bone mass, density, and strength despite the prolonged duration of exposure to PTH. It was demonstrated that a PTH-derived molecule with a sustained circulating half-life provided comparable anabolic effects on cortical and cancellous bone to daily PTH, but with a reduced dosing frequency. Another approach has been suggested by Ponnappakkam et al. (Drug Discov Today, 2014, 19(3), 204-208), in which a hybrid polypeptide of PTH and a collagen binding domain caused long-term (up to 12 months) increases in bone mineral density in normal female mice after a single dose.

[0014] Patients with hypoparathyroidism typically demonstrate an abnormally low rate of bone turnover resulting in increased bone mineral density, and as such the anabolic effects of PTH should be avoided when treating Hypoparathyroidism, and optimally treatment should normalize their rate of bone turnover, but not increase it to above the normal range, as has been demonstrated with daily treatment with PTH(1-34) and PTH(1-84).

[0015] Arrighi et al. (Biomaterials, 2009, vol. 30, no. 9, pages 1763 to 1771) disclose the use of a PTH(1-34)-transglutaminase substrate fusion protein with a plasmin sensitive link for the induction of local bone regeneration.

[0016] WO2005/027978A2 discloses certain GLP-1 derivates which have a protracted profile of action.

[0017] WO2014/033540A2 discloses conjugates of, for example, parathyroid hormone and bone targeting moieties and their use in subjects having a condition that causes loss of bone mass.

[0018] Na et al. (Analytical Biochemistry, 2004, vol. 331, no. 2, pages 322 to 328) discloses a capillary electrophoretic characterization of PEGylated human parathyroid hormone with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

[0019] Smith and Hansen (J. Am. Chem. Soc., 1998, vol. 120, pages 8910 to 8913) report the use of homogeneous, solution-phase assays to measure the rate of hydrolysis at 37°C of the peptide N-(phenylacetyl)glycyl-D-valine (PAGV) as a function of pH.

[0020] In summary, there is a need for a more efficacious PTH treatment.

[0021] It is therefore an object of the present invention to at least partially overcome the shortcomings described above.

[0022] This object is achieved with a PTH prodrug or a pharmaceutically acceptable salt thereof as described in the claims.

[0023] It was surprisingly found that the PTH prodrugs of the present invention exhibit a low residual activity of the prodrug and provide a sustained release of PTH. As a result, administration of the PTH prodrugs of the present invention leads to a concurrent normalization of serum calcium and a reduction in serum phosphate and thus to an increased serum calcium to serum phosphate ratio compared to treatment with PTH1-84, the current standard of care. At the same time no adverse effects on bone resorption and formation markers and overall bone health in the relevant animal model for the human condition were observed upon administration of physiological doses.

[0024] It was also surprisingly found that such PTH prodrugs are capable of achieving a stable plasma profile of PTH which ensures physiological serum and urinary calcium levels or even lower than normal urinary calcium levels.

[0025] Within the present invention the terms are used having the meaning as follows.

[0026] As used herein the term "PTH" refers to all PTH polypeptides, preferably from mammalian species, more preferably from human and mammalian species, more preferably from human and murine species, as well as their variants, analogs, orthologs, homologs and derivatives and fragments thereof, that are characterized by raising serum calcium and renal phosphorus excretion and lowering serum phosphorus and renal calcium excretion. The term "PTH" also refers to all PTHrP polypeptides, such as the polypeptide of SEQ ID NO: 121, that bind to and activate the common PTH/PTHrP1 receptor. Preferably, the term "PTH" refers to the PTH polypeptide of SEQ ID NO:51 as well as its variants, homologs and derivatives exhibiting essentially the same biological activity, i.e. raising serum calcium and renal phosphorus excretion and lowering serum phosphorus and renal calcium excretion.

[0027] Preferably, the term "PTH" refers to the following polypeptide sequences:

SEQ ID NO: 1 (PTH 1-84)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADVNVLTAKSQ

SEQ ID NO:2 (PTH 1-83)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADVNVLTAKS

SEQ ID NO:3 (PTH 1-82)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADVNVLTAK

SEQ ID NO:4 (PTH 1-81)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADVNVLTAKA

SEQ ID NO:5 (PTH 1-80)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADVNVLTAK

NVLVESHEKSLGEADKADVNVLT

SEQ ID NO:6 (PTH 1-79)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGEADKADVNVLT

SEQ ID NO:7 (PTH 1-78)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGEADKADVNVLT

SEQ ID NO:8 (PTH 1-77)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGEADKADVNV

SEQ ID NO:9 (PTH 1-76)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGEADKADVNT

SEQ ID NO:10 (PTH 1-75)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGEADKADV

SEQ ID NO:11 (PTH 1-74)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGEADKAD

SEQ ID NO:12 (PTH 1-73)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGEADKA

SEQ ID NO:13 (PTH 1-72)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGEADK

SEQ ID NO:14 (PTH 1-71)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGEAD

SEQ ID NO:15 (PTH 1-70)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGEA

SEQ ID NO:16 (PTH 1-69)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGE

SEQ ID NO:17 (PTH 1-68)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLG

SEQ ID NO:18 (PTH 1-67)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSL

SEQ ID NO:19 (PTH 1-66)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKS

SEQ ID NO:20 (PTH 1-65)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEK

SEQ ID NO:21 (PTH 1-64)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHE

SEQ ID NO:22 (PTH 1-63)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESH

SEQ ID NO:23 (PTH 1-62)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVES

SEQ ID NO:24 (PTH 1-61)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVE

SEQ ID NO:25 (PTH 1-60)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLV

SEQ ID NO:26 (PTH 1-59)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVL

SEQ ID NO:27 (PTH 1-58)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NV

SEQ ID NO:28 (PTH 1-57)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
N

SEQ ID NO:29 (PTH 1-56)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

SEQ ID NO:30 (PTH 1-55)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKE

SEQ ID NO:31 (PTH 1-54)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKK

SEQ ID NO:32 (PTH 1-53)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRK

SEQ ID NO:33 (PTH 1-52)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPR

SEQ ID NO:34 (PTH 1-51)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRP

SEQ ID NO:35 (PTH 1-50)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQR

SEQ ID NO:36 (PTH 1-49)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQ

SEQ ID NO:37 (PTH 1-48)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGS

SEQ ID NO:38 (PTH 1-47)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAG

SEQ ID NO:39 (PTH 1-46)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDA

SEQ ID NO:40 (PTH 1-45)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRD

SEQ ID NO:41 (PTH 1-44)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPR

SEQ ID NO:42 (PTH 1-43)

SVSEIQLMHNLGKBLNSMERVEWLRKKLQDVHNFVALGAPLAP

SEQ ID NO:43 (PTH 1-42)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLA

SEQ ID NO:44 (PTH 1-41)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPL

SEQ ID NO:45 (PTH 1-40)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAP

SEQ ID NO:46 (PTH 1-39)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGA

SEQ ID NO:47 (PTH 1-38)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALG

SEQ ID NO:48 (PTH 1-37)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVAL

SEQ ID NO:49 (PTH 1-36)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVA

SEQ ID NO:50 (PTH 1-35)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFV

SEQ ID NO:51 (PTH 1-34)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF

SEQ ID NO:52 (PTH 1-33)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHN

SEQ ID NO:53 (PTH 1-32)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVH

SEQ ID NO:54 (PTH 1-31)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDV

SEQ ID NO:55 (PTH 1-30)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQD

SEQ ID NO:56 (PTH 1-29)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQ

SEQ ID NO:57 (PTH 1-28)

SVSEIQLMHNLGKHLNSMERVEWLRKKL

SEQ ID NO:58 (PTH 1-27)

SVSEIQLMHNLGKHLNSMERVEWLRKK

SEQ ID NO:59 (PTH 1-26)

SVSEIQLMHNLGKBLNSMERVEWLRK

SEQ ID NO:60 (PTH 1-25)

SVSEIQLMHNLGKHLNSMERVEWLR

SEQ ID NO:61 (amidated PTH 1-84)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADVNVLTAKSQ; wherein the C-terminus is amidated

SEQ ID NO:62 (amidated PTH 1-83)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADVNVLTAKS; wherein the C-terminus is amidated

SEQ ID NO:63 (amidated PTH 1-82)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGEADKADVNVLTAK; wherein the C-terminus is amidated

SEQ ID NO:64 (amidated PTH 1-81)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADVNVLTAK; wherein the C-terminus is amidated

SEQ ID NO:65 (amidated PTH 1-80)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADVNVLT; wherein the C-terminus is amidated

SEQ ID NO:66 (amidated PTH 1-79)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADVNVLT; wherein the C-terminus is amidated

SEQ ID NO:67 (amidated PTH 1-78)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADVNV; wherein the C-terminus is amidated

SEQ ID NO:68 (amidated PTH 1-77)

SVSEIQLMHNLGKBLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADVNV; wherein the C-terminus is amidated

SEQ ID NO:69 (amidated PTH 1-76)

SVSEIQLMHNLGKBLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADV; wherein the C-terminus is amidated

SEQ ID NO:70 (amidated PTH 1-75)

SVSEIQLMHNLGKBLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKADV; wherein the C-terminus is amidated

SEQ ID NO:71 (amidated PTH 1-74)

SVSEIQLMHNLGKBLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKAD; wherein the C-terminus is amidated

SEQ ID NO:72 (amidated PTH 1-73)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADKA; wherein the C-terminus is amidated

SEQ ID NO:73 (amidated PTH 1-72)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEADK; wherein the C-terminus is amidated

SEQ ID NO:74 (amidated PTH 1-71)

SVSEIQLMHNLGKBLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED
NVLVESHEKSLGEAD; wherein the C-terminus is amidated

SEQ ID NO:75 (amidated PTH 1-70)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGEA; wherein the C-terminus is amidated

SEQ ID NO:76 (amidated PTH 1-69)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLGE; wherein the C-terminus is amidated

SEQ ID NO:77 (amidated PTH 1-68)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSLG; wherein the C-terminus is amidated

SEQ ID NO:78 (amidated PTH 1-67)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKSL; wherein the C-terminus is amidated

SEQ ID NO:79 (amidated PTH 1-66)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEKS; wherein the C-terminus is amidated

SEQ ID NO:80 (amidated PTH 1-65)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHEK; wherein the C-terminus is amidated

SEQ ID NO:81 (amidated PTH 1-64)

SVSEIQLMHNLGKBLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED

NVLVESHE; wherein the C-terminus is amidated

SEQ ID NO:82 (amidated PTH 1-63)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED NVLVESH;

wherein the C-terminus is amidated

SEQ ID NO:83 (amidated PTH 1-62)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED NVLVES;

wherein the C-terminus is amidated

SEQ ID NO:84 (amidated PTH 1-61)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED NVLVE;

wherein the C-terminus is amidated

SEQ ID NO:85 (amidated PTH 1-60)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED NVLV;

wherein the C-terminus is amidated

SEQ ID NO:86 (amidated PTH 1-59)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED NVL;

wherein the C-terminus is amidated

SEQ ID NO:87 (amidated PTH 1-58)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED NV;

wherein the C-terminus is amidated

SEQ ID NO:88 (amidated PTH 1-57)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED N; wherein the C-terminus is amidated

SEQ ID NO:89 (amidated PTH 1-56)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKED ; wherein the C-terminus is amidated

SEQ ID NO:90 (amidated PTH 1-55)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKE; wherein the C-terminus is amidated

SEQ ID NO:91 (amidated PTH 1-54)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKK; wherein the C-terminus is amidated

SEQ ID NO:92 (amidated PTH 1-53)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRK; wherein the C-terminus is amidated

SEQ ID NO:93 (amidated PTH 1-52)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPR; wherein the C-terminus is amidated

SEQ ID NO:94 (amidated PTH 1-51)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRP; wherein the C-terminus is amidated

SEQ ID NO:95 (amidated PTH 1-50)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQR; wherein the C-terminus is amidated

SEQ ID NO:96 (amidated PTH 1-49)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQ; wherein the C-terminus is amidated

SEQ ID NO:97 (amidated PTH 1-48)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGS; wherein the C-terminus is amidated

SEQ ID NO:98 (amidated PTH 1-47)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAG; wherein the C-terminus is amidated

SEQ ID NO:99 (amidated PTH 1-46)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDA; wherein the C-terminus is

amidated

SEQ ID NO:100 (amidated PTH 1-45)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRD; wherein the C-terminus is amidated

SEQ ID NO:101 (amidated PTH 1-44)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPR; wherein the C-terminus is amidated

SEQ ID NO:102 (amidated PTH 1-43)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAP; wherein the C-terminus is amidated

SEQ ID NO:103 (amidated PTH 1-42)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLA; wherein the C-terminus is amidated

SEQ ID NO:104 (amidated PTH 1-41)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPL; wherein the C-terminus is amidated

SEQ ID NO:105 (amidated PTH 1-40)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAP; wherein the C-terminus is amidated

SEQ ID NO:106 (amidated PTH 1-39)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGA; wherein the C-terminus is amidated

SEQ ID NO:107 (amidated PTH 1-38)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALG; wherein the C-terminus is amidated

SEQ ID NO:108 (amidated PTH 1-37)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVAL; wherein the C-terminus is amidated

SEQ ID NO:109 (amidated PTH 1-36)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVA; wherein the C-terminus is amidated

SEQ ID NO:110 (amidated PTH 1-35)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFV; wherein the C-terminus is amidated

SEQ ID NO:111 (amidated PTH 1-34)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF; wherein the C-terminus is amidated

SEQ ID NO:112 (amidated PTH 1-33)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHN; wherein the C-terminus is amidated

SEQ ID NO:113 (amidated PTH 1-32)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVH; wherein the C-terminus is amidated

SEQ ID NO:114 (amidated PTH 1-31)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDV; wherein the C-terminus is amidated

SEQ ID NO:115 (amidated PTH 1-30)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQD; wherein the C-terminus is amidated

SEQ ID NO:116 (amidated PTH 1-29)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQ; wherein the C-terminus is amidated

SEQ ID NO:117 (amidated PTH 1-28)

SVSEIQLMHNLGKHLNSMERVEWLRKKL; wherein the C-terminus is amidated

SEQ ID NO:118 (amidated PTH 1-27)

SVSEIQLMHNLGKHLNSMERVEWLRKK; wherein the C-terminus is amidated

SEQ ID NO:119 (amidated PTH 1-26)

SVSEIQLMHNLGKHLNSMERVEWLRK; wherein the C-terminus is amidated

SEQ ID NO:120 (amidated PTH 1-25)

SVSEIQLMHNLGKHLNSMERVEWLR; wherein the C-terminus is amidated

SEQ ID NO:121 (PTHrP)

AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEIRATSEVSPNSKPSNTKNHPVRF

GSDDEGRYLTQETNKVETYKEQPLKTPGKKKKKGKPGKRKEQEKKKRRTRSAWLDS

GVTGSGLEGDHLSDTSTTSLELDSRRH

[0028] More preferably, the term "PTH" refers to the sequence of SEQ ID:NOs 47, 48, 49, 50, 51, 52, 53, 54, 55, 107, 108, 109, 110, 111, 112, 113, 114 and 115. Even more preferably, the term "PTH" refers to the sequence of SEQ ID:NOs 50, 51, 52, 110, 111 and 112. In a particularly preferred embodiment the term "PTH" refers to the sequence of SEQ ID NO:51.

[0029] As used herein, the term "PTH polypeptide variant" refers to a polypeptide from the same species that differs from a reference PTH or PTHrP polypeptide. Preferably, such reference is a PTH polypeptide sequence and has the sequence of SEQ ID NO:51. Generally, differences are limited so that the amino acid sequence of the reference and the variant are closely similar overall and, in many regions, identical. Preferably, PTH polypeptide variants are at least 70%, 80%, 90% or 95% identical to a reference PTH or PTHrP polypeptide, preferably to the PTH polypeptide of SEQ ID NO:51. By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. These alterations of the reference sequence may occur at the amino (N-terminal) or carboxy terminal (C-terminal) positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either

individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence. The query sequence may be an entire amino acid sequence of the reference sequence or any fragment specified as described herein. Preferably, the query sequence is the sequence of SEQ ID NO:51.

[0030] Such PTH polypeptide variants may be naturally occurring variants, such as naturally occurring allelic variants encoded by one of several alternate forms of a PTH or PTHrP occupying a given locus on a chromosome or an organism, or isoforms encoded by naturally occurring splice variants originating from a single primary transcript. Alternatively, a PTH polypeptide variant may be a variant that is not known to occur naturally and that can be made by mutagenesis techniques known in the art.

[0031] It is known in the art that one or more amino acids may be deleted from the N-terminus or C-terminus of a bioactive polypeptide without substantial loss of biological function. Such N- and/or C-terminal deletions are also encompassed by the term PTH polypeptide variant.

[0032] It is also recognized by one of ordinary skill in the art that some amino acid sequences of PTH or PTHrP polypeptides can be varied without significant effect of the structure or function of the polypeptide. Such mutants include deletions, insertions, inversions, repeats and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al. (1990), Science 247:1306-1310, wherein the authors indicate that there are two main approaches for studying the tolerance of the amino acid sequence to change.

[0033] The term PTH polypeptide also encompasses all PTH and PTHrP polypeptides encoded by PTH and PTHrP analogs, orthologs and/or species homologs. It is also recognized by one of ordinary skill in the art that PTHrP and PTHrP analogs bind to activate the common PTH/PTHrP1 receptor, so the term PTH polypeptide also encompasses all PTHrP analogs. As used herein, the term "PTH analog" refers to PTH and PTHrP of different and unrelated organisms which perform the same functions in each organism but which did not originate from an ancestral structure that the organisms' ancestors had in common. Instead, analogous PTH and PTHrP arose separately and then later evolved to perform the same or similar functions. In other words, analogous PTH and PTHrP polypeptides are polypeptides with quite different amino acid sequences but that perform the same biological activity, namely raising serum calcium and renal phosphorus excretion and lowering serum phosphorus and renal calcium excretion.

[0034] As used herein the term "PTH ortholog" refers to PTH and PTHrP within two different species which sequences are related to each other via a common homologous PTH or PTHrP in an ancestral species, but which have evolved to become different from each other.

[0035] As used herein, the term "PTH homolog" refers to PTH and PTHrP of different organisms which perform the same functions in each organism and which originate from an

ancestral structure that the organisms' ancestors had in common. In other words, homologous PTH polypeptides are polypeptides with quite similar amino acid sequences that perform the same biological activity, namely raising serum calcium and renal phosphorus excretion and lowering serum phosphorus and renal calcium excretion. Preferably, PTH polypeptide homologs may be defined as polypeptides exhibiting at least 40%, 50%, 60%, 70%, 80%, 90% or 95% identity to a reference PTH or PTHrP polypeptide, preferably the PTH polypeptide of SEQ ID NO:51.

[0036] Thus, a PTH polypeptide according to the invention may be, for example: (i) one in which at least one of the amino acids residues is substituted with a conserved or non-conserved amino acid residue, preferably a conserved amino acid residue and such substituted amino acid residue may or may not be one encoded by the genetic code; and/or (ii) one in which at least one of the amino acid residues includes a substituent group; and/or (iii) one in which the PTH polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol); and/or (iv) one in which additional amino acids are fused to the PTH polypeptide, such as an IgG Fc fusion region polypeptide or leader or secretory sequence or a sequence which is employed for purification of the above form of the polypeptide or a pre-protein sequence.

[0037] As used herein, the term "PTH polypeptide fragment" refers to any polypeptide comprising a contiguous span of a part of the amino acid sequence of a PTH or PTHrP polypeptide, preferably the polypeptide of SEQ ID NO:51.

[0038] More specifically, a PTH polypeptide fragment comprises at least 6, such as at least 8, at least 10 or at least 17 consecutive amino acids of a PTH or PTHrP polypeptide, more preferably of the polypeptide of SEQ ID NO:51. A PTH polypeptide fragment may additionally be described as sub-genuses of PTH or PTHrP polypeptides comprising at least 6 amino acids, wherein "at least 6" is defined as any integer between 6 and the integer representing the C-terminal amino acid of a PTH or PTHrP polypeptide, preferably of the polypeptide of SEQ ID No:51. Further included are species of PTH or PTHrP polypeptide fragments at least 6 amino acids in length, as described above, that are further specified in terms of their N-terminal and C-terminal positions. Also encompassed by the term "PTH polypeptide fragment" as individual species are all PTH or PTHrP polypeptide fragments, at least 6 amino acids in length, as described above, that may be particularly specified by a N-terminal and C-terminal position. That is, every combination of a N-terminal and C-terminal position that a fragment at least 6 contiguous amino acid residues in length could occupy, on any given amino acid sequence of a PTH or PTHrP polypeptide, preferably the PTH polypeptide of SEQ ID:NO51, is included in the present invention.

[0039] The term "PTH" also includes poly(amino acid) conjugates which have a sequence as described above, but having a backbone that comprises both amide and non-amide linkages, such as ester linkages, like for example depsipeptides. Depsipeptides are chains of amino acid residues in which the backbone comprises both amide (peptide) and ester bonds. Accordingly, the term "side chain" as used herein refers either to the moiety attached to the alpha-carbon of

an amino acid moiety, if the amino acid moiety is connected through amine bonds such as in polypeptides, or to any carbon atom-comprising moiety attached to the backbone of a poly(amino acid) conjugate, such as for example in the case of depsipeptides. Preferably, the term "PTH" refers to polypeptides having a backbone formed through amide (peptide) bonds.

[0040] As the term PTH includes the above-described variants, analogs, orthologs, homologs, derivatives and fragments of PTH and PTHrP, all references to specific positions within a reference sequence also include the equivalent positions in variants, analogs, orthologs, homologs, derivatives and fragments of a PTH or PTHrP moiety, even if not specifically mentioned.

[0041] As used herein, the term "random coil" refers to a peptide or protein adopting/having/forming, preferably having, a conformation which substantially lacks a defined secondary and tertiary structure as determined by circular dichroism spectroscopy performed in aqueous buffer at ambient temperature and pH 7.4. Preferably, ambient temperature is about 20°C, i.e. between 18°C and 22°C, most preferably ambient temperature is 20°C.

[0042] As used herein the term "pharmaceutical composition" refers to a composition containing one or more active ingredients, for example a drug or a prodrug, here specifically the PTH prodrugs of the present invention, and optionally one or more excipients, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients of the composition or from dissociation of one or more of the ingredients or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing one or more PTH prodrugs of the present invention and optionally a pharmaceutically acceptable excipient.

[0043] As used herein the term "liquid composition" refers to a mixture comprising water-soluble PTH prodrug and one or more solvents, such as water.

[0044] As used herein, the term "dry composition" means that a pharmaceutical composition is provided in a dry form. Suitable methods for drying are spray-drying and lyophilization, i.e. freeze-drying. Such dry composition of prodrug has a residual water content of a maximum of 10 %, preferably less than 5% and more preferably less than 2%, determined according to Karl Fischer. Preferably, the pharmaceutical composition of the present invention is dried by lyophilization.

[0045] The term "drug" as used herein refers to a substance used in the treatment, cure, prevention or diagnosis of a disease or used to otherwise enhance physical or mental well-being. If a drug is conjugated to another moiety, the moiety of the resulting product that originated from the drug is referred to as "biologically active moiety". The PTH prodrugs of the present invention comprise a PTH moiety which is released from the PTH prodrug in the form of the drug PTH.

[0046] As used herein the term "prodrug" refers to a conjugate comprising a biologically active moiety reversibly and covalently connected to a specialized protective group through a reversible prodrug linker moiety which is a linker moiety comprising a reversible linkage with the biologically active moiety and wherein the specialized protective group alters or eliminates undesirable properties in the parent molecule. This also includes the enhancement of desirable properties in the drug and the suppression of undesirable properties. The specialized non-toxic protective group is referred to as "carrier". A prodrug releases the reversibly and covalently bound biologically active moiety in the form of its corresponding drug. In other words, a prodrug is a conjugate comprising a biologically active moiety which is covalently and reversibly conjugated to a carrier moiety via a reversible prodrug linker moiety, which covalent and reversible conjugation of the carrier to the reversible prodrug linker moiety is either directly or through a spacer. Such conjugate releases the formerly conjugated biologically active moiety in the form of a free drug.

[0047] A "biodegradable linkage" or a "reversible linkage" is a linkage that is hydrolytically degradable, i.e. cleavable, in the absence of enzymes under physiological conditions (aqueous buffer at pH 7.4, 37°C) with a half-life ranging from one hour to two months, preferably from one hour to one month. Accordingly, a stable linkage is a linkage having a half-life under physiological conditions (aqueous buffer at pH 7.4, 37°C) of more than two months.

[0048] Accordingly, a "reversible prodrug linker moiety" is a moiety which is covalently conjugated to a biologically active moiety, such as PTH, through a reversible linkage and is also covalently conjugated to a carrier moiety, such as -Z, wherein the covalent conjugation to said carrier moiety is either directly or through a spacer moiety, such as -L²-. Preferably the linkage between -Z and -L²- is a stable linkage.

[0049] As used herein, the term "traceless prodrug linker" means a reversible prodrug linker which upon cleavage releases the drug in its free form. As used herein, the term "free form" of a drug means the drug in its unmodified, pharmacologically active form.


[0050] As used herein, the term "excipient" refers to a diluent, adjuvant or vehicle with which the therapeutic, such as a drug or prodrug, is administered. Such pharmaceutical excipient can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, including peanut oil, soybean oil, mineral oil and sesame oil. Water is a preferred excipient when the pharmaceutical composition is administered orally. Saline and aqueous dextrose are preferred excipients when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions are preferably employed as liquid excipients for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, mannitol, trehalose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water and ethanol. The pharmaceutical composition, if desired, can also contain minor amounts of wetting or emulsifying agents, pH buffering agents, like, for example, acetate, succinate, tris, carbonate, phosphate, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid) or can contain

detergents, like Tween, poloxamers, poloxamines, CHAPS, Igepal or amino acids like, for example, glycine, lysine or histidine. These pharmaceutical compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders and sustained-release formulations. The pharmaceutical composition can be formulated as a suppository, with traditional binders and excipients such as triglycerides. Oral formulation can include standard excipients such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Such compositions will contain a therapeutically effective amount of the drug or biologically active moiety, together with a suitable amount of excipient so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.


[0051] As used herein, the term "reagent" means a chemical compound which comprises at least one functional group for reaction with the functional group of another chemical compound or drug. It is understood that a drug comprising a functional group (such as a primary or secondary amine or hydroxyl functional group) is also a reagent.

[0052] As used herein, the term "moiety" means a part of a molecule, which lacks one or more atom(s) compared to the corresponding reagent. If, for example, a reagent of the formula "H-X-H" reacts with another reagent and becomes part of the reaction product, the corresponding moiety of the reaction product has the structure "H-X-" or "-X-", whereas each "-" indicates attachment to another moiety. Accordingly, a biologically active moiety is released from a prodrug as a drug.


[0053] It is understood that if the sequence or chemical structure of a group of atoms is provided which group of atoms is attached to two moieties or is interrupting a moiety, said sequence or chemical structure can be attached to the two moieties in either orientation, unless explicitly stated otherwise. For example, a moiety "-C(O)N(R)-" can be attached to two moieties or interrupting a moiety either as "-C(O)N(R)-" or as "-N(R)C(O)-". Similarly, a moiety



can be attached to two moieties or can interrupt a moiety either as



or as



[0054] As used herein, the term "functional group" means a group of atoms which can react with other groups of atoms. Functional groups include but are not limited to the following groups: carboxylic acid ((C=O)OH), primary or secondary amine (-NH₂, -NH-), maleimide, thiol (-SH), sulfonic acid ((O=S=O)OH), carbonate, carbamate (-O(C=O)N<), hydroxyl (-OH),

aldehyde $-(C=O)H$, ketone $-(C=O)-$, hydrazine $(>N-N<)$, isocyanate, isothiocyanate, phosphoric acid $-(O(P=O)OHOH)$, phosphonic acid $-(O(P=O)OHH)$, haloacetyl, alkyl halide, acryloyl, aryl fluoride, hydroxylamine, disulfide, sulfonamides, sulfuric acid, vinyl sulfone, vinyl ketone, diazoalkane, oxirane and aziridine.

[0055] In case the prodrugs of the present invention comprise one or more acidic or basic groups, the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts. Thus, the prodrugs of the present invention comprising acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Prodrugs of the present invention comprising one or more basic groups, i.e. groups which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids. Examples for suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid and other acids known to the person skilled in the art. For the person skilled in the art further methods are known for converting the basic group into a cation like the alkylation of an amine group resulting in a positively-charged ammonium group and an appropriate counterion of the salt. If the prodrugs of the present invention simultaneously comprise acidic and basic groups, the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). The respective salts can be obtained by customary methods which are known to the person skilled in the art like, for example, by contacting these prodrugs with an organic or inorganic acid or base in a solvent or dispersant or by anion exchange or cation exchange with other salts. The present invention also includes all salts of the prodrugs of the present invention which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.

[0056] The term "pharmaceutically acceptable" means a substance that does cause harm when administered to a patient and preferably means approved by a regulatory agency, such as the EMA (Europe) and/or the FDA (US) and/or any other national regulatory agency for use in animals, preferably for use in humans.


[0057] As used herein the term "about" in combination with a numerical value is used to indicate a range ranging from and including the numerical value plus and minus no more than 10% of said numerical value, more preferably no more than 8% of said numerical value, even more preferably no more than 5% of said numerical value and most preferably no more than 2% of said numerical value. For example, the phrase "about 200" is used to mean a range

ranging from and including 200 +/- 10%, i.e. ranging from and including 180 to 220; preferably 200 +/-8%, i.e. ranging from and including 184 to 216; even more preferably ranging from and including 200 +/-5%, i.e. ranging from and including 190 to 210; and most preferably 200 +/-2%, i.e. ranging from and including 196 to 204. It is understood that a percentage given as "about 20%" does not mean "20% +/- 10%", i.e. ranging from and including 10 to 30%, but "about 20%" means ranging from and including 18 to 22%, i.e. plus and minus 10% of the numerical value which is 20.

[0058] As used herein, the term "polymer" means a molecule comprising repeating structural units, i.e. the monomers, connected by chemical bonds in a linear, circular, branched, crosslinked or dendrimeric way or a combination thereof, which may be of synthetic or biological origin or a combination of both. It is understood that a polymer may also comprise one or more other chemical group(s) and/or moiety/moieties, such as, for example, one or more functional group(s). Preferably, a soluble polymer has a molecular weight of at least 0.5 kDa, e.g. a molecular weight of at least 1 kDa, a molecular weight of at least 2 kDa, a molecular weight of at least 3 kDa or a molecular weight of at least 5 kDa. If the polymer is soluble, it preferable has a molecular weight of at most 1000 kDa, such as at most 750 kDa, such as at most 500 kDa, such as at most 300 kDa, such as at most 200 kDa, such as at most 100 kDa. It is understood that for insoluble polymers, such as hydrogels, no meaningful molecular weight ranges can be provided. It is understood that also a protein is a polymer in which the amino acids are the repeating structural units, even though the side chains of each amino acid may be different.

[0059] As used herein, the term "polymeric" means a reagent or a moiety comprising one or more polymer(s) or polymer moiety/moieties. A polymeric reagent or moiety may optionally also comprise one or more other moiety/moieties, which are preferably selected from the group consisting of:

- C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl, C₂₋₅₀ alkynyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, phenyl, naphthyl, indenyl, indanyl and tetralinyl; and
- linkages selected from the group comprising



wherein

dashed lines indicate attachment to the remainder of the moiety or reagent; and

-R and -R^a are independently of each other selected from the group consisting of -H, methyl, ethyl, propyl, butyl, pentyl and hexyl.

[0060] The person skilled in the art understands that the polymerization products obtained from a polymerization reaction do not all have the same molecular weight, but rather exhibit a molecular weight distribution. Consequently, the molecular weight ranges, molecular weights, ranges of numbers of monomers in a polymer and numbers of monomers in a polymer as used herein, refer to the number average molecular weight and number average of monomers, i.e. to the arithmetic mean of the molecular weight of the polymer or polymeric moiety and the arithmetic mean of the number of monomers of the polymer or polymeric moiety.

[0061] Accordingly, in a polymeric moiety comprising "x" monomer units any integer given for "x" therefore corresponds to the arithmetic mean number of monomers. Any range of integers given for "x" provides the range of integers in which the arithmetic mean numbers of monomers lies. An integer for "x" given as "about x" means that the arithmetic mean numbers of monomers lies in a range of integers of $x \pm 10\%$, preferably $x \pm 8\%$, more preferably $x \pm 5\%$ and most preferably $x \pm 2\%$.

[0062] As used herein, the term "number average molecular weight" means the ordinary arithmetic mean of the molecular weights of the individual polymers.


[0063] As used herein the term "water-soluble" with reference to a carrier means that when such carrier is part of the PTH prodrug of the present invention at least 1 g of the PTH prodrug comprising such water-soluble carrier can be dissolved in one liter of water at 20°C to form a homogeneous solution. Accordingly, the term "water-insoluble" with reference to a carrier means that when such carrier is part of the PTH prodrug of the present invention less than 1 g of the PTH prodrug comprising such water-insoluble carrier can be dissolved in one liter of water at 20°C to form a homogeneous solution.

[0064] As used herein, the term "hydrogel" means a hydrophilic or amphiphilic polymeric network composed of homopolymers or copolymers, which is insoluble due to the presence of hydrogen bonds, ionic interactions and/or covalent chemical crosslinks. The crosslinks provide the network structure and physical integrity.

[0065] As used herein the term "thermogelling" means a compound that is a liquid or a low viscosity solution having a viscosity of less than 500 cps at 25°C at a shear rate of about 0.1 /second at a low temperature, which low temperature ranges between about 0°C to about 10°C, but which is a higher viscosity compound of less than 10000 cps at 25°C at a shear rate of about 0.1/second at a higher temperature, which higher temperature ranges between about 30°C to about 40°C, such as at about 37°C.

[0066] As used herein, the term "PEG-based" in relation to a moiety or reagent means that said moiety or reagent comprises PEG. Preferably, a PEG-based moiety or reagent comprises at least 10% (w/w) PEG, such as at least 20% (w/w) PEG, such as at least 30% (w/w) PEG, such as at least 40% (w/w) PEG, such as at least 50% (w/w), such as at least 60 (w/w) PEG, such as at least 70% (w/w) PEG, such as at least 80% (w/w) PEG, such as at least 90% (w/w) PEG, such as at least 95%. The remaining weight percentage of the PEG-based moiety or reagent are other moieties preferably selected from the following moieties and linkages:

- C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl, C₂₋₅₀ alkynyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, phenyl, naphthyl, indenyl, indanyl and tetralinyl; and
- linkages selected from the group comprising




wherein


dashed lines indicate attachment to the remainder of the moiety or reagent; and

-R and -R^a are independently of each other selected from the group consisting of -H, methyl, ethyl, propyl, butyl, pentyl and hexyl.

[0067] As used herein, the term "PEG-based comprising at least X% PEG" in relation to a moiety or reagent means that said moiety or reagent comprises at least X% (w/w) ethylene glycol units (-CH₂CH₂O-), wherein the ethylene glycol units may be arranged blockwise, alternating or may be randomly distributed within the moiety or reagent and preferably all ethylene glycol units of said moiety or reagent are present in one block; the remaining weight percentage of the PEG-based moiety or reagent are other moieties preferably selected from the following moieties and linkages:

- C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl, C₂₋₅₀ alkynyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, phenyl, naphthyl, indenyl, indanyl and tetralinyl; and
- linkages selected from the group comprising





wherein

dashed lines indicate attachment to the remainder of the moiety or reagent; and

-R and -R^a are independently of each other selected from the group consisting of -H, methyl, ethyl, propyl, butyl, pentyl and hexyl.

[0068] The term "hyaluronic acid-based comprising at least X% hyaluronic acid" is used accordingly.

[0069] The term "substituted" as used herein means that one or more -H atom(s) of a molecule or moiety are replaced by a different atom or a group of atoms, which are referred to as "substituent".

[0070] Preferably, the one or more further optional substituents are independently of each other selected from the group consisting of halogen, -CN, -COOR^{x1}, -OR^{x1}, -C(O)R^{x1}, -C(O)N(R^{x1}R^{x1a}), -S(O)₂N(R^{x1}R^{x1a}), -S(O)N(R^{x1}R^{x1a}), -S(O)₂R^{x1}, -S(O)R^{x1}, -N(R^{x1})S(O)₂N(R^{x1a}R^{x1b}), -SR^{x1}, -N(R^{x1}R^{x1a}), -NO₂, -OC(O)R^{x1}, -N(R^{x1})C(O)R^{x1a}, -N(R^{x1})S(O)₂R^{x1a}, -N(R^{x1})S(O)R^{x1a}, -N(R^{x1})C(O)OR^{x1a}, -N(R^{x1})C(O)N(R^{x1a}R^{x1b}), -OC(O)N(R^{x1}R^{x1a}), -T⁰, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl; wherein -T⁰, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally substituted with one or more -R^{x2}, which are the same or different, and wherein C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T⁰-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{x3})-, -S(O)₂N(R^{x3})-, -S(O)N(R^{x3})-, -S(O)₂-, -S(O)-, -N(R^{x3})S(O)₂N(R^{x3a})-, -S-, -N(R^{x3})-, -OC(OR^{x3})(R^{x3a})-, -N(R^{x3})C(O)N(R^{x3a})- and -OC(O)N(R^{x3})-;

-R^{x1}, -R^{x1a} and -R^{x1b} are independently of each other selected from the group consisting of -H, -T⁰, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl; wherein -T⁰, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally substituted with one or more -R^{x2}, which are the same or different, and wherein C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T⁰-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{x3})-, -S(O)₂N(R^{x3})-, -S(O)N(R^{x3})-, -S(O)₂-, -S(O)-, -N(R^{x3})S(O)₂N(R^{x3a})-, -S-, -N(R^{x3})-, -OC(OR^{x3})(R^{x3a})-, -N(R^{x3})C(O)N(R^{x3a})- and -OC(O)N(R^{x3})-;

each T^0 is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl and 8- to 11-membered heterobicyclyl; wherein each T^0 is independently optionally substituted with one or more $-R^{x2}$, which are the same or different;

each $-R^{x2}$ is independently selected from the group consisting of halogen, $-CN$, oxo ($=O$), $-COOR^{x4}$, $-OR^{x4}$, $-C(O)R^{x4}$, $-C(O)N(R^{x4}R^{x4a})$, $-S(O)_2N(R^{x4}R^{x4a})$, $-S(O)N(R^{x4}R^{x4a})$, $-S(O)_2R^{x4}$, $-S(O)R^{x4}$, $-N(R^{x4})S(O)_2N(R^{x4a}R^{x4b})$, $-SR^{x4}$, $-N(R^{x4}R^{x4a})$, $-NO_2$, $-OC(O)R^{x4}$, $-N(R^{x4})C(O)R^{x4a}$, $-N(R^{x4})S(O)_2R^{x4a}$, $-N(R^{x4})S(O)R^{x4a}$, $-N(R^{x4})C(O)OR^{x4a}$, $-N(R^{x4})C(O)N(R^{x4a}R^{x4b})$, $-OC(O)N(R^{x4}R^{x4a})$ and C_{1-6} alkyl; wherein C_{1-6} alkyl is optionally substituted with one or more halogen, which are the same or different;

each $-R^{x3}$, $-R^{x3a}$, $-R^{x4}$, $-R^{x4a}$ and $-R^{x4b}$ is independently selected from the group consisting of H and C_{1-6} alkyl; wherein C_{1-6} alkyl is optionally substituted with one or more halogen, which are the same or different.

[0071] More preferably, the one or more further optional substituents are independently of each other selected from the group consisting of halogen, $-CN$, $-COOR^{x1}$, $-OR^{x1}$, $-C(O)R^{x1}$, $-C(O)N(R^{x1}R^{x1a})$, $-S(O)_2N(R^{x1}R^{x1a})$, $-S(O)N(R^{x1}R^{x1a})$, $-S(O)_2R^{x1}$, $-S(O)R^{x1}$, $-N(R^{x1})S(O)_2N(R^{x1a}R^{x1b})$, $-SR^{x1}$, $-N(R^{x1}R^{x1a})$, $-NO_2$, $-OC(O)R^{x1}$, $-N(R^{x1})C(O)R^{x1a}$, $-N(R^{x1})S(O)_2R^{x1a}$, $-N(R^{x1})S(O)R^{x1a}$, $-N(R^{x1})C(O)OR^{x1a}$, $-N(R^{x1})C(O)N(R^{x1a}R^{x1b})$, $-OC(O)N(R^{x1}R^{x1a})$, $-T^0$, C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkynyl; wherein $-T^0$, C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkynyl are optionally substituted with one or more $-R^{x2}$, which are the same or different, and wherein C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkynyl are optionally interrupted by one or more groups selected from the group consisting of $-T^0$ -, $-C(O)O$ -, $-O$ -, $-C(O)$ -, $-C(O)N(R^{x3})$ -, $-S(O)_2N(R^{x3})$ -, $-S(O)N(R^{x3})$ -, $-S(O)_2$ -, $-S(O)$ -, $-N(R^{x3})S(O)_2N(R^{x3a})$ -, $-S$ -, $-N(R^{x3})$ -, $-OC(OR^{x3})(R^{x3a})$ -, $-N(R^{x3})C(O)N(R^{x3a})$ - and $-OC(O)N(R^{x3})$ -;

each $-R^{x1}$, $-R^{x1a}$, $-R^{x1b}$, $-R^{x3}$ and $-R^{x3a}$ is independently selected from the group consisting of H , halogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

each T^0 is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl and 8- to 11-membered heterobicyclyl; wherein each T^0 is independently optionally substituted with one or more $-R^{x2}$, which are the same or different;

each $-R^{x2}$ is independently selected from the group consisting of halogen, $-CN$, oxo ($=O$), $-$

COOR^{x4}, -OR^{x4}, -C(O)R^{x4}, -C(O)N(R^{x4}R^{x4a}), -S(O)₂N(R^{x4}R^{x4a}), -S(O)N(R^{x4}R^{x4a}), -S(O)₂R^{x4}, -S(O)R^{x4}, -N(R^{x4})S(O)₂N(R^{x4a}R^{x4b}), -SR^{x4}, -N(R^{x4}R^{x4a}), -NO₂, -OC(O)R^{x4}, -N(R^{x4})C(O)R^{x4a}, -N(R^{x4})S(O)₂R^{x4a}, -N(R^{x4})S(O)R^{x4a}, -N(R^{x4})C(O)OR^{x4a}, -N(R^{x4})C(O)N(R^{x4a}R^{x4b}), -OC(O)N(R^{x4}R^{x4a}) and C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different;

each -R^{x4}, -R^{x4a} and -R^{x4b} is independently selected from the group consisting of -H, halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl and C₂₋₆ alkynyl;

[0072] Even more preferably, the one or more further optional substituents are independently of each other selected from the group consisting of halogen, -CN, -COOR^{x1}, -OR^{x1}, -C(O)R^{x1}, -C(O)N(R^{x1}R^{x1a}), -S(O)₂N(R^{x1}R^{x1a}), -S(O)N(R^{x1}R^{x1a}), -S(O)₂R^{x1}, -S(O)R^{x1}, -N(R^{x1})S(O)₂N(R^{x1a}R^{x1b}), -SR^{x1}, -N(R^{x1}R^{x1a}), -NO₂, -OC(O)R^{x1}, -N(R^{x1})C(O)R^{x1a}, -N(R^{x1})S(O)₂R^{x1a}, -N(R^{x1})S(O)R^{x1a}, -N(R^{x1})C(O)OR^{x1a}, -N(R^{x1})C(O)N(R^{x1a}R^{x1b}), -OC(O)N(R^{x1}R^{x1a}), -T⁰, C₁₋₆ alkyl, C₂₋₆ alkenyl and C₂₋₆ alkynyl; wherein -T⁰, C₁₋₆ alkyl, C₂₋₆ alkenyl and C₂₋₆ alkynyl are optionally substituted with one or more -R^{x2}, which are the same or different, and wherein C₁₋₆ alkyl, C₂₋₆ alkenyl and C₂₋₆ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T⁰-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{x3})-, -S(O)₂N(R^{x3})-, -S(O)N(R^{x3})-, -S(O)₂-, -S(O)-, -N(R^{x3})S(O)₂N(R^{x3a})-, -S-, -N(R^{x3})-, -OC(OR^{x3})(R^{x3a})-, -N(R^{x3})C(O)N(R^{x3a})- and -OC(O)N(R^{x3})-;

each -R^{x1}, -R^{x1a}, -R^{x1b}, -R^{x2}, -R^{x3} and -R^{x3a} is independently selected from the group consisting of -H, halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl and C₂₋₆ alkynyl;

each T⁰ is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl and 8- to 11-membered heterobicyclyl; wherein each T⁰ is independently optionally substituted with one or more -R^{x2}, which are the same or different.

[0073] Preferably, a maximum of 6 -H atoms of an optionally substituted molecule are independently replaced by a substituent, e.g. 5 -H atoms are independently replaced by a substituent, 4 -H atoms are independently replaced by a substituent, 3 -H atoms are independently replaced by a substituent, 2 -H atoms are independently replaced by a substituent or 1 -H atom is replaced by a substituent.

[0074] The term "interrupted" means that a moiety is inserted between two carbon atoms or - if

the insertion is at one of the moiety's ends - between a carbon or heteroatom and a hydrogen atom, preferably between a carbon and a hydrogen atom.

[0075] The term "spacer" refers to any moiety that is suitable to connect two moieties. Preferably, a spacer is -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y1})-, -S(O)₂N(R^{y1})-, -S(O)N(R^{y1})-, -S(O)₂-, -S(O)-, -N(R^{y1})S(O)₂N(R^{y1a})-, -S-, -N(R^{y1})-, -OC(OR^{y1})(R^{y1a})-, -N(R^{y1})C(O)N(R^{y1a})-, -OC(O)N(R^{y1})-, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl or C₂₋₅₀ alkynyl; wherein -T-, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally substituted with one or more -R^{y2}, which are the same or different, and wherein C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y3})-, -S(O)₂N(R^{y3})-, -S(O)N(R^{y3})-, -S(O)₂-, -S(O)-, -N(R^{y3})S(O)₂N(R^{y3a})-, -S-, -N(R^{y3})-, -OC(OR^{y3})(R^{y3a})-, -N(R^{y3})C(O)N(R^{y3a})- and -OC(O)N(R^{y3})-;

-R^{y1} and -R^{y1a} are independently of each other selected from the group consisting of -H, -T, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl; wherein -T, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally substituted with one or more -R^{y2}, which are the same or different, and wherein C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y4})-, -S(O)₂N(R^{y4})-, -S(O)N(R^{y4})-, -S(O)₂-, -S(O)-, -N(R^{y4})S(O)₂N(R^{y4a})-, -S-, -N(R^{y4})-, -OC(OR^{y4})(R^{y4a})-, -N(R^{y4})C(O)N(R^{y4a})- and -OC(O)N(R^{y4})-;

each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl and 8- to 30-membered heteropolycyclyl; wherein each T is independently optionally substituted with one or more -R^{y2}, which are the same or different;

each -R^{y2} is independently selected from the group consisting of halogen, -CN, oxo (=O), -COOR^{y5}, -OR^{y5}, -C(O)R^{y5}, -C(O)N(R^{y5}R^{y5a}), -S(O)₂N(R^{y5}R^{y5a}), -S(O)N(R^{y5}R^{y5a}), -S(O)₂R^{y5}, -S(O)R^{y5}, -N(R^{y5})S(O)₂N(R^{y5a}R^{y5b}), -SR^{y5}, -N(R^{y5}R^{y5a}), -NO₂, -OC(O)R^{y5}, -N(R^{y5})C(O)R^{y5a}, -N(R^{y5})S(O)₂R^{y5a}, -N(R^{y5})S(O)R^{y5a}, -N(R^{y5})C(O)OR^{y5a}, -N(R^{y5})C(O)N(R^{y5a}R^{y5b}), -OC(O)N(R^{y5}R^{y5a}) and C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different; and

each -R^{y3}, -R^{y3a}, -R^{y4}, -R^{y4a}, -R^{y5}, -R^{y5a} and -R^{y5b} is independently selected from the group consisting of -H and C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different.

[0076] Even more preferably the spacer is -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y1})-, -S(O)₂N(R^{y1})-, -S(O)N(R^{y1})-, -S(O)₂-, -S(O)-, -N(R^{y1})S(O)₂N(R^{y1a})-, -S-, -N(R^{y1})-, -OC(OR^{y1})(R^{y1a})-, -N(R^{y1})C(O)N(R^{y1a})-, -OC(O)N(R^{y1})-, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl or C₂₋₅₀ alkynyl; wherein -T-, C₁₋₂₀ alkyl, C₂₋₂₀ alkenyl and C₂₋₂₀ alkynyl are optionally substituted with one or more -R^{y2}, which are the same or different, and wherein C₁₋₂₀ alkyl, C₂₋₂₀ alkenyl and C₂₋₂₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y3})-, -S(O)₂N(R^{y3})-, -S(O)N(R^{y3})-, -S(O)₂-, -S(O)-, -N(R^{y3})S(O)₂N(R^{y3a})-, -S-, -N(R^{y3})-, -OC(OR^{y3})(R^{y3a})-, -N(R^{y3})C(O)N(R^{y3a})- and -OC(O)N(R^{y3})-;

-R^{y1} and -R^{y1a} are independently of each other selected from the group consisting of -H, -T, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl; wherein -T, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl are optionally substituted with one or more -R^{y2}, which are the same or different, and wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y4})-, -S(O)₂N(R^{y4})-, -S(O)N(R^{y4})-, -S(O)₂-, -S(O)-, -N(R^{y4})S(O)₂N(R^{y4a})-, -S-, -N(R^{y4})-, -OC(OR^{y4})(R^{y4a})-, -N(R^{y4})C(O)N(R^{y4a})- and -OC(O)N(R^{y4})-;

each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl and 8- to 30-membered heteropolycyclyl; wherein each T is independently optionally substituted with one or more -R^{y2}, which are the same or different;

-R^{y2} is halogen, -CN, oxo (=O), -COOR^{y5}, -OR^{y5}, -C(O)R^{y5}, -C(O)N(R^{y5}R^{y5a})-, -S(O)₂N(R^{y5}R^{y5a})-, -S(O)N(R^{y5}R^{y5a})-, -S(O)₂R^{y5}, -S(O)R^{y5}, -N(R^{y5})S(O)₂N(R^{y5a}R^{y5b})-, -SR^{y5}, -N(R^{y5}R^{y5a})-, -NO₂, -OC(O)R^{y5}, -N(R^{y5})C(O)R^{y5a}, -N(R^{y5})S(O)₂R^{y5a}, -N(R^{y5})S(O)R^{y5a}, -N(R^{y5})C(O)OR^{y5a}, -N(R^{y5})C(O)N(R^{y5a}R^{y5b})-, -OC(O)N(R^{y5}R^{y5a}) or C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different; and

each -R^{y3}, -R^{y3a}, -R^{y4}, -R^{y4a}, -R^{y5}, -R^{y5a} and -R^{y5b} is independently of each other selected from the group consisting of -H and C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different.

[0077] Even more preferably the spacer is -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y1})-, -S(O)₂N(R^{y1})-, -S(O)N(R^{y1})-, -S(O)₂-, -S(O)-, -N(R^{y1})S(O)₂N(R^{y1a})-, -S-, -N(R^{y1})-, -OC(OR^{y1})

(R^{y1a})-, -N(R^{y1})C(O)N(R^{y1a})-, -OC(O)N(R^{y1})-, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl or C₂₋₅₀ alkynyl; wherein -T-, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally substituted with one or more -R^{y2}, which are the same or different, and wherein C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y3})-, -S(O)₂N(R^{y3})-, -S(O)N(R^{y3})-, -S(O)₂-, -S(O)-, -N(R^{y3})S(O)₂N(R^{y3a})-, -S-, -N(R^{y3})-, -OC(OR^{y3})(R^{y3a})-, -N(R^{y3})C(O)N(R^{y3a})- and -OC(O)N(R^{y3})-;

-R^{y1} and -R^{y1a} are independently selected from the group consisting of -H, -T, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl;

each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicycyl, 8- to 30-membered carbopolycyclyl and 8- to 30-membered heteropolycyclyl;

each -R^{y2} is independently selected from the group consisting of halogen and C₁₋₆ alkyl; and

each -R^{y3}, -R^{y3a}, -R^{y4}, -R^{y4a}, -R^{y5}, -R^{y5a} and -R^{y5b} is independently of each other selected from the group consisting of -H and C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different.

[0078] As used herein, the term "C₁₋₄ alkyl" alone or in combination means a straight-chain or branched alkyl moiety having 1 to 4 carbon atoms. If present at the end of a molecule, examples of straight-chain or branched C₁₋₄ alkyl are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. When two moieties of a molecule are linked by the C₁₋₄ alkyl, then examples for such C₁₋₄ alkyl groups are -CH₂-, -CH₂-CH₂-, -CH(CH₃)-, -CH₂-CH₂-CH₂-, -CH(C₂H₅)- and -C(CH₃)₂-. Each hydrogen of a C₁₋₄ alkyl carbon may optionally be replaced by a substituent as defined above. Optionally, a C₁₋₄ alkyl may be interrupted by one or more moieties as defined below.

[0079] As used herein, the term "C₁₋₆ alkyl" alone or in combination means a straight-chain or branched alkyl moiety having 1 to 6 carbon atoms. If present at the end of a molecule, examples of straight-chain and branched C₁₋₆ alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl. When two moieties of a molecule are linked by the C₁₋₆ alkyl group, then examples for such C₁₋₆ alkyl groups are -CH₂-, -CH₂-CH₂-, -CH(CH₃)-, -CH₂-CH₂-CH₂-, -CH(C₂H₅)- and -C(CH₃)₂-. Each hydrogen atom of a C₁₋₆ carbon may optionally be replaced by a substituent as defined above. Optionally, a C₁₋₆ alkyl may be interrupted by one or more

moieties as defined below.

[0080] Accordingly, "C₁₋₁₀ alkyl", "C₁₋₂₀ alkyl" or "C₁₋₅₀ alkyl" means an alkyl chain having 1 to 10, 1 to 20 or 1 to 50 carbon atoms, respectively, wherein each hydrogen atom of the C₁₋₁₀, C₁₋₂₀ or C₁₋₅₀ carbon may optionally be replaced by a substituent as defined above. Optionally, a C₁₋₁₀ or C₁₋₅₀ alkyl may be interrupted by one or more moieties as defined below.

[0081] As used herein, the term "C₂₋₆ alkenyl" alone or in combination means a straight-chain or branched hydrocarbon moiety comprising at least one carbon-carbon double bond having 2 to 6 carbon atoms. If present at the end of a molecule, examples are -CH=CH₂, -CH=CH-CH₃, -CH₂-CH=CH₂, -CH=CHCH₂-CH₃ and -CH=CH-CH=CH₂. When two moieties of a molecule are linked by the C₂₋₆ alkenyl group, then an example for such C₂₋₆ alkenyl is -CH=CH-. Each hydrogen atom of a C₂₋₆ alkenyl moiety may optionally be replaced by a substituent as defined above. Optionally, a C₂₋₆ alkenyl may be interrupted by one or more moieties as defined below.


[0082] Accordingly, the term "C₂₋₁₀ alkenyl", "C₂₋₂₀ alkenyl" or "C₂₋₅₀ alkenyl" alone or in combination means a straight-chain or branched hydrocarbon moiety comprising at least one carbon-carbon double bond having 2 to 10, 2 to 20 or 2 to 50 carbon atoms. Each hydrogen atom of a C₂₋₁₀ alkenyl, C₂₋₂₀ alkenyl or C₂₋₅₀ alkenyl group may optionally be replaced by a substituent as defined above. Optionally, a C₂₋₁₀ alkenyl, C₂₋₂₀ alkenyl or C₂₋₅₀ alkenyl may be interrupted by one or more moieties as defined below.

[0083] As used herein, the term "C₂₋₆ alkynyl" alone or in combination means straight-chain or branched hydrocarbon moiety comprising at least one carbon-carbon triple bond having 2 to 6 carbon atoms. If present at the end of a molecule, examples are -C≡CH, -CH₂-C≡CH, CH₂-CH₂-C≡CH and CH₂-C≡C-CH₃. When two moieties of a molecule are linked by the alkynyl group, then an example is -C≡C-. Each hydrogen atom of a C₂₋₆ alkynyl group may optionally be replaced by a substituent as defined above. Optionally, one or more double bond(s) may occur. Optionally, a C₂₋₆ alkynyl may be interrupted by one or more moieties as defined below.

[0084] Accordingly, as used herein, the term "C₂₋₁₀ alkynyl", "C₂₋₂₀ alkynyl" and "C₂₋₅₀ alkynyl" alone or in combination means a straight-chain or branched hydrocarbon moiety comprising at least one carbon-carbon triple bond having 2 to 10, 2 to 20 or 2 to 50 carbon atoms, respectively. Each hydrogen atom of a C₂₋₁₀ alkynyl, C₂₋₂₀ alkynyl or C₂₋₅₀ alkynyl group may optionally be replaced by a substituent as defined above. Optionally, one or more double bond(s) may occur. Optionally, a C₂₋₁₀ alkynyl, C₂₋₂₀ alkynyl or C₂₋₅₀ alkynyl may be interrupted by one or more moieties as defined below.

[0085] As mentioned above, a C₁₋₄ alkyl, C₁₋₆ alkyl, C₁₋₁₀ alkyl, C₁₋₂₀ alkyl, C₁₋₅₀ alkyl, C₂₋₆ alkenyl, C₂₋₁₀ alkenyl, C₂₋₂₀ alkenyl, C₂₋₅₀ alkenyl, C₂₋₆ alkynyl, C₂₋₁₀ alkynyl, C₂₋₂₀ alkynyl or C₂₋₅₀ alkynyl may optionally be interrupted by one or more moieties which are preferably

selected from the group consisting of



wherein

dashed lines indicate attachment to the remainder of the moiety or reagent; and

-R and -R^a are independently of each other selected from the group consisting of -H, methyl, ethyl, propyl, butyl, pentyl and hexyl.

[0086] As used herein, the term "C₃₋₁₀ cycloalkyl" means a cyclic alkyl chain having 3 to 10 carbon atoms, which may be saturated or unsaturated, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl. Each hydrogen atom of a C₃₋₁₀ cycloalkyl carbon may be replaced by a substituent as defined above. The term "C₃₋₁₀ cycloalkyl" also includes bridged bicycles like norbornane or norbornene.

[0087] The term "8- to 30-membered carbopolycyclyl" or "8- to 30-membered carbopolycycle" means a cyclic moiety of two or more rings with 8 to 30 ring atoms, where two neighboring rings share at least one ring atom and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated). Preferably an 8- to 30-membered carbopolycyclyl means a cyclic moiety of two, three, four or five rings, more preferably of two, three or four rings.

[0088] As used herein, the term "3- to 10-membered heterocyclyl" or "3- to 10-membered heterocycle" means a ring with 3, 4, 5, 6, 7, 8, 9 or 10 ring atoms that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 4 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)₂-), oxygen and nitrogen (including =N(O)-) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for 3- to 10-membered heterocycles include but are not limited to aziridine, oxirane, thiirane, azirine, oxirene, thiirene, azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine,

isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyrimidine, piperazine, piperidine, morpholine, tetrazole, triazole, triazolidine, tetrazolidine, diazepane, azepine and homopiperazine. Each hydrogen atom of a 3- to 10-membered heterocyclyl or 3- to 10-membered heterocyclic group may be replaced by a substituent as defined below.


[0089] As used herein, the term "8- to 11-membered heterobicycyl" or "8- to 11-membered heterobicycle" means a heterocyclic moiety of two rings with 8 to 11 ring atoms, where at least one ring atom is shared by both rings and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 6 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including $-S(O)-$, $-S(O)_2-$), oxygen and nitrogen (including $=N(O)-$) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for an 8- to 11-membered heterobicycle are indole, indoline, benzofuran, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline, dihydroquinoline, tetrahydroquinoline, decahydroquinoline, isoquinoline, decahydroisoquinoline, tetrahydroisoquinoline, dihydroisoquinoline, benzazepine, purine and pteridine. The term 8- to 11-membered heterobicycle also includes spiro structures of two rings like 1,4-dioxa-8-azaspiro[4.5]decane or bridged heterocycles like 8-aza-bicyclo[3.2.1]octane. Each hydrogen atom of an 8- to 11-membered heterobicycyl or 8- to 11-membered heterobicycle carbon may be replaced by a substituent as defined below.

[0090] Similarly, the term "8- to 30-membered heteropolycyclyl" or "8- to 30-membered heteropolycycle" means a heterocyclic moiety of more than two rings with 8 to 30 ring atoms, preferably of three, four or five rings, where two neighboring rings share at least one ring atom and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or unsaturated), wherein at least one ring atom up to 10 ring atoms are replaced by a heteroatom selected from the group of sulfur (including $-S(O)-$, $-S(O)_2-$), oxygen and nitrogen (including $=N(O)-$) and wherein the ring is linked to the rest of a molecule via a carbon or nitrogen atom.

[0091] It is understood that the phrase "the pair R^x/R^y is joined together with the atom to which they are attached to form a C_{3-10} cycloalkyl or a 3- to 10-membered heterocyclyl" in relation with a moiety of the structure




means that R^x and R^y form the following structure:




wherein R is C_{3-10} cycloalkyl or 3- to 10-membered heterocyclyl.


[0092] It is also understood that the phrase "the pair R^x/R^y is joined together with the atoms to which they are attached to form a ring A" in relation with a moiety of the structure



means that R^x and R^y form the following structure:



[0093] As used herein, the term "terminal alkyne" means a moiety



[0094] As used herein, "halogen" means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.

[0095] In general, the term "comprise" or "comprising" also encompasses "consist of" or "consisting of".

[0096] It is understood that in formula (Ia) -D is connected to $-L^1-$ via a covalent and reversible linkage.

[0097] Preferably, -D has the sequence of SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114 or SEQ ID NO:115. More preferably -D has the sequence of SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:110, SEQ ID NO:111 or SEQ ID NO:112.

[0098] In one embodiment -D has the sequence of SEQ ID NO:50.

[0099] In another embodiment -D has the sequence of SEQ ID NO:52.

[0100] In another embodiment -D has the sequence of SEQ ID NO:110.

[0101] In another embodiment -D has the sequence of SEQ ID NO:111.

[0102] In another embodiment -D has the sequence of SEQ ID NO:112.

[0103] Most preferably -D has the sequence of SEQ ID NO:51.

[0104] The moiety $-L^1$ - is conjugated to the N-terminal amine functional group of PTH, either directly through the corresponding amine functional group or indirectly wherein a spacer moiety is first conjugated to the amine functional group to which spacer moiety $-L^1$ - is conjugated. Preferably, $-L^1$ - is directly conjugated to the N-terminal amine functional group of PTH, preferably PTH 1-34, i.e. PTH having the sequence of SEQ ID NO:51.

[0105] It was surprisingly found that N-terminal attachment of $-L^1$ - is advantageous, i.e. attachment of $-L^1$ - to the N-terminus of PTH, because it was found that such attachment site protects the N-terminus which is crucial for PTH activity. Furthermore, it was surprisingly found that the main metabolite formed from a PTH prodrug with N-terminal attachment of $-L^1$ - is PTH 1-33, i.e. the 33 N-terminal amino acids of PTH, which metabolite is known to be active.

[0106] The moiety $-L^1$ - can be connected to -D through any type of linkage, provided that it is reversible. Preferably, $-L^1$ - is connected to -D through a linkage selected from the group consisting of amide, ester, carbamate, acetal, aminal, imine, oxime, hydrazone, disulfide and acylguanidine. Even more preferably $-L^1$ - is connected to -D through a linkage selected from the group consisting of amide, ester, carbamate and acylguanidin. It is understood that some of these linkages *per se* are not reversible, but that in the present invention neighboring groups comprised in $-L^1$ - render these linkages reversible.

[0107] In one embodiment $-L^1$ - is connected to -D through an ester linkage.

[0108] In another embodiment $-L^1$ - is connected to -D through a carbamate linkage.

[0109] In another embodiment $-L^1$ - is connected to -D through an acylguanidine.


[0110] In a preferred embodiment $-L^1$ - is connected to -D through an amide linkage.

[0111] The moiety $-L^1$ - is a reversible prodrug linker from which the drug, i.e. PTH, is released in its free form, i.e. it is a traceless prodrug linker. Suitable prodrug linkers are known in the art, such as for example the reversible prodrug linker moieties disclosed in WO 2005/099768 A2, WO 2006/136586 A2, WO 2011/089216 A1 and WO 2013/024053 A1.

[0112] In another embodiment $-L^1$ - is a reversible prodrug linker as described in WO 2011/012722 A1, WO 2011/089214 A1, WO 2011/089215 A1, WO 2013/024052 A1 and WO 2013/160340 A1.

[0113] A particularly preferred moiety $-L^1$ - is disclosed in WO 2009/095479 A2. Accordingly, in a preferred embodiment the moiety $-L^1$ - is of formula (II):

3a 3 1 1a



wherein the dashed line indicates the attachment to the N-terminal amine functional group of -D;

-X- is -C(R⁴R^{4a})-, -N(R⁴)-, -O-, -C(R⁴R^{4a})-C(R⁵R^{5a})-, -C(R⁵R^{5a})-C(R⁴R^{4a})-, -C(R⁴R^{4a})-N(R⁶)-, -N(R⁶)-C(R⁴R^{4a})-, -C(R⁴R^{4a})-O-, -O-C(R⁴R^{4a})- or -C(R⁷R^{7a})-;

X¹ is C or S(O);

-X²- is -C(R⁸R^{8a})- or -C(R⁸R^{8a})-C(R⁹R^{9a})-; =X³ is =O, =S or =N-CN;

-R¹ -R^{1a} -R², -R^{2a} -R⁴ -R^{4a}, -R⁵, -R^{5a} -R⁶ -R⁸ -R^{8a} -R⁹ and -R^{9a} are independently selected from the group consisting of -H and C₁₋₆ alkyl;

-R³ and -R^{3a} are independently selected from the group consisting of -H and C₁₋₆ alkyl, provided that in case one of -R³ and -R^{3a} or both are other than -H they are connected to N to which they are attached through an sp³-hybridized carbon atom;

-R⁷ is -N(R¹⁰R^{10a}) or -NR¹⁰-(C=O)-R¹¹;

-R^{7a}, -R¹⁰, -R^{10a} and -R¹¹ are independently of each other selected from the group consisting of -H and C₁₋₆ alkyl;

optionally, one or more of the pairs -R^{1a}/R^{4a}, -R^{1a}/R^{5a}, -R^{1a}/R^{7a}, -R^{4a}/R^{5a} and -R^{8a}/R^{9a} form a chemical bond;

optionally, one or more of the pairs -R¹/R^{1a}, -R²/R^{2a}, -R⁴/R^{4a}, -R⁵/R^{5a}, -R⁸/R^{8a} and -R⁹/R^{9a} are joined together with the atom to which they are attached to form a C₃₋₁₀ cycloalkyl or 3- to 10-membered heterocyclyl;

optionally, one or more of the pairs -R¹/R⁴, -R¹/R⁵, -R¹/R⁶, -R¹/R^{7a}, -R⁴/R⁵, -R⁴/R⁶, -R⁸/R⁹ and -R²/R³ are joined together with the atoms to which they are attached to form a ring A;

optionally, R³/R^{3a} are joined together with the nitrogen atom to which they are attached to form a 3- to 10-membered heterocycle;

A is phenyl, naphthyl, indenyl, indanyl, tetralinyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl or 8- to 11-membered heterobicyclyl; and


wherein -L¹- is substituted with -L²-Z and wherein -L¹- is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (II) is not replaced by -L²-Z or a

substituent.

[0114] Preferably $-L^1-$ of formula (II) is substituted with one moiety $-L^2-Z$.

[0115] In one embodiment $-L^1-$ of formula (II) is not further substituted.

[0116] It is understood that if $-R^3/-R^{3a}$ of formula (II) are joined together with the nitrogen atom to which they are attached to form a 3- to 10-membered heterocycle, only such 3- to 10-membered heterocycles may be formed in which the atoms directly attached to the nitrogen are sp^3 -hybridized carbon atoms. In other words, such 3- to 10-membered heterocycle formed by $-R^3/-R^{3a}$ together with the nitrogen atom to which they are attached has the following structure:



wherein



the dashed line indicates attachment to the rest of $-L^1-$;

the ring comprises 3 to 10 atoms comprising at least one nitrogen; and

$R^{\#}$ and $R^{\#\#}$ represent an sp^3 -hybridized carbon atom.

[0117] It is also understood that the 3- to 10-membered heterocycle may be further substituted.

[0118] Exemplary embodiments of suitable 3- to 10-membered heterocycles formed by $-R^3/-R^{3a}$ of formula (II) together with the nitrogen atom to which they are attached are the following:




wherein

dashed lines indicate attachment to the rest of the molecule; and

$-R$ is $-H$ or C_{1-6} alkyl.

$-L^1-$ of formula (II) may optionally be further substituted. In general, any substituent may be

used as far as the cleavage principle is not affected, i.e. the hydrogen marked with the asterisk in formula (II) is not replaced and the nitrogen of the moiety



of formula (II) remains part of a primary, secondary or tertiary amine, i.e. -R^3 and -R^{3a} are independently of each other -H or are connected to -N< through an sp^3 -hybridized carbon atom.

[0119] In one embodiment -R^1 or -R^{1a} of formula (II) is substituted with $\text{-L}^2\text{-Z}$. In another embodiment -R^2 or -R^{2a} of formula (II) is substituted with $\text{-L}^2\text{-Z}$. In another embodiment -R^3 or -R^{3a} of formula (II) is substituted with $\text{-L}^2\text{-Z}$. In another embodiment -R^4 of formula (II) is substituted with $\text{-L}^2\text{-Z}$. In another embodiment -R^5 or -R^{5a} of formula (II) is substituted with $\text{-L}^2\text{-Z}$. In another embodiment -R^6 of formula (II) is substituted with $\text{-L}^2\text{-Z}$. In another embodiment -R^7 or -R^{7a} of formula (II) is substituted with $\text{-L}^2\text{-Z}$. In another embodiment -R^8 or -R^{8a} of formula (II) is substituted with $\text{-L}^2\text{-Z}$. In another embodiment -R^9 or -R^{9a} of formula (II) is substituted with $\text{-L}^2\text{-Z}$. In another embodiment -R^{10} is substituted with $\text{-L}^2\text{-Z}$. In another embodiment -R^{11} is substituted with $\text{-L}^2\text{-Z}$.

[0120] Preferably, -X- of formula (II) is $\text{-C(R}^4\text{R}^{4a})\text{-}$, $\text{-N(R}^4\text{)-}$ or $\text{-C(R}^7\text{R}^{7a})\text{-}$.

[0121] In one embodiment -X- of formula (II) is $\text{-C(R}^4\text{R}^{4a})\text{-}$.

[0122] In one preferred embodiment -X- of formula (II) is $\text{-C(R}^7\text{R}^{7a})\text{-}$.

[0123] Preferably, -R^7 of formula (II) is $\text{-NR}^{10}\text{-(C=O)-R}^{11}$.

[0124] Preferably, -R^{7a} of formula (II) is -H, methyl or ethyl. Most preferably -R^{7a} of formula (II) is -H.

[0125] Preferably, -R^{10} is -H, methyl or ethyl. Most preferably -R^{10} is methyl.

[0126] Preferably, -R^{11} is -H, methyl or ethyl. Most preferably -R^{11} is -H.

[0127] Preferably, -R^{11} is substituted with $\text{-L}^2\text{-Z}$.

[0128] In another preferred embodiment -X- of formula (II) is $\text{-N(R}^4\text{)-}$.

[0129] Preferably, -R^4 is -H, methyl or ethyl. Preferably, -R^4 is -H.

[0130] Preferably, X^1 of formula (II) is C.

[0131] Preferably, $=X^3$ of formula (II) is $=O$.

[0132] Preferably, $-X^2-$ of formula (II) is $-C(R^8R^{8a})-$.

[0133] Preferably $-R^8$ and $-R^{8a}$ of formula (II) are independently selected from the group consisting of -H, methyl and ethyl. More preferably at least one of $-R^8$ and $-R^{8a}$ of formula (II) is -H. Even more preferably both $-R^8$ and $-R^{8a}$ of formula (II) are -H.

[0134] Preferably, $-R^1$ and $-R^{1a}$ of formula (II) are independently selected from the group consisting of -H, methyl and ethyl.

[0135] In one preferred embodiment at least one of $-R^1$ and $-R^{1a}$ of formula (II) is -H, more preferably both $-R^1$ and $-R^{1a}$ of formula (II) are -H.

[0136] In another preferred embodiment at least one of $-R^1$ and $-R^{1a}$ of formula (II) is methyl, more preferably both $-R^1$ and $-R^{1a}$ of formula (II) are methyl.

[0137] Preferably, $-R^2$ and $-R^{2a}$ of formula (II) are independently selected from the group consisting of -H, methyl and ethyl. More preferably, at least one of $-R^2$ and $-R^{2a}$ of formula (II) is -H. Even more preferably both $-R^2$ and $-R^{2a}$ of formula (II) are H.


[0138] Preferably, $-R^3$ and $-R^{3a}$ of formula (II) are independently selected from the group consisting of -H, methyl, ethyl, propyl and butyl.

[0139] In one preferred embodiment at least one of $-R^3$ and $-R^{3a}$ of formula (II) is methyl, more preferably $-R^3$ of formula (II) is methyl and $-R^{3a}$ of formula (II) is -H.

[0140] In another preferred embodiment $-R^3$ and $-R^{3a}$ of formula (II) are both -H.

[0141] Preferably, -D is connected to $-L^1-$ through a nitrogen by forming an amide bond.

[0142] In one preferred embodiment the moiety $-L^1-$ is of formula (IIa-i):



wherein

the dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond;

$-R^1$, $-R^{1a}$, $-R^2$, $-R^{2a}$, $-R^3$, $-R^{3a}$, $-R^7$, $-R^{7a}$ and $-X^2$ are used as defined in formula (II); and

wherein $-L^1$ is substituted with $-L^2-Z$ and wherein $-L^1$ is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (IIa-i) is not replaced by $-L^2-Z$ or a substituent.

[0143] Preferably $-L^1$ of formula (IIa-i) is substituted with one moiety $-L^2-Z$.

[0144] Preferably the moiety $-L^1$ of formula (IIa-i) is not further substituted.

[0145] Preferably, $-R^1$ and $-R^{1a}$ of formula (IIa-i) are independently selected from the group consisting of -H, methyl and ethyl. More preferably, at least one of $-R^1$ and $-R^{1a}$ of formula (IIa-i) is -H. Even more preferably both $-R^1$ and $-R^{1a}$ of formula (IIa-i) are -H.

[0146] Preferably, $-R^7$ of formula (IIa-i) is $-NR^{10}-(C=O)-R^{11}$.

[0147] Preferably, $-R^{7a}$ of formula (II-i) is -H, methyl or ethyl. Most preferably $-R^{7a}$ of formula (II-i) is -H.

[0148] Preferably, $-R^{10}$ of formula (IIa-i) is -H, methyl or ethyl. Most preferably $-R^{10}$ of formula (IIa-i) is methyl.

[0149] Preferably, $-R^{11}$ of formula (IIa-i) is -H, methyl or ethyl. Most preferably $-R^{11}$ of formula (IIa-i) is -H.

[0150] Preferably, $-R^{11}$ of formula (IIa-i) is substituted with $-L^2-Z$.

[0151] Preferably, $-X^2$ of formula (IIa-i) is $-C(R^8R^{8a})-$.

[0152] Preferably $-R^8$ and $-R^{8a}$ of formula (IIa-i) are independently selected from the group consisting of -H, methyl and ethyl. More preferably at least one of $-R^8$ and $-R^{8a}$ of formula (IIa-i) is -H. Even more preferably both $-R^8$ and $-R^{8a}$ of formula (IIa-i) are -H.


[0153] Preferably, $-R^2$ and $-R^{2a}$ of formula (IIa-i) are independently selected from the group

consisting of -H, methyl and ethyl. More preferably, at least one of $-R^2$ and $-R^{2a}$ of formula (IIa-i) is -H. Even more preferably both $-R^2$ and $-R^{2a}$ of formula (IIa-i) are H.

[0154] Preferably, $-R^3$ and $-R^{3a}$ of formula (IIa-i) are independently selected from the group consisting of -H, methyl, ethyl, propyl and butyl. Even more preferably at least one of $-R^3$ and $-R^{3a}$ of formula (IIa-i) is methyl.

[0155] Preferably, $-R^3$ of formula (IIa-i) is -H and $-R^{3a}$ of formula (IIa-i) is methyl.

[0156] More preferably the moiety $-L^1-$ is of formula (IIa-ii):



wherein the dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond;

$-R^2$, $-R^{2a}$, $-R^{10}$, $-R^{11}$ and $-X^2-$ are used as defined in formula (II); and

wherein $-L^1-$ is substituted with $-L^2-Z$ and wherein $-L^1-$ is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (IIa-ii) is not replaced by $-L^2-Z$ or a substituent.

[0157] Preferably $-L^1-$ of formula (IIa-ii) is substituted with one moiety $-L^2-Z$.

[0158] Preferably the moiety $-L^1-$ of formula (IIa-ii) is not further substituted.

[0159] Preferably, $-X^2-$ of formula (IIa-ii) is $-C(R^8R^{8a})-$.

[0160] Preferably $-R^8$ and $-R^{8a}$ of formula (IIa-ii) are independently selected from the group consisting of -H, methyl and ethyl. More preferably at least one of $-R^8$ and $-R^{8a}$ of formula (IIa-ii) is -H. Even more preferably both $-R^8$ and $-R^{8a}$ of formula (IIa-ii) are -H.

[0161] Preferably, $-R^3$ and $-R^{3a}$ of formula (IIa-ii) are independently selected from the group consisting of -H, methyl, ethyl, propyl and butyl. Even more preferably at least one of $-R^3$ and -

R^{3a} of formula (IIa-ii) is methyl.


[0162] Preferably, $-R^3$ of formula (IIa-ii) is -H and $-R^{3a}$ of formula (IIa-ii) is methyl.

[0163] Preferably, $-R^{10}$ of formula (IIa-ii) is selected from -H, methyl and ethyl. Most preferably $-R^{10}$ of formula (IIa-ii) is methyl.

[0164] Preferably, $-R^{11}$ of formula (IIa-ii) is selected from -H, methyl and ethyl. Most preferably $-R^{11}$ of formula (IIa-ii) is -H.

[0165] Preferably, $-R^{11}$ of formula (IIa-ii) is substituted with $-L^2-Z$.

[0166] In an even more preferred embodiment the moiety $-L^1-$ is of formula (IIa-ii'):



wherein

wherein the dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond;

the dashed line marked with the asterisk indicates attachment to $-L^2-$;

$-R^3$, $-R^{3a}$, $-R^{10}$ and $-X^2-$ are used as defined in formula (II); and

wherein $-L^1-$ is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (IIa-ii') is not replaced by a substituent.

[0167] Preferably the moiety $-L^1-$ of formula (IIa-ii') is not further substituted.

[0168] Preferably, $-X^2-$ of formula (IIa-ii') is $-C(R^8R^{8a})-$.


[0169] Preferably $-R^8$ and $-R^{8a}$ of formula (IIa-ii') are independently selected from the group consisting of -H, methyl and ethyl. More preferably at least one of $-R^8$ and $-R^{8a}$ of formula (IIa-ii') is -H. Even more preferably both $-R^8$ and $-R^{8a}$ of formula (IIa-ii') are -H.

[0170] Preferably, $-R^3$ and $-R^{3a}$ of formula (IIa-ii') are independently selected from the group consisting of -H, methyl, ethyl, propyl and butyl. Even more preferably at least one of $-R^3$ and $-R^{3a}$ of formula (IIa-ii') is methyl.

[0171] Preferably, $-R^3$ of formula (IIa-ii') is -H and $-R^{3a}$ of formula (IIa-ii') is methyl.

[0172] Preferably, $-R^{10}$ of formula (IIa-ii') is -H, methyl or ethyl. Most preferably $-R^{10}$ of formula (IIa-ii') is methyl.

[0173] Even more preferably the moiety $-L^1$ - is of formula (IIa-iii):




wherein the dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond; and

wherein $-L^1$ - is substituted with $-L^2-Z$ and wherein $-L^1$ - is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (IIa-iii) is not replaced by $-L^2-Z$ or a substituent.

[0174] Preferably $-L^1$ - of formula (IIa-iii) is substituted with one moiety $-L^2-Z$.

[0175] Preferably the moiety $-L^1$ - of formula (IIa-iii) is not further substituted.

[0176] Most preferably the moiety $-L^1$ - is of formula (IIa-iii'):



wherein

wherein the dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond;


the dashed line marked with the asterisk indicates attachment to $-L^2-$;

$-R^2$, $-R^{2a}$, $-R^3$, $-R^{3a}$ and $-X^2-$ are used as defined in formula (II); and

wherein $-L^1-$ is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (IIa-iii') is not replaced by a substituent.

[0177] Preferably the moiety $-L^1-$ of formula (IIa-iii') is not further substituted.

[0178] In another preferred embodiment the moiety $-L^1-$ is of formula (IIb-i)



wherein

the dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond;

$-R^1$, $-R^{1a}$, $-R^2$, $-R^{2a}$, $-R^3$, $-R^{3a}$, $-R^4$ and $-X^2-$ are used as defined in formula (II); and

wherein $-L^1-$ is substituted with $-L^2-Z$ and wherein $-L^1-$ is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (IIb-i) is not replaced by $-L^2-Z$ or a substituent.

[0179] Preferably $-L^1-$ of formula (IIb-i) is substituted with one moiety $-L^2-Z$.

[0180] Preferably the moiety $-L^1-$ of formula (IIb-i) is not further substituted.

[0181] Preferably, $-R^1$ and $-R^{1a}$ of formula (IIb-i) are independently selected from the group consisting of -H, methyl and ethyl. More preferably, at least one of $-R^1$ and $-R^{1a}$ of formula (IIb-i) is methyl. Even more preferably both $-R^1$ and $-R^{1a}$ of formula (IIb-i) are methyl.

[0182] Preferably, $-R^4$ of formula (IIb-i) is -H, methyl or ethyl. More preferably, $-R^4$ of formula (IIb-i) is -H.


[0183] Preferably, $-X^2-$ of formula (IIb-i) is $-C(R^8R^{8a})-$.

[0184] Preferably $-R^8$ and $-R^{8a}$ of formula (IIb-i) are independently selected from the group consisting of -H, methyl and ethyl. More preferably at least one of $-R^8$ and $-R^{8a}$ of formula (IIb-i) is -H. Even more preferably both $-R^8$ and $-R^{8a}$ of formula (IIb-i) are -H.

[0185] Preferably, $-R^2$ and $-R^{2a}$ of formula (IIb-i) are independently selected from the group consisting of -H, methyl and ethyl. More preferably, at least one of $-R^2$ and $-R^{2a}$ of formula (IIb-i) is -H. Even more preferably both $-R^2$ and $-R^{2a}$ of formula (IIb-i) are H.

[0186] Preferably, $-R^3$ and $-R^{3a}$ of formula (IIb-i) are independently selected from the group consisting of -H, methyl, ethyl, propyl and butyl. Even more preferably at least one of $-R^3$ and $-R^{3a}$ of formula (IIb-i) is -H. Even more preferably both $-R^3$ and $-R^{3a}$ of formula (IIb-i) are -H.

[0187] More preferably the moiety $-L^1-$ is of formula (IIb-ii):



wherein the dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond;

$-R^2$, $-R^{2a}$, $-R^3$, $-R^{3a}$ and $-X^2-$ are used as defined in formula (II); and

wherein $-L^1-$ is substituted with $-L^2-Z$ and wherein $-L^1-$ is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (IIb-ii) is not replaced by $-L^2-Z$ or a substituent.

[0188] Preferably $-L^1-$ of formula (IIb-ii) is substituted with one moiety $-L^2-Z$.

[0189] Preferably the moiety $-L^1-$ of formula (IIb-ii) is not further substituted.

[0190] Preferably, $-X^2-$ of formula (IIb-ii) is $-C(R^8R^{8a})-$.


[0191] Preferably $-R^8$ and $-R^{8a}$ of formula (IIb-ii) are independently selected from the group consisting of -H, methyl and ethyl. More preferably at least one of $-R^8$ and $-R^{8a}$ of formula (IIb-ii) is -H. Even more preferably both $-R^8$ and $-R^{8a}$ of formula (IIb-ii) are -H.

[0192] Preferably, $-R^2$ and $-R^{2a}$ of formula (IIb-ii) are independently selected from the group

consisting of -H, methyl and ethyl. More preferably, at least one of $-R^2$ and $-R^{2a}$ of formula (IIb-ii) is -H. Even more preferably both $-R^2$ and $-R^{2a}$ of formula (IIb-ii) are H.

[0193] Preferably, $-R^3$ and $-R^{3a}$ of formula (IIb-ii) are independently selected from the group consisting of -H, methyl, ethyl, propyl and butyl. Even more preferably at least one of $-R^3$ and $-R^{3a}$ of formula (IIb-ii) is -H. Even more preferably both $-R^3$ and $-R^{3a}$ of formula (IIb-ii) are -H.

[0194] Even more preferably the moiety $-L^1-$ is of formula (IIb-ii'):



wherein

the dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond;

$-R^2$, $-R^{2a}$, $-R^3$, $-R^{3a}$ and $-X^2-$ are used as defined in formula (II); and

wherein $-L^1-$ is substituted with $-L^2-Z$ and wherein $-L^1-$ is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (IIb-ii') is not replaced by $-L^2-Z$ or a substituent.

[0195] Preferably the moiety $-L^1-$ of formula (IIb-ii') is not further substituted.


[0196] Preferably, $-X^2-$ of formula (IIb-ii') is $-C(R^8R^{8a})-$.

[0197] Preferably $-R^8$ and $-R^{8a}$ of formula (IIb-ii') are independently selected from the group consisting of -H, methyl and ethyl. More preferably at least one of $-R^8$ and $-R^{8a}$ of formula (IIb-ii') is -H. Even more preferably both $-R^8$ and $-R^{8a}$ of formula (IIb-ii') are -H.

[0198] Preferably, $-R^2$ and $-R^{2a}$ of formula (IIb-ii') are independently selected from the group consisting of -H, methyl and ethyl. More preferably, at least one of $-R^2$ and $-R^{2a}$ of formula (IIb-ii') is -H. Even more preferably both $-R^2$ and $-R^{2a}$ of formula (IIb-ii') are H.

[0199] Preferably, $-R^3$ and $-R^{3a}$ of formula (IIb-ii') are independently selected from the group consisting of -H, methyl, ethyl, propyl and butyl. Even more preferably at least one of $-R^3$ and $-R^{3a}$ of formula (IIb-ii') is -H. Even more preferably both $-R^3$ and $-R^{3a}$ of formula (IIb-ii') are -H.

[0200] Even more preferably the moiety $-L^1-$ is of formula (IIb-iii):



wherein


the dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond; and

wherein $-L^1-$ is substituted with $-L^2-Z$ and wherein $-L^1-$ is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (IIb-iii) is not replaced by $-L^2-Z$ or a substituent.

[0201] Preferably $-L^1-$ of formula (IIb-iii) is substituted with one moiety $-L^2-Z$.

[0202] Preferably the moiety $-L^1-$ of formula (IIb-iii) is not further substituted.

[0203] Most preferably the moiety $-L^1-$ is of formula (IIb-iii'):



wherein

the dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond;


$-R^2$, $-R^{2a}$, $-R^3$, $-R^{3a}$ and $-X^2-$ are used as defined in formula (II); and

wherein $-L^1-$ is substituted with $-L^2-Z$ and wherein $-L^1-$ is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (IIb-iii') is not replaced by $-L^2-Z$ or a substituent.

[0204] Preferably the moiety $-L^1-$ of formula (IIb-iii') is not further substituted.

[0205] Another preferred moiety $-L^1-$ is disclosed in unpublished European patent application 14180004, which corresponds to the international application with the application number PCT/EP2015/067929. Accordingly, in another preferred embodiment the moiety $-L^1-$ is of

formula (III):



wherein

the dashed line indicates attachment to the N-terminal amine functional group of -D by forming an amide or ester linkage, respectively;

$-R^1$, $-R^{1a}$, $-R^2$, $-R^{2a}$, $-R^3$ and $-R^{3a}$ are independently of each other selected from the group consisting of $-H$, $-C(R^8R^{8a}R^{8b})$, $-C(=O)R^8$, $-C=N$, $-C(=NR^8)R^{8a}$, $-CR^8(=CR^{8a}R^{8b})$, $-C\equiv CR^8$ and $-T$;

$-R^4$, $-R^5$ and $-R^{5a}$ are independently of each other selected from the group consisting of $-H$, $-C(R^9R^{9a}R^{9b})$ and $-T$;

a_1 and a_2 are independently of each other 0 or 1;

each $-R^6$, $-R^{6a}$, $-R^7$, $-R^{7a}$, $-R^8$, $-R^{8a}$, $-R^{8b}$, $-R^9$, $-R^{9a}$ and $-R^{9b}$ are independently of each other selected from the group consisting of $-H$, halogen, $-CN$, $-COOR^{10}$, $-OR^{10}$, $-C(O)R^{10}$, $-C(O)N(R^{10}R^{10a})$, $-S(O)_2N(R^{10}R^{10a})$, $-S(O)N(R^{10}R^{10a})$, $-S(O)_2R^{10}$, $-S(O)R^{10}$, $-N(R^{10})S(O)_2N(R^{10a}R^{10b})$, $-SR^{10}$, $-N(R^{10}R^{10a})$, $-NO_2$, $-OC(O)R^{10}$, $-N(R^{10})C(O)R^{10a}$, $-N(R^{10})S(O)_2R^{10a}$, $-N(R^{10})S(O)R^{10a}$, $-N(R^{10})C(O)OR^{10a}$, $-N(R^{10})C(O)N(R^{10a}R^{10b})$, $-OC(O)N(R^{10}R^{10a})$, $-T$, C_{1-20} alkyl, C_{2-20} alkenyl and C_{2-20} alkynyl; wherein $-T$, C_{1-20} alkyl, C_{2-20} alkenyl and C_{2-20} alkynyl are optionally substituted with one or more $-R^{11}$, which are the same or different, and wherein C_{1-20} alkyl, C_{2-20} alkenyl and C_{2-20} alkynyl are optionally interrupted by one or more groups selected from the group consisting of $-T$, $-C(O)O$, $-O$, $-C(O)$, $-C(O)N(R^{12})$, $-S(O)_2N(R^{12})$, $-S(O)N(R^{12})$, $-S(O)_2$, $-S(O)$, $-N(R^{12})S(O)_2N(R^{12a})$, $-S$, $-N(R^{12})$, $-OC(OR^{12})(R^{12a})$, $-N(R^{12})C(O)N(R^{12a})$ and $-OC(O)N(R^{12})$;

each $-R^{10}$, $-R^{10a}$ and $-R^{10b}$ is independently selected from the group consisting of $-H$, $-T$, C_{1-20} alkyl, C_{2-20} alkenyl and C_{2-20} alkynyl; wherein $-T$, C_{1-20} alkyl, C_{2-20} alkenyl and C_{2-20} alkynyl are optionally substituted with one or more $-R^{11}$, which are the same or different, and wherein C_{1-20} alkyl, C_{2-20} alkenyl and C_{2-20} alkynyl are optionally interrupted by one or more groups selected from the group consisting of $-T$, $-C(O)O$, $-O$, $-C(O)$, $-C(O)N(R^{12})$, $-S(O)_2N(R^{12})$, $-S(O)N(R^{12})$, $-S(O)_2$, $-S(O)$, $-N(R^{12})S(O)_2N(R^{12a})$, $-S$, $-N(R^{12})$, $-OC(OR^{12})(R^{12a})$, $-N(R^{12})C(O)N(R^{12a})$ and $-OC(O)N(R^{12})$;

each T is independently of each other selected from the group consisting of phenyl, naphthyl,

indenyl, indanyl, tetralinyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl and 8- to 11-membered heterobicycyl; wherein each T is independently optionally substituted with one or more -R¹¹, which are the same or different;

each -R¹¹ is independently of each other selected from the group consisting of halogen, -CN, oxo (=O), -COOR¹³, -OR¹³, -C(O)R¹³, -C(O)N(R¹³R^{13a}), -S(O)₂N(R¹³R^{13a}), -S(O)N(R¹³R^{13a}), -S(O)₂R¹³, -S(O)R¹³, -N(R¹³)S(O)₂N(R^{13a}R^{13b}), -SR¹³, -N(R¹³R^{13a}), -NO₂, -OC(O)R¹³, -N(R¹³)C(O)R^{13a}, -N(R¹³)S(O)₂R^{13a}, -N(R¹³)S(O)R^{13a}, -N(R¹³)C(O)OR^{13a}, -N(R¹³)C(O)N(R^{13a}R^{13b}), -OC(O)N(R¹³R^{13a}) and C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different;

each -R¹², -R^{12a}, -R¹³, -R^{13a} and -R^{13b} is independently selected from the group consisting of H and C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different;

optionally, one or more of the pairs -R¹/-R^{1a}, -R²/-R^{2a}, -R³/-R^{3a}, -R⁶/-R^{6a} and -R⁷/-R^{7a} are joined together with the atom to which they are attached to form a C₃₋₁₀ cycloalkyl or a 3- to 10-membered heterocyclyl;

optionally, one or more of the pairs -R¹/-R², -R¹/-R³, -R¹/-R⁴, -R¹/-R⁵, -R¹/-R⁶, -R¹/-R⁷, -R²/-R³, -R²/-R⁴, -R²/-R⁵, -R²/-R⁶, -R²/-R⁷, -R³/-R⁴, -R³/-R⁵, -R³/-R⁶, -R³/-R⁷, -R⁴/-R⁵, -R⁴/-R⁶, -R⁴/-R⁷, -R⁵/-R⁶, -R⁵/-R⁷ and -R⁶/-R⁷ are joined together with the atoms to which they are attached to form a ring A;

A is phenyl, naphthyl, indenyl, indanyl, tetralinyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl or 8- to 11-membered heterobicycyl;

wherein -L¹- is substituted with -L²-Z and wherein -L¹- is optionally further substituted.

[0206] The optional further substituents of -L¹- of formula (III) are preferably as described above.


[0207] Preferably -L¹- of formula (III) is substituted with one moiety -L²-Z.

[0208] In one embodiment -L¹- of formula (III) is not further substituted.

[0209] Additional preferred embodiments for -L¹- are disclosed in EP1536334B1, WO2009/009712A1, WO2008/034122A1, WO2009/143412A2, WO2011/082368A2 and US8618124B2.

[0210] Additional preferred embodiments for -L¹- are disclosed in US8946405B2 and US8754190B2.

[0211] Accordingly, a preferred moiety -L¹- is of formula (IV):



wherein

the dashed line indicates attachment to the N-terminal amine functional group of -D;

m is 0 or 1;

at least one or both of -R¹ and -R² is/are independently of each other selected from the group consisting of -CN, -NO₂, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkenyl, optionally substituted alkynyl, -C(O)R³, -S(O)R³, -S(O)₂R³ and -SR⁴,

one and only one of -R¹ and -R² is -H, optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl;

-R³ is -H, optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -OR⁹ or -N(R⁹)₂;

-R⁴ is optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;

each -R⁵ is independently selected from the group consisting of -H, optionally substituted alkyl, optionally substituted alkenylalkyl, optionally substituted alkynylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

-R⁹ is -H or optionally substituted alkyl;

-Y- is absent and -X- is -O- or -S-; or

-Y- is -N(Q)CH₂- and -X- is -O-;

Q is optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;

optionally, -R¹ and -R² may be joined to form a 3 to 8-membered ring; and

optionally, both -R⁹ together with the nitrogen to which they are attached form a heterocyclic ring;

wherein -L¹- is substituted with -L²-Z and wherein -L¹- is optionally further substituted.

[0212] Only in the context of formula (IV) the terms used have the following meaning:

The term "alkyl" as used herein includes linear, branched or cyclic saturated hydrocarbon groups of 1 to 8 carbons or in some embodiments 1 to 6 or 1 to 4 carbon atoms.

[0213] The term "alkoxy" includes alkyl groups bonded to oxygen, including methoxy, ethoxy, isopropoxy, cyclopropoxy, cyclobutoxy and similar.

[0214] The term "alkenyl" includes non-aromatic unsaturated hydrocarbons with carbon-carbon double bonds.

[0215] The term "alkynyl" includes non-aromatic unsaturated hydrocarbons with carbon-carbon triple bonds.

[0216] The term "aryl" includes aromatic hydrocarbon groups of 6 to 18 carbons, preferably 6 to 10 carbons, including groups such as phenyl, naphthyl and anthracenyl. The term "heteroaryl" includes aromatic rings comprising 3 to 15 carbons containing at least one N, O or S atom, preferably 3 to 7 carbons containing at least one N, O or S atom, including groups such as pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl and indenyl.

[0217] In some instance, alkenyl, alkynyl, aryl or heteroaryl moieties may be coupled to the remainder of the molecule through an alkylene linkage. Under those circumstances, the substituent will be referred to as alkenylalkyl, alkynylalkyl, arylalkyl or heteroarylalkyl, indicating that an alkylene moiety is between the alkenyl, alkynyl, aryl or heteroaryl moiety and the molecule to which the alkenyl, alkynyl, aryl or heteroaryl is coupled.


[0218] The term "halogen" includes bromo, fluoro, chloro and iodo.

[0219] The term "heterocyclic ring" refers to a 4 to 8 membered aromatic or non-aromatic ring comprising 3 to 7 carbon atoms and at least one N, O or S atom. Examples are piperidinyl, piperazinyl, tetrahydropyranyl, pyrrolidine and tetrahydrofuranyl, as well as the exemplary groups provided for the term "heteroaryl" above.

[0220] When a ring system is optionally substituted, suitable substituents are selected from the group consisting of alkyl, alkenyl, alkynyl or an additional ring, each optionally further substituted. Optional substituents on any group, including the above, include halo, nitro, cyano, -OR, -SR, -NR₂, -OCOR, -NRCOR, -COOR, -CONR₂, -SOR, -SO₂R, -SONR₂ and -SO₂NR₂, wherein each -R is independently alkyl, alkenyl, alkynyl, aryl or heteroaryl, or two -R groups taken together with the atoms to which they are attached form a ring.

[0221] Preferably -L¹- of formula (IV) is substituted with one moiety -L²-Z.

[0222] An additional preferred embodiment for -L¹- is disclosed in WO2013/036857A1. Accordingly, a preferred moiety -L¹- is of formula (V):



wherein

the dashed line indicates attachment to the N-terminal amine functional group of -D and wherein attachment is through the N-terminal amine functional group of -D;

-R¹

is optionally substituted C₁-C₆ linear, branched or cyclic alkyl, optionally substituted aryl, optionally substituted heteroaryl, alkoxy or -NR⁵₂;

-R²

is -H, optionally substituted C₁-C₆ alkyl, optionally substituted aryl or optionally substituted heteroaryl;

-R³

is -H, optionally substituted C₁-C₆ alkyl, optionally substituted aryl or optionally substituted heteroaryl;

-R⁴

is -H, optionally substituted C₁-C₆ alkyl, optionally substituted aryl or optionally substituted heteroaryl;

each -R⁵ is independently of each other selected from the group consisting of -H, optionally substituted C₁-C₆ alkyl, optionally substituted aryl and optionally substituted heteroaryl or when taken together two -R⁵ can be cycloalkyl or cycloheteroalkyl;

wherein -L¹- is substituted with -L²-Z and wherein -L¹- is optionally further substituted.

[0223] Only in the context of formula (V) the terms used have the following meaning:

"Alkyl", "alkenyl" and "alkynyl" include linear, branched or cyclic hydrocarbon groups of 1-8 carbons or 1-6 carbons or 1-4 carbons wherein alkyl is a saturated hydrocarbon, alkenyl includes one or more carbon-carbon double bonds and alkynyl includes one or more carbon-carbon triple bonds. Unless otherwise specified these contain 1-6 C.


"Aryl" includes aromatic hydrocarbon groups of 6-18 carbons, preferably 6-10 carbons, including groups such as phenyl, naphthyl and anthracene. "Heteroaryl" includes aromatic

rings comprising 3-15 carbons containing at least one N, O or S atom, preferably 3-7 carbons containing at least one N, O or S atom, including groups such as pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl and indenyl.

[0224] The term "substituted" means an alkyl, alkenyl, alkynyl, aryl or heteroaryl group comprising one or more substituent groups in place of one or more hydrogen atoms. Substituents may generally be selected from halogen including -F, -Cl, -Br and -I; lower alkyl including linear, branched and cyclic; lower haloalkyl including fluoroalkyl, chloroalkyl, bromoalkyl and iodoalkyl; -OH; lower alkoxy including linear, branched and cyclic; -SH; lower alkylthio including linear, branched and cyclic; amino, alkylamino, dialkylamino, silyl including alkylsilyl, alkoxysilyl and arylsilyl; nitro; cyano; carbonyl; carboxylic acid, carboxylic ester, carboxylic amide, aminocarbonyl; aminoacyl; carbamate; urea; thiocarbamate; thiourea; ketone; sulfone; sulfonamide; aryl including phenyl, naphthyl and anthracenyl; heteroaryl including 5-member heteroaryls including as pyrrole, imidazole, furan, thiophene, oxazole, thiazole, isoxazole, isothiazole, thiadiazole, triazole, oxadiazole and tetrazole, 6-member heteroaryls including pyridine, pyrimidine, pyrazine and fused heteroaryls including benzofuran, benzothiophene, benzoxazole, benzimidazole, indole, benzothiazole, benzisoxazole and benzisothiazole.

[0225] Preferably -L¹- of formula (V) is substituted with one moiety -L²-Z.

[0226] A further preferred embodiment for -L¹- is disclosed in US7585837B2. Accordingly, a preferred moiety -L¹- is of formula (VI):



wherein

the dashed line indicates attachment to the N-terminal amine functional group of -D and wherein attachment is through the N-terminal amine functional group of -D;

-R¹ and -R² are independently selected from the group consisting of hydrogen, alkyl, alkoxy, alkoxyalkyl, aryl, alkaryl, aralkyl, halogen, nitro, -SO₃H, -SO₂NHR⁵, amino, ammonium, carboxyl, PO₃H₂ and OPO₃H₂;

-R³, -R⁴ and -R⁵ are independently selected from the group consisting of hydrogen, alkyl and aryl;

wherein -L¹- is substituted with -L²-Z and wherein -L¹- is optionally further substituted.


[0227] Suitable substituents for formula (VI) are alkyl (such as C₁₋₆ alkyl), alkenyl (such as C₂₋₆ alkenyl), alkynyl (such as C₂₋₆ alkynyl), aryl (such as phenyl), heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl (such as aromatic 4 to 7 membered heterocycle) or halogen moieties.

[0228] Only in the context of formula (VI) the terms used have the following meaning:

The terms "alkyl", "alkoxy", "alkoxyalkyl", "aryl", "alkaryl" and "aralkyl" mean alkyl radicals of 1-8, preferably 1-4 carbon atoms, e.g. methyl, ethyl, propyl, isopropyl and butyl and aryl radicals of 6-10 carbon atoms, e.g. phenyl and naphthyl. The term "halogen" includes bromo, fluoro, chloro and iodo.

[0229] Preferably -L¹- of formula (VI) is substituted with one moiety -L²-Z.

[0230] A further preferred embodiment for -L¹- is disclosed in WO2002/089789A1. Accordingly, a preferred moiety -L¹- is of formula (VII):



wherein

the dashed line indicates attachment to the N-terminal amine functional group of -D and wherein attachment is through the N-terminal amine functional group of -D;

-L₁- is a bifunctional linking group,

=Y₁ and =Y₂ are independently selected from the group consisting of =O, =S and =NR⁷; -R², -R³, -R⁴, -R⁵, -R⁶ and -R⁷ are independently selected from the group consisting of hydrogen, C₁₋₆ alkyls, C₃₋₁₂ branched alkyls, C₃₋₈ cycloalkyls, C₁₋₆ substituted alkyls, C₃₋₈ substituted cycloalkyls, aryls, substituted aryls, aralkyls, C₁₋₆ heteroalkyls, substituted C₁₋₆ heteroalkyls, C₁₋₆ alkoxy, phenoxy and C₁₋₆ heteroalkoxy;

Ar is a moiety which when included in formula (VII) forms a multi substituted aromatic hydrocarbon or a multi-substituted heterocyclic group;

-X- is a chemical bond or a moiety that is actively transported into a target cell, a hydrophobic moiety or a combination thereof,

y is 0 or 1;

wherein $-L^1-$ is substituted with $-L^2-Z$ and wherein $-L^1-$ is optionally further substituted.

[0231] Only in the context of formula (VII) the terms used have the following meaning:


The term "alkyl" shall be understood to include, e.g. straight, branched, substituted C_{1-12} alkyls, including alkoxy, C_{3-8} cycloalkyls or substituted cycloalkyls.

[0232] The term "substituted" shall be understood to include adding or replacing one or more atoms contained within a functional group or compounds with one or more different atoms.

[0233] Substituted alkyls include carboxyalkyls, aminoalkyls, dialkylaminos, hydroxyalkyls and mercaptoalkyls, substituted cycloalkyls include moieties such as 4-chlorocyclohexyl, aryls include moieties such as naphthyl, substituted aryls include moieties such as 3-bromo-phenyl, aralkyls include moieties such as toluyl, heteroalkyls include moieties such as ethylthiophene, substituted heteroalkyls include moieties such as 3-methoxythiophene, alkoxy includes moieties such as methoxy, and phenoxy includes moieties such as 3-nitrophenoxy. Halo- shall be understood to include fluoro, chloro, iodo and bromo.

[0234] Preferably $-L^1-$ of formula (VII) is substituted with one moiety $-L^2-Z$.

[0235] In another preferred embodiment $-L^1-$ comprises a substructure of formula (VIII)



wherein

the dashed line marked with the asterisk indicates attachment to the N-terminal amine functional group of $-D$ by forming an amide bond;

the unmarked dashed lines indicate attachment to the remainder of $-L^1-$; and


wherein $-L^1-$ is substituted with $-L^2-Z$ and wherein $-L^1-$ is optionally further substituted.

[0236] Preferably $-L^1-$ of formula (VIII) is substituted with one moiety $-L^2-Z$.

[0237] In one embodiment $-L^1-$ of formula (VIII) is not further substituted.

[0238] In another preferred embodiment $-L^1-$ comprises a substructure of formula (IX)





wherein

the dashed line marked with the asterisk indicates attachment to the N-terminal amine functional group of -D by forming a carbamate bond;

the unmarked dashed lines indicate attachment to the remainder of -L¹-; and

wherein -L¹- is substituted with -L²-Z and wherein -L¹- is optionally further substituted.

[0239] Preferably -L¹- of formula (IX) is substituted with one moiety -L²-Z.

[0240] In one embodiment -L¹- of formula (IX) is not further substituted.

[0241] In the prodrugs of the present invention -L²- is a chemical bond or a spacer moiety.

[0242] In one embodiment -L²- is a chemical bond.

[0243] In another embodiment -L²- is a spacer moiety.

When -L²- is other than a single chemical bond, -L²- is preferably -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y1})-, -S(O)₂N(R^{y1})-, -S(O)N(R^{y1})-, -S(O)₂-, -S(O)-, -N(R^{y1})S(O)₂N(R^{y1a})-, -S-, -N(R^{y1})-, -OC(OR^{y1})(R^{y1a})-, -N(R^{y1})C(O)N(R^{y1a})-, -OC(O)N(R^{y1})-, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl or C₂₋₅₀ alkynyl; wherein -T-, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally substituted with one or more -R^{y2}, which are the same or different, and wherein C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y3})-, -S(O)₂N(R^{y3})-, -S(O)N(R^{y3})-, -S(O)₂-, -S(O)-, -N(R^{y3})S(O)₂N(R^{y3a})-, -S-, -N(R^{y3})-, -OC(OR^{y3})(R^{y3a})-, -N(R^{y3})C(O)N(R^{y3a})- and -OC(O)N(R^{y3})-;

-R^{y1} and -R^{y1a} are independently of each other selected from the group consisting of -H-, -T-, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl; wherein -T-, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally substituted with one or more -R^{y2}, which are the same or different, and wherein C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y4})-, -S(O)₂N(R^{y4})-, -S(O)N(R^{y4})-, -S(O)₂-, -S(O)-, -N(R^{y4})S(O)₂N(R^{y4a})-, -S-, -N(R^{y4})-, -OC(OR^{y4})

(R^{y4a})-, -N(R^{y4})C(O)N(R^{y4a})- and -OC(O)N(R^{y4})-;

each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl and 8- to 30-membered heteropolycyclyl; wherein each T is independently optionally substituted with one or more -R^{y2}, which are the same or different;

each -R^{y2} is independently selected from the group consisting of halogen, -CN, oxo (=O), -COOR^{y5}, -OR^{y5}, -C(O)R^{y5}, -C(O)N(R^{y5}R^{y5a}), -S(O)₂N(R^{y5}R^{y5a}), -S(O)N(R^{y5}R^{y5a}), -S(O)₂R^{y5}, -S(O)R^{y5}, -N(R^{y5})S(O)₂N(R^{y5a}R^{y5b}), -SR^{y5}, -N(R^{y5}R^{y5a}), -NO₂, -OC(O)R^{y5}, -N(R^{y5})C(O)R^{y5a}, -N(R^{y5})S(O)₂R^{y5a}, -N(R^{y5})S(O)R^{y5a}, -N(R^{y5})C(O)OR^{y5a}, -N(R^{y5})C(O)N(R^{y5a}R^{y5b}), -OC(O)N(R^{y5}R^{y5a}) and C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different; and

each -R^{y3}, -R^{y3a}, -R^{y4}, -R^{y4a}, -R^{y5}, -R^{y5a} and -R^{y5b} is independently selected from the group consisting of -H and C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different.

[0244] When -L²- is other than a single chemical bond, -L²- is even more preferably -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y1})-, -S(O)₂N(R^{y1})-, -S(O)N(R^{y1})-, -S(O)₂-, -S(O)-, -N(R^{y1})S(O)₂N(R^{y1a})-, -S-, -N(R^{y1})-, -OC(OR^{y1})(R^{y1a})-, -N(R^{y1})C(O)N(R^{y1a})-, -OC(O)N(R^{y1})-, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl or C₂₋₅₀ alkynyl; wherein -T-, C₁₋₂₀ alkyl, C₂₋₂₀ alkenyl and C₂₋₂₀ alkynyl are optionally substituted with one or more -R^{y2}, which are the same or different, and wherein C₁₋₂₀ alkyl, C₂₋₂₀ alkenyl and C₂₋₂₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y3})-, -S(O)₂N(R^{y3})-, -S(O)N(R^{y3})-, -S(O)₂-, -S(O)-, -N(R^{y3})S(O)₂N(R^{y3a})-, -S-, -N(R^{y3})-, -OC(OR^{y3})(R^{y3a})-, -N(R^{y3})C(O)N(R^{y3a})- and -OC(O)N(R^{y3})-;

-R^{y1} and -R^{y1a} are independently of each other selected from the group consisting of -H, -T, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl; wherein -T, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl are optionally substituted with one or more -R^{y2}, which are the same or different, and wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y4})-, -S(O)₂N(R^{y4})-, -S(O)N(R^{y4})-, -S(O)₂-, -S(O)-, -N(R^{y4})S(O)₂N(R^{y4a})-, -S-, -N(R^{y4})-, -OC(OR^{y4})(R^{y4a})-, -N(R^{y4})C(O)N(R^{y4a})- and -OC(O)N(R^{y4})-;

each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicycyl, 8-to 30-membered carbopolycyclyl and 8- to 30-membered heteropolycyclyl; wherein each T is independently optionally substituted with one or more -R^{y2}, which are the same or different;

-R^{y2} is halogen, -CN, oxo (=O), -COOR^{y5}, -OR^{y5}, -C(O)R^{y5}, -C(O)N(R^{y5}R^{y5a}), -S(O)₂N(R^{y5}R^{y5a}), -S(O)N(R^{y5}R^{y5a}), -S(O)₂R^{y5}, -S(O)R^{y5}, -N(R^{y5})S(O)₂N(R^{y5a}R^{y5b}), -SR^{y5}, -N(R^{y5}R^{y5a}), -NO₂, -OC(O)R^{y5}, -N(R^{y5})C(O)R^{y5a}, -N(R^{y5})S(O)₂R^{y5a}, -N(R^{y5})S(O)R^{y5a}, -N(R^{y5})C(O)OR^{y5a}, -N(R^{y5})C(O)N(R^{y5a}R^{y5b}), -OC(O)N(R^{y5}R^{y5a}) or C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different; and

each -R^{y3}, -R^{y3a}, -R^{y4}, -R^{y4a}, -R^{y5}, -R^{y5a} and -R^{y5b} is independently of each other selected from the group consisting of -H and C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different.

[0245] When -L²- is other than a single chemical bond, -L²- is even more preferably -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y1})-, -S(O)₂N(R^{y1})-, -S(O)N(R^{y1})-, -S(O)₂-, -S(O)-, -N(R^{y1})S(O)₂N(R^{y1a})-, -S-, -N(R^{y1})-, -OC(OR^{y1})(R^{y1a})-, -N(R^{y1})C(O)N(R^{y1a})-, -OC(O)N(R^{y1})-, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl or C₂₋₅₀ alkynyl; wherein -T-, C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally substituted with one or more -R^{y2}, which are the same or different, and wherein C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl and C₂₋₅₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R^{y3})-, -S(O)₂N(R^{y3})-, -S(O)N(R^{y3})-, -S(O)₂-, -S(O)-, -N(R^{y3})S(O)₂N(R^{y3a})-, -S-, -N(R^{y3})-, -OC(OR^{y3})(R^{y3a})-, -N(R^{y3})C(O)N(R^{y3a})-and -OC(O)N(R^{y3})-;

-R^{y1} and -R^{y1a} are independently selected from the group consisting of -H, -T, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl;

each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicycyl, 8-to 30-membered carbopolycyclyl and 8- to 30-membered heteropolycyclyl;


each -R^{y2} is independently selected from the group consisting of halogen and C₁₋₆ alkyl; and


each -R^{y3}, -R^{y3a}, -R^{y4}, -R^{y4a}, -R^{y5}, -R^{y1a} and -R^{y5b} is independently of each other selected from the group consisting of -H and C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different.

[0246] Even more preferably, $-L^2-$ is a C_{1-20} alkyl chain, which is optionally interrupted by one or more groups independently selected from $-O-$, $-T-$ and $-C(O)N(R^{y1})-$; and which C_{1-20} alkyl chain is optionally substituted with one or more groups independently selected from $-OH$, $-T$ and $-C(O)N(R^{y6}R^{y6a})$; wherein $-R^{y1}$, $-R^{y6}$ and $-R^{y6a}$ are independently selected from the group consisting of $-H$ and C_{1-4} alkyl and wherein T is selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl and 8- to 30-membered heteropolycyclyl.

[0247] Preferably, $-L^2-$ has a molecular weight in the range of from 14 g/mol to 750 g/mol.

[0248] Preferably, $-L^2-$ comprises a moiety selected from





wherein


dashed lines indicate attachment to the rest of $-L^2-$, $-L^1-$ and/or $-Z$, respectively; and

$-R$ and $-R^a$ are independently of each other selected from the group consisting of $-H$, methyl, ethyl, propyl, butyl, pentyl and hexyl.

[0249] In one preferred embodiment $-L^2-$ has a chain length of 1 to 20 atoms.

[0250] As used herein the term "chain length" with regard to the moiety $-L^2-$ refers to the number of atoms of $-L^2-$ present in the shortest connection between $-L^1-$ and $-Z$.

[0251] Preferably, $-L^2-$ is of formula (i)



wherein

the dashed line marked with the asterisk indicates attachment to $-L^1-$;


the unmarked dashed line indicates attachment to $-Z$;




n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18; and

wherein the moiety of formula (i) is optionally further substituted.

[0252] Preferably, n of formula (i) is 3, 4, 5, 6, 7, 8 or 9. Even more preferably n of formula (i) is 4, 5, 6 or 7. In one embodiment n of formula (i) is 4. In another embodiment n of formula (i) is 5. In another embodiment n of formula (i) is 6.

[0253] In one preferred embodiment the moiety $-L^1-L^2-$ is








wherein

the unmarked dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond; and

the dashed line marked with the asterisk indicates attachment to -Z.

[0254] In one preferred embodiment the moiety $-L^1-L^2-$ is



wherein

the unmarked dashed line indicates the attachment to the N-terminal amine functional group of - by forming an amide bond; and

the dashed line marked with the asterisk indicates attachment to -Z.

[0255] In a preferred embodiment the moiety $-L^1-L^2-$ is of formula (IIca-ii).

[0256] In another preferred embodiment the moiety $-L^1-L^2-$ is of formula (IIcb-iii).

[0257] Preferably, the PTH prodrug of the present invention is of formula (Ia) with $x = 1$.

[0258] Preferably, -Z has a molecular weight ranging from 5 to 200 kDa. Even more preferably, -Z has a molecular weight ranging from 8 to 100 kDa, even more preferably ranging from 10 to 80 kDa, even more preferably from 12 to 60, even more preferably from 15 to 40 and most preferably -Z has a molecular weight of about 20 kDa. In another equally preferred embodiment -Z has a molecular weight of about 40 kDa.

[0259] -Z is a PEG-based polymer, such as a linear, branched or multi-arm PEG-based polymer.


[0260] In one embodiment -Z is a linear PEG-based polymer.

[0261] In another embodiment -Z is a multi-arm PEG-based polymer. Preferably, -Z is a multi-arm PEG-based polymer having at least 4 PEG-based arms.

[0262] Preferably, such multi-arm PEG-based polymer -Z is connected to a multitude of moieties $-L^2-L^1-D$, wherein each moiety $-L^2-L^1-D$ is preferably connected to the end of an arm, preferably to the end of an arm. Preferably such multi-arm PEG-based polymer -Z is connected to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 moieties $-L^2-L^1-D$. Even more preferably such multi-arm PEG-based polymer -Z is connected to 2, 3, 4, 6 or 8 moieties $-L^2-L^1-D$. Even more preferably such multi-arm PEG-based polymer -Z is connected to 2, 4 or 6 moieties $-L^2-L^1-D$, even more preferably such multi-arm PEG-based polymer -Z is connected to 4 or 6 moieties $-L^2-L^1-D$ and most preferably such multi-arm PEG-based polymer -Z is connected to 4 moieties $-L^2-L^1-D$.


[0263] Preferably, such multi-arm PEG-based polymer -Z is a multi-arm PEG derivative as, for instance, detailed in the products list of JenKem Technology, USA (accessed by download from <http://www.jenkemusa.com/Pages/PEGProducts.aspx> on Dec 18, 2014), such as a 4-arm-PEG derivative, in particular a 4-arm-PEG comprising a pentaerythritol core, an 8-arm-PEG derivative comprising a hexaglycerin core and an 8-arm-PEG derivative comprising a tripentaerythritol core. More preferably, the water-soluble PEG-based carrier -Z comprises a moiety selected from:

a 4-arm PEG Amine comprising a pentaerythritol core:



with n ranging from 20 to 500;


an 8-arm PEG Amine comprising a hexaglycerin core:



with n ranging from 20 to 500; and

R = hexaglycerin or tripentaerythritol core structure; and

a 6-arm PEG Amine comprising a sorbitol or dipentaerythritol core:



with n ranging from 20 to 500; and

R = comprising a sorbitol or dipentaerythritol core;

and wherein dashed lines indicate attachment to the rest of the PTH prodrug.

[0264] In a preferred embodiment -Z is a branched PEG-based polymer. In one embodiment -Z is a branched PEG-based polymer having one, two, three, four, five or six branching points. Preferably, -Z is a branched PEG-based polymer having one, two or three branching points. In one embodiment -Z is a branched PEG-based polymer having one branching point. In another embodiment -Z is a branched PEG-based polymer having two branching points. In another embodiment -Z is a branched PEG-based polymer having three branching points.


[0265] A branching point is preferably selected from the group consisting of -N<, -CH< and >C<.

[0266] Preferably, such branched PEG-based moiety -Z has a molecular weight of at least 10 kDa.

[0267] In one embodiment such branched moiety -Z has a molecular weight ranging from and including 10 kDa to 500 kDa, more preferably ranging from and including 10 kDa to 250 Da, even more preferably ranging from and including 10 kDa to 150 kDa, even more preferably ranging from and including 12 kDa to 100 kDa and most preferably ranging from and including 15 kDa to 80 kDa.


[0268] Preferably, such branched moiety -Z has a molecular weight ranging from and including 10 kDa to 80 kDa. In one embodiment the molecular weight is about 10 kDa. In another embodiment the molecular weight of such branched moiety -Z is about 20 kDa. In another embodiment the molecular weight of such branched moiety -Z is about 30 kDa. In another embodiment the molecular weight of such a branched moiety -Z is about 40 kDa. In another embodiment the molecular weight of such a branched moiety -Z is about 50 kDa. In another embodiment the molecular weight of such a branched moiety -Z is about 60 kDa. In another embodiment the molecular weight of such a branched moiety -Z is about 70 kDa. In another embodiment the molecular weight of such a branched moiety -Z is about 80 kDa. Most preferably, such branched moiety -Z has a molecular weight of about 40 kDa.

[0269] Preferably, -Z comprises a moiety



[0270] In an equally preferred embodiment -Z comprises an amide bond.

[0271] Preferably -Z comprises a moiety of formula (a)



wherein

the dashed line indicates attachment to $-\text{L}^2-$ or to the remainder of -Z;

BP^{a} is a branching point and is $-\text{N}<$, $-\text{CR}<$ or $>\text{C}<$;

-R is -H or C_{1-6} alkyl;

a is 0 if BP^{a} is $-\text{N}<$ or $-\text{CR}<$ and n is 1 if BP^{a} is $>\text{C}<$;

$-\text{S}^{\text{a}}-$, $-\text{S}^{\text{a}'}-$, $-\text{S}^{\text{a}''}-$ and $-\text{S}^{\text{a}'''}-$ are independently of each other a chemical bond or are selected from the group consisting of C_{1-50} alkyl, C_{2-50} alkenyl and C_{2-50} alkynyl; wherein C_{1-50} alkyl, C_{2-50} alkenyl and C_{2-50} alkynyl are optionally substituted with one or more $-\text{R}^1$, which are the same or different, and wherein C_{1-50} alkyl, C_{2-50} alkenyl and C_{2-50} alkynyl are optionally interrupted by one or more groups selected from the group consisting of $-\text{T}-$, $-\text{C}(\text{O})\text{O}-$, $-\text{O}-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{N}(\text{R}^2)-$, $-\text{S}(\text{O})_2\text{N}(\text{R}^2)-$, $-\text{S}(\text{O})\text{N}(\text{R}^2)-$, $-\text{S}(\text{O})_2-$, $-\text{S}(\text{O})-$, $-\text{N}(\text{R}^2)\text{S}(\text{O})_2\text{N}(\text{R}^{2\text{a}})-$, $-\text{S}-$, $-\text{N}(\text{R}^2)-$, $-\text{OC}(\text{OR}^2)(\text{R}^{2\text{a}})-$, $-\text{N}(\text{R}^2)\text{C}(\text{O})\text{N}(\text{R}^{2\text{a}})-$ and $-\text{OC}(\text{O})\text{N}(\text{R}^2)-$;

each -T- is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicycyl, 8- to 30-membered carbopolycyclyl and 8- to 30-membered heteropolycyclyl; wherein each -T- is independently optionally substituted with one or more -R¹, which are the same or different;

each -R¹ is independently selected from the group consisting of halogen, -CN, oxo (=O), -COOR³, -OR³, -C(O)R³, -C(O)N(R³R^{3a}), -S(O)₂N(R³R^{3a}), -S(O)N(R³R^{3a}), -S(O)₂R³, -S(O)R³, -N(R³)S(O)₂N(R^{3a}R^{3b}), -SR³, -N(R³R^{3a}), -NO₂, -OC(O)R³, -N(R³)C(O)R^{3a}, -N(R³)S(O)₂R^{3a}, -N(R³)S(O)R^{3a}, -N(R³)C(O)OR^{3a}, -N(R³)C(O)N(R^{3a}R^{3b}), -OC(O)N(R³R^{3a}) and C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different;

each -R², -R^{2a}, -R³, -R^{3a} and -R^{3b} is independently selected from the group consisting of -H and C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different; and

-Pa', -Pa'' and -Pa''' are independently a PEG-based moiety.

[0272] In one embodiment BP^a of formula (a) is -N<.

[0273] In another embodiment BP^a of formula (a) is >C<.

[0274] In a preferred embodiment BP^a of formula (a) is -CR<. Preferably, -R is -H. Accordingly, a of formula (a) is 0.

[0275] In one embodiment -S^a- of formula (a) is a chemical bond.

[0276] In another embodiment -S^a- of formula (a) is C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl, which C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl are optionally interrupted by one or more chemical groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R⁴)-, -S(O)₂N(R⁴)-, -S(O)N(R⁴)-, -S(O)₂-, -S(O)-, -N(R⁴)S(O)₂N(R^{4a})-, -S-, -N(R⁴)-, -OC(OR⁴)(R^{4a})-, -N(R⁴)C(O)N(R^{4a})- and -OC(O)N(R⁴)-; wherein -T- is a 3- to 10-membered heterocyclyl; and -R⁴ and -R^{4a} are independently selected from the group consisting of -H, methyl, ethyl, propyl and butyl.

[0277] Preferably -S^a- of formula (a) is C₁₋₁₀ alkyl which is interrupted by one or more chemical

groups selected from the group consisting of -T-, -C(O)N(R⁴)- and -O-.

[0278] In one embodiment -S^{a'}- of formula (a) is a chemical bond.

[0279] In another embodiment -S^{a'}- of formula (a) is C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl, which C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl are optionally interrupted by one or more chemical groups selected from the group consisting of -C(O)O-, -O-, -C(O)-, -C(O)N(R⁴)-, -S(O)₂N(R⁴)-, -S(O)N(R⁴)-, -S(O)₂-, -S(O)-, -N(R⁴)S(O)₂N(R^{4a})-, -S-, -N(R⁴)-, -OC(OR⁴)(R^{4a})-, -N(R⁴)C(O)N(R^{4a})- and -OC(O)N(R⁴)-; wherein -R⁴ and -R^{4a} are independently selected from the group consisting of -H, methyl, ethyl, propyl and butyl. Preferably -S^{a'}- of formula (a) is selected from the group consisting of methyl, ethyl, propyl and butyl, which are optionally interrupted by one or more chemical groups selected from the group consisting of -O-, -C(O)- and -C(O)N(R⁴)-.

[0280] In one embodiment -S^{a''}- of formula (a) is a chemical bond.

[0281] In another embodiment -S^{a''}- of formula (a) is C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl, which C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl are optionally interrupted by one or more chemical groups selected from the group consisting of -C(O)O-, -O-, -C(O)-, -C(O)N(R⁴)-, -S(O)₂N(R⁴)-, -S(O)N(R⁴)-, -S(O)₂-, -S(O)-, -N(R⁴)S(O)₂N(R^{4a})-, -S-, -N(R⁴)-, -OC(OR⁴)(R^{4a})-, -N(R⁴)C(O)N(R^{4a})- and -OC(O)N(R⁴)-; wherein -R⁴ and -R^{4a} are independently selected from the group consisting of -H, methyl, ethyl, propyl and butyl. Preferably -S^{a''}- of formula (a) is selected from the group consisting of methyl, ethyl, propyl and butyl, which are optionally interrupted by one or more chemical groups selected from the group consisting of -O-, -C(O)- and -C(O)N(R⁴)-.

[0282] In one embodiment -S^{a'''}- of formula (a) is a chemical bond.

[0283] In another embodiment -S^{a'''}- of formula (a) is C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl, which C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkynyl are optionally interrupted by one or more chemical groups selected from the group consisting of -C(O)O-, -O-, -C(O)-, -C(O)N(R⁴)-, -S(O)₂N(R⁴)-, -S(O)N(R⁴)-, -S(O)₂-, -S(O)-, -N(R⁴)S(O)₂N(R^{4a})-, -S-, -N(R⁴)-, -OC(OR⁴)(R^{4a})-, -N(R⁴)C(O)N(R^{4a})- and -OC(O)N(R⁴)-; wherein -R⁴ and -R^{4a} are independently selected from the group consisting of -H, methyl, ethyl, propyl and butyl. Preferably -S^{a'''}- of formula (a) is methyl, ethyl, propyl and butyl, which are optionally interrupted by one or more chemical groups selected from the group consisting of -O-, -C(O)- and -C(O)N(R⁴)-.

[0284] $-Pa'$, $-Pa''$ and $-Pa'''$ of formula (a) independently comprise a PEG-based moiety. Even more preferably, $-Pa'$, $-Pa''$ and $-Pa'''$ of formula (a) independently comprise a PEG-based moiety comprising at least 20% PEG, even more preferably at least 30%, even more preferably at least 40% PEG, even more preferably at least 50% PEG, even more preferably at least 60% PEG, even more preferably at least 70% PEG, even more preferably at least 80% PEG and most preferably at least 90% PEG.

[0285] Preferably, $-Pa'$, $-Pa''$ and $-Pa'''$ of formula (a) independently have a molecular weight ranging from and including 5 kDa to 50 kDa, more preferably have a molecular weight ranging from and including 5 kDa to 40 kDa, even more preferably ranging from and including 7.5 kDa to 35 kDa, even more preferably ranging from and including 7.5 to 30 kDa, even more preferably ranging from and including 10 to 30 kDa.

[0286] In one embodiment $-Pa'$, $-Pa''$ and $-Pa'''$ of formula (a) have a molecular weight of about 5 kDa.

[0287] In another embodiment $-Pa'$, $-Pa''$ and $-Pa'''$ of formula (a) have a molecular weight of about 7.5 kDa.

[0288] In another embodiment $-Pa'$, $-Pa''$ and $-Pa'''$ of formula (a) have a molecular weight of about 10 kDa.

[0289] In another embodiment $-Pa'$, $-Pa''$ and $-Pa'''$ of formula (a) have a molecular weight of about 12.5 kDa.

[0290] In another embodiment $-Pa'$, $-Pa''$ and $-Pa'''$ of formula (a) have a molecular weight of about 15 kDa.

[0291] In another embodiment $-Pa'$, $-Pa''$ and $-Pa'''$ of formula (a) have a molecular weight of about 20 kDa.


[0292] In one embodiment $-Z$ comprises one moiety of formula (a).


[0293] In another embodiment $-Z$ comprises two moieties of formula (a).

[0294] In another embodiment $-Z$ comprises three moieties of formula (a).

[0295] Preferably, $-Z$ is a moiety of formula (a).

[0296] More preferably, $-Z$ comprises a moiety of formula (b)





wherein

the dashed line indicates attachment to $-L^2-$ or to the remainder of $-Z$; and

m and p are independently of each other an integer ranging from and including 150 to 1000; preferably an integer ranging from and including 150 to 500; more preferably an integer ranging from and including 200 to 500; and most preferably an integer ranging from and including 400 to 500.


[0297] Preferably, m and p of formula (b) are the same integer.

[0298] Most preferably m and p of formula (b) are about 450.

[0299] Preferably, -Z is a moiety of formula (b).

[0300] Preferably, the total mass of the PTH prodrug of the present invention is at least 10 kDa, such as at least 12 kDa, such as at least 15 kDa, such as at least 20 kDa or such as at least 30 kDa. It is preferred that the total mass of the PTH prodrug of the present invention is at most 250 kDa, such as at most 200 kDa, 180 kDa, 150 kDa or 100 kDa.


[0301] In a preferred embodiment the PTH prodrug of the present invention is of formula (Ile-i):



wherein

the unmarked dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond; and


the dashed line marked with the asterisk indicates attachment to a moiety



wherein

m and p are independently an integer ranging from and including 400 to 500.


[0302] In another preferred embodiment the PTH prodrug of the present invention is of formula (IIf-i):



wherein

the unmarked dashed line indicates the attachment to the N-terminal amine functional group of -D by forming an amide bond; and

the dashed line marked with the asterisk indicates attachment to a moiety



wherein

m and p are independently an integer ranging from and including 400 to 500.

[0303] In a preferred embodiment the residual activity of the PTH prodrug of the present invention is less than 10%, more preferably less than 1%, even more preferably less than 0.1%, even more preferably less than 0.01%, even more preferably less than 0.001% and most preferably less than 0.0001%.

[0304] As used herein the term "residual activity" refers to the activity exhibited by the PTH prodrug of the present invention with the PTH moiety bound to a carrier in relation to the activity exhibited by the corresponding free PTH. In this context the term "activity" refers to binding to an activation of the PTH/PTHrP1 receptor resulting in activation of adenylate cyclase to generate cAMP, phospholipase C to generate intracellular calcium or osteoblastic expression of RANKL (which binds to RANK (Receptor Activator of Nuclear Factor kB) on osteoclasts. It is understood that measuring the residual activity of the PTH prodrug of the present invention takes time during which a certain amount of PTH will be released from the PTH prodrug of the present invention and that such released PTH will distort the results measured for the PTH prodrug. It is thus accepted practice to test the residual activity of a prodrug with a conjugate in which the drug moiety, in this case PTH, is non-reversibly, i.e. stably, bound to a carrier, which as closely as possible resembles the structure of the PTH prodrug for which residual activity is to be measured.

[0305] A suitable assay for measuring PTH activity and the residual activity of the PTH prodrug of the present invention, preferably in the form of a stable analog, is for example measuring cAMP production from HEK293 cells over-expressing the PTH/PTHrP1 receptor (Hohenstein et

al., Journal of Pharmaceutical and Biomedical Analysis, September 2014, 98: 345-350) or a cell-based assay to detect cyclicAMP release, detected by homogenous time-resolved fluorescence (HTRF) or ELISA, that has been validated according to ICHQ2(R1) (http://www.criver.com/files/pdfs/bps/bp_r_in_vitro_bioassays.aspx).

[0306] It was surprisingly found that using N-terminal attachment of -L¹- and using a branched PEG carrier for -Z, i.e. a 2x 20 kDa PEG, results in a particularly low residual activity. Reduced residual activity is desirable as it reduces side-effects.

[0307] It was also surprisingly found that PTH produgs of the present invention are capable of achieving a stable plasma profile of PTH which ensures physiological serum and urinary calcium levels or even reduced urinary calcium levels.

[0308] Preferably, after subcutaneous administration the pharmacokinetic profile of a PTH prodrug of the present invention exhibits a peak to trough ratio of less than 4 within one injection interval.

[0309] As used herein the term "injection interval" refers to the time between two consecutive administrations of the pharmaceutical composition of the present invention.

[0310] As used herein the term "peak to trough ratio" refers to the ratio between the highest plasma concentration and the lowest plasma concentration of PTH released from the PTH prodrug of the present invention within the time period between two consecutive administrations to a non-human primate, preferably to a cynomolgus monkey.

[0311] The time period between two consecutive subcutaneous administrations, i.e. the administration interval, is preferably at least 24 hours, such as 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, every 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, one week, two weeks, three weeks or four weeks.

[0312] In one embodiment the time period between two consecutive subcutaneous administrations is 24 hours.

[0313] In another embodiment the time period between two consecutive subcutaneous administrations is 48 hours.

[0314] In another embodiment the time period between two consecutive subcutaneous administrations is 72 hours.

[0315] In another embodiment the time period between two consecutive subcutaneous administrations is 96 hours.

[0316] In another embodiment the time period between two consecutive subcutaneous administrations is 120 hours.

[0317] In another embodiment the time period between two consecutive subcutaneous administrations is 144 hours.

[0318] In another embodiment the time period between two consecutive subcutaneous administrations is one week.

[0319] The peak to trough ratio measured in each administration interval is less than 4, preferably less than 3.8, more preferably less than 3.6, even more preferably less than 3.4, even more preferably less than 3.2, even more preferably less than 3, even more preferably less than 2.8, even more preferably less than 2.6, even more preferably less than 2.4, even more preferably less than 2.2 and most preferably less than 2.

[0320] Another aspect of the present invention is a pharmaceutical composition comprising at least one PTH prodrug of the present invention and at least one excipient.

[0321] Preferably, the pharmaceutical composition comprising at least one PTH prodrug of the present invention has a pH ranging from and including pH 3 to pH 8. More preferably, the pharmaceutical composition has a pH ranging from and including pH 4 to pH 6. Most preferably, the pharmaceutical composition has a pH ranging from and including pH 4 to pH 5.

[0322] In one embodiment the pharmaceutical composition comprising at least one PTH prodrug of the present invention and at least one excipient is a liquid or suspension formulation.

[0323] In another embodiment the pharmaceutical composition comprising at least one PTH prodrug of the present invention and at least one excipient is a dry formulation.

[0324] Such liquid, suspension or dry pharmaceutical composition comprises at least one excipient. Excipients used in parenteral formulations may be categorized as, for example, buffering agents, isotonicity modifiers, preservatives, stabilizers, anti-adsorption agents, oxidation protection agents, viscosifiers/viscosity enhancing agents or other auxiliary agents. However, in some cases, one excipient may have dual or triple functions. Preferably, the at least one excipient comprised in the pharmaceutical composition of the present invention is selected from the group consisting of

1. (i) Buffering agents: physiologically tolerated buffers to maintain pH in a desired range, such as sodium phosphate, bicarbonate, succinate, histidine, citrate, acetate, sulphate, nitrate, chloride and pyruvate; antacids such as $\text{Mg}(\text{OH})_2$ or ZnCO_3 may also be used;
2. (ii) Isotonicity modifiers: to minimize pain that can result from cell damage due to osmotic pressure differences at the injection depot; glycerin and sodium chloride are examples; effective concentrations can be determined by osmometry using an assumed osmolality of 285-315 mOsmol/kg for serum;
3. (iii) Preservatives and/or antimicrobials: multidose parenteral formulations require the

addition of preservatives at a sufficient concentration to minimize risk of patients becoming infected upon injection and corresponding regulatory requirements have been established; typical preservatives include m-cresol, phenol, methylparaben, ethylparaben, propylparaben, butylparaben, chlorobutanol, benzyl alcohol, phenylmercuric nitrate, thimerosal, sorbic acid, potassium sorbate, benzoic acid, chlorocresol and benzalkonium chloride;

4. (iv) Stabilizers: Stabilisation is achieved by strengthening of the protein-stabilising forces, by destabilisation of the denatured state or by direct binding of excipients to the protein; stabilizers may be amino acids such as alanine, arginine, aspartic acid, glycine, histidine, lysine and proline; sugars such as glucose, sucrose and trehalose; polyols such as glycerol, mannitol and sorbitol; salts such as potassium phosphate and sodium sulphate; chelating agents such as EDTA and hexaphosphate, ligands such as divalent metal ions (zinc and calcium); other salts or organic molecules such as phenolic derivatives; in addition, oligomers or polymers such as cyclodextrins, dextran, dendrimers, PEG or PVP or protamine or HSA may be used;
5. (v) Anti-adsorption agents: Mainly ionic or non-ionic surfactants or other proteins or soluble polymers are used to coat or adsorb competitively to the inner surface of the formulation's container; e.g., poloxamer (Pluronic F-68), PEG dodecyl ether (Brij 35), polysorbate 20 and 80, dextran, polyethylene glycol, PEG-polyhistidine, BSA and HSA and gelatins; chosen concentration and type of excipient depends on the effect to be avoided but typically a monolayer of surfactant is formed at the interface just above the CMC value;
6. (vi) Oxidation protection agents: antioxidants such as ascorbic acid, ectoine, methionine, glutathione, monothioglycerol, morin, polyethylenimine (PEI), propyl gallate and vitamin E; chelating agents such as citric acid, EDTA, hexaphosphate and thioglycolic acid may also be used;
7. (vii) Viscosifiers or viscosity enhancers: in case of a suspension retard settling of the particles in the vial and syringe and are used in order to facilitate mixing and resuspension of the particles and to make the suspension easier to inject (i.e., low force on the syringe plunger); suitable viscosifiers or viscosity enhancers are, for example, carbomer viscosifiers like Carbopol 940, Carbopol Ultrez 10, cellulose derivatives like hydroxypropylmethylcellulose (hypromellose, HPMC) or diethylaminoethyl cellulose (DEAE or DEAE-C), colloidal magnesium silicate (Veegum) or sodium silicate, hydroxyapatite gel, tricalcium phosphate gel, xanthans, carrageenans like Satia gum UTC 30, aliphatic poly(hydroxy acids), such as poly(D,L- or L-lactic acid) (PLA) and poly(glycolic acid) (PGA) and their copolymers (PLGA), terpolymers of D,L-lactide, glycolide and caprolactone, poloxamers, hydrophilic poly(oxyethylene) blocks and hydrophobic poly(oxypropylene) blocks to make up a triblock of poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) (e.g. Pluronic®), polyetherester copolymer, such as a polyethylene glycol terephthalate/polybutylene terephthalate copolymer, sucrose acetate isobutyrate (SAIB), dextran or derivatives thereof, combinations of dextrans and PEG, polydimethylsiloxane, collagen, chitosan, polyvinyl alcohol (PVA) and derivatives, polyalkylimides, poly (acrylamide-co-diallyldimethyl ammonium (DADMA)), polyvinylpyrrolidone (PVP), glycosaminoglycans (GAGs) such as dermatan sulfate,

chondroitin sulfate, keratan sulfate, heparin, heparan sulfate, hyaluronan, ABA triblock or AB block copolymers composed of hydrophobic A-blocks, such as polylactide (PLA) or poly(lactide-co-glycolide) (PLGA) and hydrophilic B-blocks, such as polyethylene glycol (PEG) or polyvinyl pyrrolidone; such block copolymers as well as the abovementioned poloxamers may exhibit reverse thermal gelation behavior (fluid state at room temperature to facilitate administration and gel state above sol-gel transition temperature at body temperature after injection);

8. (viii) Spreading or diffusing agent: modifies the permeability of connective tissue through the hydrolysis of components of the extracellular matrix in the intrastitial space such as hyaluronic acid, a polysaccharide found in the intercellular space of connective tissue; a spreading agent hyaluronidase temporarily decreases the viscosity of the extracellular matrix and promotes diffusion of injected drugs; and
9. (ix) Other auxiliary agents: such as wetting agents, viscosity modifiers, antibiotics, hyaluronidase; acids and bases such as hydrochloric acid and sodium hydroxide are auxiliary agents necessary for pH adjustment during manufacture.

[0325] The pharmaceutical composition comprising at least one PTH prodrug may be administered to a patient by various modes of administration, such as via topical, enteral or parenteral administration and by methods of external application, injection or infusion, including intraarticular, periarticular, intradermal, subcutaneous, intramuscular, intravenous, intraosseous, intraperitoneal, intrathecal, intracapsular, intraorbital, intravitreal, intratympanic, intravesical, intracardiac, transtracheal, subcuticular, subcapsular, subarachnoid, intraspinal, intraventricular, intrasternal injection and infusion, direct delivery to the brain via implanted device allowing delivery of the invention to brain tissue or brain fluids (e.g., Ommaya Reservoir), direct intracerebroventricular injection or infusion, injection or infusion into brain or brain associated regions, injection into the subchoroidal space, retro-orbital injection and ocular instillation. Preferably the pharmaceutical composition comprising at least one PTH prodrug is administered via subcutaneous injection.

[0326] Subcutaneous injection is preferably done with a syringe and needle or with a pen injector, even more preferably with a pen injector.

[0327] Another aspect of the present invention is the use of the PTH prodrug or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising at least one PTH prodrug of the present invention as a medicament.

[0328] Another aspect of the present invention is the PTH prodrug or a pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising at least one PTH prodrug of the present invention for use in the treatment of a disease which can be treated with PTH.

[0329] Preferably, said disease is selected from the group consisting of hypoparathyroidism,

hyperphosphatemia, osteoporosis, osteomalacia, arthritis, osteogenesis imperfecta, fibrous dysplasia, Paget's disease, humoral hypercalcemia associated with malignancy, osteopenia, periodontal disease, bone fracture, alopecia, and thrombocytopenia. Most preferably said disease is hypoparathyroidism.

[0330] In one embodiment the patient undergoing the treatment of the present invention is a mammalian patient, preferably a human patient.

[0331] Another aspect of the present invention is the use of the PTH prodrug or a pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising at least one PTH prodrug of the present invention for the manufacture of a medicament for treating a disease which can be treated with PTH.

[0332] Preferably, said disease is selected from the group consisting of hypoparathyroidism, hyperphosphatemia, osteoporosis, osteomalacia, arthritis, osteogenesis imperfecta, fibrous dysplasia, Paget's disease, humoral hypercalcemia associated with malignancy, osteopenia, periodontal disease, bone fracture, alopecia and thrombocytopenia. Most preferably said disease is hypoparathyroidism.

[0333] In one embodiment the disease to be treated with the PTH prodrug or a pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising at least one PTH prodrug of the present invention occurs in a mammalian patient, preferably in a human patient.

[0334] In a preferred embodiment, the present invention relates to a PTH prodrug or pharmaceutically acceptable salt thereof or a pharmaceutical composition of the present invention, for use in the treatment of hypoparathyroidism via subcutaneous injection.

Examples

Materials and Methods

[0335] Side chain protected PTH(1-34) (SEQ ID NO:51) on TCP resin having Boc protected N-terminus and ivDde protected side chain of Lys26 (synthesized by Fmoc-strategy) was obtained from CASLO ApS, Kongens Lyngby, Denmark and Peptide Specialty Laboratories GmbH, Heidelberg, Germany.

[0336] Side chain protected PTH(1-34) on TCP resin having Fmoc protected N-terminus (synthesized by Fmoc-strategy) was obtained from CASLO ApS, Kongens Lyngby, Denmark and Peptide Specialty Laboratories GmbH, Heidelberg, Germany.

[0337] PEG 2x20 kDa maleimide, Sunbright GL2-400MA and PEG 2x10 kDa maleimide, Sunbright GL2-200MA were purchased from NOF Europe N.V., Grobbendonk, Belgium. S-Trityl-6-mercaptophexanoic acid was purchased from Polypeptide, Strasbourg, France. HATU was obtained from Merck Biosciences GmbH, Schwalbach/Ts, Germany. Fmoc-N-Me-Asp(OBn)-OH was obtained from Peptide International Inc., Louisville, KY, USA. Fmoc-Aib-OH was purchased from Iris Biotech GmbH, Marktredwitz, Germany. All other chemicals and reagents were purchased from Sigma Aldrich GmbH, Taufkirchen, Germany, unless a different supplier is mentioned.

[0338] Compound **11a** (examples 11-15) was synthesized following the procedure described in patent WO29095479A2, example 1.

[0339] Syringes equipped with polyethylenene frits (MultiSynTech GmbH, Witten, Germany) were used as reaction vessels or for washing steps of peptide resins.

[0340] General procedure for the removal of ivDde protecting group from side chain protected PTH on resin: The resin was pre-swollen in DMF for 30 min and the solvent was discarded. The ivDde group was removed by incubating the resin with DMF/hydrazine hydrate 4/1 (v/v, 2.5 mL/g resin) for 8 × 15 min. For each step fresh DMF/hydrazine hydrate solution was used. Finally, the resin was washed with DMF (10 ×), DCM (10 ×) and dried *in vacuo*.

[0341] General procedure for the removal of Fmoc protecting group from protected PTH on resin: The resin was pre-swollen in DMF for 30 min and the solvent was discarded. The Fmoc group was removed by incubating the resin with DMF/piperidine/DBU 96/2/2 (v/v/v, 2.5 mL/g resin) for 3 × 10 min. For each step fresh DMF/piperidine/DBU solution was used. Finally, the resin was washed with DMF (10 ×), DCM (10 ×) and dried *in vacuo*.

RP-HPLC purification:

[0342] For preparative RP-HPLC a Waters 600 controller and a 2487 Dual Absorbance Detector was used, equipped with the following columns: Waters XBridge™ BEH300 Prep C18 5 µm, 150 × 10 mm, flow rate 6 mL/min, or Waters XBridge™ BEH300 Prep C18 10 µm, 150 × 30 mm, flow rate 40 mL/min. Linear gradients of solvent system A (water containing 0.1 % TFA v/v) and solvent system B (acetonitrile containing 0.1 % TFA v/v) were used. HPLC fractions containing product were pooled and lyophilized if not stated otherwise.

Flash Chromatography:

[0343] Flash chromatography purifications were performed on an Isolera One system from Biotage AB, Sweden, using Biotage KP-Sil silica cartridges and n-heptane and ethyl acetate as eluents. Products were detected at 254 nm.

Ion exchange chromatography:

[0344] Ion exchange chromatography (IEX) was performed using an Amersham Bioscience AEKTAbasic system equipped with a MacroCap SP cation exchanger column (Amersham Bioscience/GE Healthcare). 17 mM acetic acid pH 4.5 (solvent A) and 17 mM acetic acid, 1 M NaCl, pH 4.5 (solvent B) were used as mobile phases.

Size exclusion chromatography:

[0345] Size exclusion chromatography (SEC) was performed using an Amersham Bioscience AEKTAbasic system equipped with HiPrep 26/10 desalting columns (Amersham Bioscience/GE Healthcare). 0.1 % (v/v) acetic acid was used as mobile phase.

[0346] For *in vitro* release kinetics studies of compound 31, a pH 7.40 buffer (100 mM phosphate, 10 mM L-methionine, 3 mM EDTA, 0.05 % Tween-20) was used instead of 0.1 % AcOH as mobile phase.

Analytical methods

[0347] Analytical ultra-performance LC (UPLC)-MS was performed on a Waters Acquity system equipped with a Waters BEH300 C18 column (2.1 × 50 mm, 1.7 µm particle size, flow: 0.25 mL/min; solvent A: water containing 0.04% TFA (v/v), solvent B: acetonitrile containing 0.05% TFA (v/v)) coupled to a LTQ Orbitrap Discovery mass spectrometer from Thermo Scientific or coupled to a Waters Micromass ZQ.

[0348] Quantitative measurements of serum calcium (sCa), urinary calcium and serum phosphorous (sP) were performed on a Roche-Hitachi P800 modular biochemistry instrument.

Quantification of plasma total PTH(1-34) concentrations:

[0349] Plasma total PTH(1-34) concentrations were determined by quantification of a signature peptide close to the N-terminus (sequence: IQLMHNLGK) and a C-terminal signature peptide (sequence: LQDVHNF) after plasma protein precipitation, followed by sequential digestion with Endoproteinase Lys-C (origin: Lysobacter enzymogenes) and Endoproteinase Glu-C (origin: Staphylococcus aureus V8) of the supernatant. Subsequently, analysis by reversed phase liquid chromatography and detection by mass spectrometry (RP-HPLC-MS) was performed.

[0350] Calibration standards of PTH(1-34) conjugate in blank plasma were prepared as

follows: The PTH(1-34) conjugate formulation was pre-diluted with formulation buffer to aqueous standard solutions ranging from 5 to 300 µg/mL PTH(1-34) eq (concentration range 1) and 0.5 µg/mL to 100 µg/mL PTH(1-34) eq (concentration range 2), respectively. Each aqueous standard solution was then diluted 1:100 with thawed heparinized plasma to obtain concentration ranges from 50 to 3000 ng/mL PTH(1-34) eq (dilution with rat plasma of concentration range 1) and 5 to 1000 ng/mL PTH(1-34) eq (dilution with monkey plasma of concentration range 2).

[0351] These solutions were used for the generation of a calibration curve. Calibration curves were weighted $1/\times 2$ for both signature peptides. For quality control, three samples independent from the calibration standard solutions were prepared accordingly. Concentrations at the lower end (3-5-fold concentration of the respective LLOQ), the middle range (0.05 - 0.1-fold concentration of the respective ULOQ) and the upper end (0.5-0.8-fold concentration of the respective ULOQ).

[0352] Sample preparation volumes can be altered depending on the targeted signal response after sample preparation. Processing procedure of the protein precipitation is described here for the analysis of plasma samples originated in monkey species. Protein precipitation was carried out by addition of 200 µL of precooled (5-10 °C) methanol to 100 µL of the plasma sample. 180 µL of the supernatant were transferred into a new well-plate and evaporated to dryness (under a gentle nitrogen stream at 45 °C). 50 µL of reconstitution solvent (50 mM Tris 0.5 mM CaCl₂ buffer, adjusted to pH 8.0) were used to dissolve the residue. Proteolytic digestion was performed as follows:

20 µg of Lys-C (order number 125-05061, Wako Chemicals GmbH, Neuss, Germany) were dissolved in 80 µL of 10 mM acetic acid. 3 µL of the Lys-C solution were added to each cavity and samples incubated for 15 hours at 37°C. Afterwards 10 µg of Glu-C (order number V1651, Promega GmbH, Mannheim, Germany) were dissolved in 25 µL water, added to each cavity and incubation continued for 1.5 hours at 37°C. After incubation samples were acidified with 2 µL water/formic acid 4:6 (v/v) and 10 µL were injected into the UPLC-MS system.

[0353] LC-MS analysis was carried out by using an Agilent 1290 UPLC coupled to an Agilent 6460 TripleQuad mass spectrometer via an ESI probe. Chromatography was performed on a Waters Acquity BEH300 C18 analytical column (1.7 µm particle size; column dimensions used are 50x2.1 mm for analysis of samples originated from rat species or 100x2.1 mm for analysis of samples originated from monkey species) with pre-filter at a flow rate of 0.30 mL/min (T = 60 °C). Water (UPLC grade) containing 0.1 % formic acid (v/v) was used as mobile phase A and acetonitrile (UPLC grade) with 0.1 % formic acid as mobile phase B.

[0354] The gradient system for the analysis of samples originated from rat plasma comprised a linear increase from 0.1 % B to 40 % B in 7 min. The gradient system for the analysis of samples originated from monkey plasma comprised a linear increase from 8.0 % B to 11.0 % B in 6 min, followed by a linear increase to 26% B in 4 minutes. Mass analysis was performed in multiple reaction monitoring (MRM) mode, monitoring the transitions m/z 437.2 to 131.0 and m/z 352.3 to 463.0.

[0355] Alternatively, quantification of plasma total PTH(1-34) concentrations was performed according to the following procedure:

Plasma total PTH(1-34) concentrations were determined by quantification of a signature peptide close to the N-terminus (sequence: IQLMHNLGK) and a C-terminal signature peptide (sequence: LQDVHNF) after plasma protein precipitation, followed by sequential digestion with Endoproteinase Lys-C (origin: *Lysobacter enzymogenes*) and Endoproteinase Glu-C (origin: *Staphylococcus aureus* V8) of the supernatant. Subsequently, analysis by reversed phase liquid chromatography and detection by mass spectrometry (RP-HPLC-MS) was performed.

[0356] Calibration standards of PTH(1-34) conjugate in blank heparinized plasma were prepared in concentration ranges from 50 to 3000 ng/mL PTH(1-34) eq (dilution with rat plasma) and 1 to 1000 ng/mL PTH(1-34) eq (dilution with monkey plasma).

[0357] These solutions were used for the generation of a calibration curve. For quality control, three samples independent from the calibration standard solutions were prepared accordingly. Concentrations at the lower end (3-5-fold concentration of the respective LLOQ), the middle range (0.05 - 0.1-fold concentration of the respective ULOQ) and the upper end (0.5-0.8-fold concentration of the respective ULOQ).

[0358] Sample preparation volumes can be altered depending on the targeted signal response after sample preparation. Processing procedure of the protein precipitation is described here for the analysis of plasma samples originated in rat species. Protein precipitation was carried out by addition of 100 µL of precooled (5-10 °C) methanol to 50 µL of the plasma sample. 60 µL of the supernatant were transferred into a new well-plate and evaporated to dryness (under a gentle nitrogen stream at 45 °C). 60 µL of reconstitution solvent (50 mM Tris 0.5 mM CaCl₂ buffer, adjusted to pH 8.0) were used to dissolve the residue. Proteolytic digestion was performed as follows:

20 µg of Lys-C (order number 125-05061, Wako Chemicals GmbH, Neuss, Germany) were dissolved in 80 µL of 10 mM acetic acid. 3 µL of the Lys-C solution were added to each cavity and samples incubated for 15 hours at 37°C. Afterwards 10 µg of Glu-C (order number V1651, Promega GmbH, Mannheim, Germany) were dissolved in 25 µL water, and 1.5 µL of the Glu-C solution added to each cavity and incubation continued for 1.5 hours at 37°C. After incubation samples were acidified with 2 µL water/formic acid 4:6 (v/v) and 10 µL were injected into the UPLC-MS system.

[0359] Chromatography was performed on a Waters Acquity BEH300 C18 analytical column (1.7 µm particle size; column dimensions 50 × 2.1 mm). Water (UPLC grade) containing 0.1 % formic acid (v/v) was used as mobile phase A and acetonitrile (UPLC grade) with 0.1 % formic acid as mobile phase B.

Quantification of plasma PEG concentrations:

[0360] Plasma total PEG concentrations were determined by quantification of the polymeric part of PTH(1-34) conjugates after plasma protein precipitation and enzymatic digestion of the supernatant. Analysis by size exclusion chromatography and detection by mass spectrometry (SEC-MS) followed.

[0361] Calibration standards of PTH(1-34) conjugate in blank heparinized monkey plasma were prepared in concentration ranges from 50 to 1200 ng/mL PEG equivalents.

[0362] These solutions were used for the generation of a quadratic calibration curve. Calibration curves were weighted $1/x$. For quality control, three samples independent from the calibration standard solutions were prepared accordingly. Concentrations at the lower end (2-4-fold concentration of the LLOQ), the middle range (0.1 - 0.2-fold concentration of the ULOQ) and the upper end (0.8-fold concentration of the ULOQ). Protein precipitation was carried out by addition of 200 μ L of precooled (5-10 °C) methanol to 100 μ L of the plasma sample. 180 μ L of the supernatant were transferred into a new well-plate and evaporated to dryness (under a gentle nitrogen stream at 45 °C). 50 μ L of reconstitution solvent (50 mM Tris 0.5 mM CaCl_2 buffer, adjusted to pH 8.0) were used to dissolve the residue. Proteolytic digestion was performed as follows: 20 μ g of Lys-C (order number 125-05061, Wako Chemicals GmbH, Neuss, Germany) were dissolved in 80 μ L of 10 mM acetic acid. 3 μ L of the Lys-C solution were added to each cavity and samples incubated for 15 hours at 37°C. Afterwards 10 μ g of Glu-C (order number V1651, Promega GmbH, Mannheim, Germany) were dissolved in 25 μ L water, and 1.5 μ L of the Glu-C solution added to each cavity and incubation continued for 1.5 hours at 37°C. After incubation samples were acidified with 2 μ L water/formic acid 4:6 (v/v) and 5 μ L were injected into the SEC-MS system.

[0363] SEC-MS analysis was carried out by using an Agilent 1290 UPLC coupled to an Agilent 6460 TripleQuad mass spectrometer via an ESI probe. Acquisition of a distinct precursor ion of the polymer was achieved by applying high voltage in-source fragmentation (200-300V) at the MS interface. Chromatography was performed on a TOSOH TSK Gel SuperAW3000 analytical column (4.0 μ m particle size; column dimensions 150 $\times$ 6.0 mm) at a flow rate of 0.50 mL/min (T = 65 °C). Water (UPLC grade) containing 0.1 % formic acid (v/v) was used as mobile phase A and acetonitrile (UPLC grade) with 0.1 % formic acid as mobile phase B. The chromatographic setup for sample analysis comprises an isocratic elution of 50% B over 8 minutes.

[0364] Mass analysis was performed in single reaction monitoring (SRM) mode, monitoring the transition m/z 133.1 to 45.1.

[0365] Due to the reversible nature of the attachment of $-L^1-$ to $-D$, measurements for PTH receptor activity were made using stable analogs of the PTH prodrugs of the present invention, i.e. they were made using similar structures to those of the PTH prodrugs of the present invention, which instead of a reversible attachment of $-Z$ to $-D$ have a stable attachment.


[0366] This was necessary, because the PTH prodrugs of the present invention would release

PTH in the course of the experiment and said released PTH would have influenced the result.

Example 1

Synthesis of linker reagent 1f

[0367] Linker reagent **1f** was synthesized according to the following scheme:



[0368] To a solution of N-methyl-N-Boc-ethylenediamine (2 g, 11.48 mmol) and NaCNBH₃ (819 mg, 12.63 mmol) in MeOH (20 mL) was added 2,4,6-trimethoxybenzaldehyde (2.08 g, 10.61 mmol) portion wise. The mixture was stirred at rt for 90 min, acidified with 3 M HCl (4 mL) and stirred further 15 min. The reaction mixture was added to saturated NaHCO₃ solution (200 mL) and extracted 5 × with DCM. The combined organic phases were dried over Na₂SO₄ and the solvents were evaporated *in vacuo*. The resulting N-methyl-N-Boc-N'-Tmob-ethylenediamine **1a** was dried in high vacuum and used in the next reaction step without further purification.

Yield:	3.76 g (11.48 mmol, 89 % purity, 1a : double Tmob protected product = 8 :1)
--------	--

MS:	m/z 355.22 = [M+H] ⁺ , (calculated monoisotopic mass = 354.21).
-----	--

[0369] To a solution of **1a** (2 g, 5.65 mmol) in DCM (24 mL) COMU (4.84 g, 11.3 mmol), N-Fmoc-N-Me-Asp(OBn)-OH (2.08 g, 4.52 mmol) and 2,4,6-collidine (2.65 mL, 20.34 mmol) were added. The reaction mixture was stirred for 3 h at rt, diluted with DCM (250 mL) and washed 3 × with 0.1 M H₂SO₄ (100 mL) and 3 × with brine (100 mL). The aqueous phases were re-extracted with DCM(100 mL). The combined organic phases were dried over Na₂SO₄, filtrated and the residue concentrated to a volume of 24 mL. **1b** was purified using flash chromatography.

Yield:	5.31 g (148 %, 6.66 mmol)
MS:	m/z 796.38 = [M+H] ⁺ , (calculated monoisotopic mass = 795.37)

[0370] To a solution of **1b** (5.31 g, max. 4.52 mmol ref. to N-Fmoc-N-Me-Asp(OBn)-OH) in THF (60 mL) DBU (1.8 mL, 3 % v/v) was added. The solution was stirred for 12 min at rt, diluted with DCM (400 mL) and washed 3 × with 0.1 M H₂SO₄ (150 mL) and 3 x with brine (150 mL). The aqueous phases were re-extracted with DCM (100 mL). The combined organic phases were dried over Na₂SO₄ and filtrated. **1c** was isolated upon evaporation of the solvent and used in the next reaction without further purification.

MS:	m/z 574.31 = [M+H] ⁺ , (calculated monoisotopic mass = 573.30).
-----	--

[0371] **1c** (5.31 g, 4.52 mmol, crude) was dissolved in acetonitrile (26 mL) and COMU (3.87 g, 9.04 mmol), 6-tritylmercaptohexanoic acid (2.12 g, 5.42 mmol) and 2,4,6-collidine (2.35 mL, 18.08 mmol) were added. The reaction mixture was stirred for 4 h at rt, diluted with DCM (400 mL) and washed 3 × with 0.1 M H₂SO₄ (100 mL) and 3 × with brine (100 mL). The aqueous phases were re-extracted with DCM(100 mL). The combined organic phases were dried over Na₂SO₄, filtered and **1d** was isolated upon evaporation of the solvent. Product **1d** was purified using flash chromatography.

Yield:	2.63 g (62 %, 94 % purity)
MS:	m/z 856.41 = [M+H] ⁺ , (calculated monoisotopic mass = 855.41)

[0372] To a solution of **1d** (2.63 g, 2.78 mmol) in i-PrOH (33 mL) and H₂O (11 mL) was added LiOH (267 mg, 11.12 mmol) and the reaction mixture was stirred for 70 min at rt. The mixture was diluted with DCM (200 mL) and washed 3 × with 0.1 M H₂SO₄ (50 mL) and 3 × with brine (50 mL). The aqueous phases were re-extracted with DCM(100 mL). The combined organic phases were dried over Na₂SO₄, filtered and **1e** was isolated upon evaporation of the solvent. **1e** was purified using flash chromatography.

Yield:	2.1 g (88%)
MS:	m/z 878.4 = [M+Na] ⁺ , (calculated monoisotopic mass = 837.40)

[0373] To a solution of **1e** (170 mg, 0.198 mmol) in anhydrous DCM (4 mL) were added DCC (123 mg, 0.59 mmol), and a catalytic amount of DMAP. After 5 min, N-hydroxy-succinimide (114 mg, 0.99 mmol) was added and the reaction mixture was stirred at rt for 1 h. The reaction mixture was filtered, the solvent was removed *in vacuo* and the residue was taken up in 90 % acetonitrile plus 0.1 % TFA (3.4 mL). The crude mixture was purified by RP-HPLC. Product fractions were neutralized with 0.5 M pH 7.4 phosphate buffer and concentrated. The remaining aqueous phase was extracted with DCM and **1f** was isolated upon evaporation of the solvent.


Yield: 154 mg (81%)


MS: m/z 953.4 = [M+H]⁺, (calculated monoisotopic mass = 952.43).

Example 2

Synthesis of linker reagent 2g

[0374]





[0375] 4-Methoxytriphenylmethyl chloride (3.00 g, 9.71 mmol) was dissolved in DCM (20 mL) and added dropwise under stirring to a solution of ethylenediamine **2a** (6.5 mL, 97.3 mmol) in DCM (20 mL). The reaction mixture was stirred for 2 h at rt after which it was diluted with diethyl ether (300 mL), washed 3 × with brine/0.1 M NaOH 30/1 (v/v) and once with brine. The organic phase was dried over Na₂SO₄ and **2b** was isolated upon evaporation of the solvent.

Yield:	3.18 g (98%)
--------	--------------

[0376] Mmt protected intermediate **2b** (3.18 g, 9.56 mmol) was dissolved in DCM (30 mL). 6-(Tritylthio)-hexanoic acid (4.48 g, 11.5 mmol), PyBOP (5.67 g, 10.9 mmol) and DIPEA (5.0 mL, 28.6 mmol) were added and the mixture was stirred for 30 min at rt. The solution was diluted with diethyl ether (250 mL), washed 3 × with brine/0.1 M NaOH 30/1 (v/v) and once with brine. The organic phase was dried over Na₂SO₄ and the solvent was removed in vacuo. **2c** was purified using flash chromatography.

Yield:	5.69 g (85 %)
MS:	m/z 705.4 = [M+H] ⁺ , (calculated monoisotopic mass = 704.34)

[0377] Compound **2c** (3.19 g, 4.53 mmol) was dissolved in anhydrous THF (50 mL), 1 M BH₃·THF solution in THF (8.5 mL, 8.5 mmol) was added and the mixture was stirred for 16 h at rt. More 1 M BH₃·THF solution in THF (14 mL, 14.0 mmol) was added and the mixture was stirred for further 16 h at rt. Methanol (8.5 mL) and N,N'-dimethyl-ethylenediamine (3.00 mL, 27.9 mmol) were added and the mixture was heated under reflux for 3 h. The mixture was allowed to cool down and ethyl acetate (300 mL) was added. The solution was washed 2 × with aqueous Na₂CO₃ and 2 × with aqueous NaHCO₃. The organic phase was dried over Na₂SO₄ and the solvent was removed in vacuo to obtain **2d**.

Yield:	3.22 g (103 %)
MS:	m/z 691.4 = [M+H] ⁺ , (calculated monoisotopic mass = 690.36)

[0378] Di-tert-butyl dicarbonate (2.32 g, 10.6 mmol) and DIPEA (3.09 mL, 17.7 mmol) were dissolved in DCM (5 mL) and added to a solution of **2d** (2.45 g, 3.55 mmol) in DCM (5 mL). The mixture was stirred for 30 min at rt. The solution was concentrated *in vacuo* and purified by flash chromatography to obtain product **2e**.

Yield:	2.09 g (74 %)
MS:	m/z 791.4 = [M+H] ⁺ , (calculated monoisotopic mass = 790.42)

[0379] Compound **2e** (5.01 g, 6.34 mmol) was dissolved in acetonitrile (80 mL). 0.4 M aqueous HCl (80 mL) followed by acetonitrile (20 mL) was added and the mixture was stirred for 1 h at rt. The pH was adjusted to pH 5.5 by addition of aqueous 5 M NaOH. The organic solvent was removed *in vacuo* and the remaining aqueous solution was extracted 4 x with DCM. The combined organic phases were dried over Na₂SO₄ and the solvent was removed *in vacuo* to obtain product **2f**.

Yield:	4.77 g (95 %)
MS:	m/z 519.3 = [M+H] ⁺ , (calculated monoisotopic mass = 518.30)


[0380] Compound **2f** (5.27 g, 6.65 mmol) was dissolved in DCM (30 mL) and added to a solution of p-nitrophenyl chloroformate (2.01 g, 9.98 mmol) in DCM (25 mL). 2,4,6-trimethylpyridine (4.38 mL, 33.3 mmol) was added and the solution was stirred for 45 min at rt. The solution was concentrated *in vacuo* and purified by flash chromatography to obtain product **2g**.

Yield:	4.04 g (89 %)
MS:	m/z 706.32 = [M+Na] ⁺ , (calculated monoisotopic mass = 683.30)

Example 3

Synthesis of permanent S1 PTH(1-34) conjugate 3

[0381]



3

[0382] Side chain protected PTH(1-34) on TCP resin having Fmoc protected N-terminus was Fmoc deprotected according to the procedure given in Materials and Methods. A solution of 6-


tritylmercaptohexanoic acid (62.5 mg, 160 μ mol), PyBOP (80.1 mg, 154 μ mol) and DIPEA (53 μ L, 306 μ mol) in DMF (2 mL) was added to 0.21 g (51 μ mol) of the resin. The suspension was agitated for 80 min at rt. The resin was washed 10 $\times$ with DMF, 10 $\times$ with DCM and dried *in vacuo*. Cleavage of the peptide from the resin and removal of protecting groups was achieved by adding 10 mL cleavage cocktail 100/3/3/2/1 (v/w/v/v/v) TFA/DTT/TES/water/thioanisole and agitating the suspension for 1 h at rt. Crude **3** was precipitated in pre-cooled diethyl ether (-18 $^{\circ}$ C). The precipitate was dissolved in ACN/water and purified by RP-HPLC. The product fractions were freeze-dried.

Yield:	36 mg (14 %), 3*8 TFA
MS:	m/z 1062.31 = [M+4H] ⁴⁺ , (calculated monoisotopic mass for [M+4H] ⁴⁺ = 1062.30).

Example 4

Synthesis of permanent K26 PTH(1-34) conjugate **4**

[0383]




[0384] Side chain protected PTH(1-34) on TCP resin having Boc protected N-terminus and ivDde protected side chain of Lys26 was ivDde deprotected according to the procedure given in Materials and Methods. A solution of 6-tritylmercaptohexanoic acid (107 mg, 273 μ mol), PyBOP (141 mg, 273 μ mol) and DIPEA (95 μ L, 545 μ mol) in DMF (3 mL) was added to 0.80 g (90.9 μ mol) of the resin. The suspension was agitated for 1 h at rt. The resin was washed 10 $\times$ with DMF, 10 $\times$ with DCM and dried *in vacuo*. Cleavage of the peptide from the resin and removal of protecting groups was achieved by adding 6 mL cleavage cocktail 100/3/3/2/1 (v/w/v/v/v) TFA/DTT/TES/water/thioanisole and agitating the suspension for 1 h at rt. Crude **4** was precipitated in pre-cooled diethyl ether (-18 $^{\circ}$ C). The precipitate was dissolved in ACN/water and purified by RP-HPLC. The product fractions were freeze-dried.

Yield:	40 mg (8 %), 4*8 TFA
MS:	m/z 1062.30 = [M+4H] ⁴⁺ , (calculated monoisotopic mass for [M+4H] ⁴⁺ = 1062.30).

Example 5

Synthesis of transient S1 PTH(1-34) conjugate

[0385]




[0386] Side chain protected PTH(1-34) on TCP resin having Fmoc protected N-terminus was Fmoc deprotected according to the procedure given in Materials and Methods. A solution of Fmoc-Aib-OH (79 mg, 244 μ mol), PyBOP (127 mg, 244 μ mol) and DIPEA (64 μ L, 365 μ mol) in DMF (1.5 mL) was added to 0.60 g (61 μ mol) of the resin. The suspension was agitated for 16 h at rt. The resin was washed 10 $\times$ with DMF and Fmoc-deprotected as described above. A solution of **2g** (167 mg, 244 μ mol) and DIPEA (64 μ L, 365 μ mol) in DMF (1.5 mL) was added to the resin. The suspension was agitated for 24 h at rt. The resin was washed 10 $\times$ with DMF, 10 $\times$ with DCM and dried *in vacuo*. Cleavage of the peptide from the resin and removal of protecting groups was achieved by adding 7 mL cleavage cocktail 100/3/3/2/1 (v/w/v/v/v) TFA/DTT/TES/water/thioanisole and agitating the suspension for 1 h at rt. Crude **5** was precipitated in pre-cooled diethyl ether (-18 $^{\circ}$ C). The precipitate was dissolved in ACN/water and purified by RP-HPLC. The product fractions were freeze-dried.

Yield:	78 mg (24 %), 5*9 TFA
MS:	m/z 1101.59 = $[M+4H]^{4+}$, (calculated monoisotopic mass for $[M+4H]^{4+}$ = 1101.57).

Example 6

Synthesis of transient S1 PTH(1-34) conjugate 6

[0387]



[0388] Side chain protected PTH(1-34) on TCP resin having Fmoc protected N-terminus was


Fmoc deprotected according to the procedure given in Materials and Methods. A solution of Fmoc-Ala-OH (32 mg, 102 μ mol), PyBOP (53 mg, 102 μ mol) and DIPEA (27 μ L, 152 μ mol) in DMF (3 mL) was added to 0.25 g (25 μ mol) of the resin. The suspension was shaken for 1 h at rt. The resin was washed 10 x with DMF, 10 x with DCM and dried under vacuum. Fmoc-deprotection was performed as described above. A solution of **2g** (69 mg, 102 μ mol) and DIPEA (27 μ L, 152 μ mol) in DMF (3 mL) was added to the resin. The suspension was agitated for 1.5 h at rt. The resin was washed 10 x with DMF, 10 x with DCM and dried *in vacuo*. Cleavage of the peptide from the resin and removal of protecting groups was achieved by adding 3 mL cleavage cocktail 100/3/3/2/1 (v/w/v/v/v) TFA/DTT/TES/water/thioanisole and agitating the suspension for 1 h at rt. Crude **6** was precipitated in pre-cooled diethyl ether (-18 °C). The precipitate was dissolved in ACN/water and purified by RP-HPLC. The product fractions were freeze-dried.

Yield:	25 mg (18 %), 6*9 TFA
MS:	m/z 1098.75 = $[M+4H]^{4+}$, (calculated monoisotopic mass for $[M+4H]^{4+}$ = 1098.07).

Example 7

Synthesis of transient S1 PTH(1-34) conjugate **7**

[0389]




[0390] Side chain protected PTH(1-34) on TCP resin having Fmoc protected N-terminus was Fmoc deprotected according to the procedure given in Materials and Methods. A solution of Fmoc-Ser(Trt)-OH (117 mg, 205 μ mol), PyBOP (108 mg, 207 μ mol) and DIPEA (53 μ L, 305 μ mol) in DMF (2 mL) was added to 0.50 g (51 μ mol) of the resin. The suspension was agitated for 1 h at rt. The resin was washed 10 x with DMF, 10 x with DCM and dried under vacuum. Fmoc-deprotection was performed as described above. A solution of **2g** (144 mg, 211 μ mol) and DIPEA (53 μ L, 305 μ mol) in DMF (1.8 mL) was added to the resin. The suspension was shaken for 7 h at rt. The resin was washed 10 x with DMF, 10 x with DCM and dried *in vacuo*. Cleavage of the peptide from the resin and removal of protecting groups was achieved by adding 6 mL cleavage cocktail 100/3/3/2/1 (v/w/v/v/v) TFA/DTT/TES/water/thioanisole and agitating the suspension for 1 h at rt. Crude **7** was precipitated in pre-cooled diethyl ether (-18 °C). The precipitate was dissolved in ACN/water and purified by RP-HPLC. The product fractions were freeze-dried.

Yield:	54 mg (20 %), 7*9 TFA
MS:	m/z 1102.08 = [M+4H] ⁴⁺ , (calculated monoisotopic mass for [M+4H] ⁴⁺ = 1102.07).

Example 8

Synthesis of transient S1 PTH(1-34) conjugate 8

[0391]




[0392] Side chain protected PTH(1-34) on TCP resin having Fmoc protected N-terminus was Fmoc deprotected according to the procedure given in Materials and Methods. A solution of Fmoc-Leu-OH (36 mg, 102 μ mol), PyBOP (53 mg, 102 μ mol) and DIPEA (27 μ L, 152 μ mol) in DMF (3 mL) was added to 0.25 g (25 μ mol) of the resin. The suspension was agitated for 1 h at rt. The resin was washed 10 x with DMF, 10 x with DCM and dried under vacuum. Fmoc-deprotection was performed as described above. A solution of **2g** (69 mg, 102 μ mol) and DIPEA (27 μ L, 152 μ mol) in DMF (3 mL) was added to the resin. The suspension was agitated for 1.5 h at rt. The resin was washed 10 x with DMF, 10 x with DCM and dried *in vacuo*. Cleavage of the peptide from the resin and removal of protecting groups was achieved by adding 3 mL cleavage cocktail 100/3/3/2/1 (v/w/v/v/v) TFA/DTT/TES/water/thioanisole and agitating the suspension for 1 h at rt. Crude **8** was precipitated in pre-cooled diethyl ether (-18 °C). The precipitate was dissolved in ACN/water and purified by RP-HPLC. The product fractions were freeze-dried.

Yield:	31 mg (22 %), 8*9 TFA
MS:	m/z 1109.32 = [M+4H] ⁴⁺ , (calculated monoisotopic mass for [M+4H] ⁴⁺ = 1108.58).

Example 9

Synthesis of transient S1 PTH(1-34) conjugate 9

[0393]

**9**


[0394] Side chain protected PTH(1-34) on TCP resin having Fmoc protected N-terminus was Fmoc deprotected according to the procedure given in Materials and Methods. A solution of **1e** (182 mg, 213 μ mol), PyBOP (111 mg, 213 μ mol) and DIPEA (93 μ L, 532 μ mol) in DMF (5 mL) was added to 2.00 g (107 μ mol) of the resin. The suspension was agitated for 16 h at rt. The resin was washed 10 x with DMF, 10 x with DCM and dried under vacuum. Cleavage of the peptide from the resin and removal of protecting groups was achieved by adding 20 mL cleavage cocktail 100/3/3/2/1 (v/w/v/v/v) TFA/DTT/TES/water/thioanisole and agitating the suspension for 1 h at rt. Crude **9** was precipitated in pre-cooled diethyl ether (-18 °C). The precipitate was dissolved in ACN/water and purified by RP-HPLC. The product fractions were freeze-dried.

Yield:	47 mg (8 %), 9 *9 TFA
MS:	m/z 1108.58 = $[M+4H]^{4+}$, (calculated monoisotopic mass for $[M+4H]^{4+}$ = 1108.57).

Example 10

Synthesis of transient K26 PTH(1-34) conjugate **10**

[0395]

**10**

S11


[0396] Side chain protected PTH(1-34) on TCP resin having Boc protected N-terminus and ivDde protected side chain of Lys26 was ivDde deprotected according to the procedure given in Materials and Methods. A solution of **1f** (867 mg, 910 μ mol) and DIPEA (0.24 mL, 1.36 mmol) in DMF (5 mL) was added to 1.91 g (227 μ mol) of the resin. The suspension was agitated for 1 h at rt. The resin was washed 10 x with DMF, 10 x with DCM and dried under vacuum. Cleavage of the peptide from the resin and removal of protecting groups was achieved by adding 20 mL cleavage cocktail 100/3/3/2/1 (v/w/v/v/v) TFA/DTT/TES/water/thioanisole and shaking the suspension for 1 h at rt. Crude **10** was precipitated in pre-cooled diethyl ether (-18 °C). The precipitate was dissolved in ACN/water and purified by RP-HPLC. The product fractions were freeze-dried.


Yield:	92 mg (7 %), 10*9 TFA
MS:	m/z 1108.58 = $[M+4H]^{4+}$, (calculated monoisotopic mass for $[M+4H]^{4+}$ = 1108.57).

Example 11

Synthesis of low molecular weight transient S1 PEG conjugate **11b**

[0397]






[0398] 0.15 mL of a 0.5 M NaH₂PO₄ buffer (pH 7.4) was added to 0.5 mL of a 20 mg/mL solution of thiol 5 (10 mg, 1.84 μmol) in 1/1 (v/v) acetonitrile/water containing 0.1 % TFA (v/v). The solution was incubated at rt for 10 min after which 238 μL of a 10 mg/mL solution of maleimide **11a** (2.4 mg, 2.21 μmol) in 1/1 (v/v) acetonitrile/water containing 0.1 % TFA (v/v) were added. The solution was incubated for 20 min at rt. 10 μL TFA was added and the mixture was purified by RP-HPLC. The product fractions were freeze-dried to obtain **11b**.

Yield:	3.1 mg (26 %), 11b *9 TFA
MS:	m/z 1097.00 = [M+4H] ⁴⁺ , (calculated monoisotopic mass for [M+5H] ⁵⁺ = 1096.99).

Example 12

Synthesis of low molecular weight transient S1 PEG conjugate **12**

[0399]




[0400] Conjugate **12** was synthesized as described for **11b** by using thiol **6** (10 mg, 1.85 μmol) and maleimide **11a** (2.4 mg, 2.21 μmol).

Yield:	10 mg (83 %), 12 *9 TFA
MS:	m/z 1094.20 = [M+4H] ⁴⁺ , (calculated monoisotopic mass for [M+4H] ⁴⁺ = 1094.19).

Example 16

Synthesis of permanent 2×20 kDa S1 PEG conjugate 16

[0407]




[0408] 772 μL of a solution containing thiol **3** (19.4 mg/mL, 15 mg, 3.54 μmol) and 2.5 mg/mL Boc-L-Met in 1/1 (v/v) acetonitrile/water containing 0.1 % TFA (v/v) were added to 1.87 mL of a solution containing PEG 2x20 kDa maleimide (Sunbright GL2-400MA, 187 mg, 4.32 μmol) and 2.5 mg/mL Boc-L-Met in water containing 0.1 % TFA (v/v). 0.5 M NaH_2PO_4 buffer (0.66 mL, pH 7.0) was added and the mixture was stirred for 30 min at rt. 10 μL of a 270 mg/mL solution of 2-mercaptoethanol in water was added. The mixture was stirred for 5 min at rt and 0.33 mL 1 M HCl were added. Conjugate **16** was purified by IEX followed by RP-HPLC using a linear gradient of solvent system A (water containing 0.1 % AcOH v/v) and solvent system B (acetonitrile containing 0.1 % AcOH v/v). The product containing fractions were freeze-dried.

Yield:	97 mg (2.01 μ mol, 57 %) conjugate 16*8 AcOH
--------	---

Example 17

Synthesis of permanent 2x20 kDa K26 PEG conjugate 17

[0409]




[0410] Conjugate **17** was prepared as described for **16** by reaction of thiol **4** (15 mg, 3.53 μ mol) and PEG 2x20 kDa maleimide (Sunbright GL2-400MA, 187 mg, 4.32 μ mol).

Yield:	80 mg (1.79 μ mol, 51 %) conjugate 17*8 AcOH
--------	---

Example 18

Synthesis of transient 2x20 kDa S1 PEG conjugate 18

[0411]




[0412] Conjugate **18** was prepared as described for **16** by reaction of thiol **5** (37 mg, 8.40 μ mol) and PEG 2x20 kDa maleimide (Sunbright GL2-400MA, 445 mg, 9.24 μ mol). The reaction was quenched by addition of 50 μ L TFA without prior addition of 2-mercaptoethanol. Conjugate **18** was purified by IEX followed by SEC for desalting. The product containing fractions were freeze-dried.

Yield:	161 mg (3.33 μ mol, 40 %) conjugate 18 *9 AcOH
--------	---

Example 19

Synthesis of transient 2x20 kDa S1 PEG conjugate 19

[0413]




[0414] Conjugate **19** was prepared as described for **16** by reaction of thiol **7** (27 mg, 6.14 μ mol) and PEG 2x20 kDa maleimide (Sunbright GL2-400MA, 325 mg, 7.50 μ mol).

Yield:	249 mg (5.16 μ mol, 84 %) conjugate 19 *9 AcOH
--------	---

Example 20

Synthesis of transient 2x20 kDa S1 PEG conjugate 20

[0415]




[0416] Conjugate **20** was prepared as described for **16** by reaction of thiol **9** (38 mg, 8.59 μ mol) and PEG 2x20 kDa maleimide (Sunbright GL2-400MA, 455 mg, 9.45 μ mol). The reaction was quenched by addition of 50 μ L TFA without prior addition of 2-mercaptoethanol. Conjugate **20** was purified by IEX followed by SEC for desalting. The product containing fractions were freeze-dried.

Yield:	194 mg (4.01 μ mol, 47 %) conjugate 20 *9 AcOH
--------	---

Example 21

Synthesis of transient 2x20 kDa K26 PEG conjugate 21

[0417]



[0418] Conjugate **21** was prepared as described for **16** by reaction of thiol **10** (34 mg, 7.58 μ mol) and PEG 2x20 kDa maleimide (Sunbright GL2-400MA, 401 mg, 9.26 μ mol).

Yield:	256 mg (5.30 μ mol, 70 %) conjugate 21 *9 AcOH
--------	---

Example 22**In vitro release kinetics of transient low molecular weight PEG conjugates**

[0419] Conjugates **11b**, **12**, **13**, **14** and **15** were dissolved in pH 7.4 phosphate buffer (60 mM NaH_2PO_4 , 3 mM EDTA, 0.01 % Tween-20, adjusted to pH 7.4 by NaOH) containing 0.05 mg/mL pentafluorophenol as internal standard at a concentration of approximately 1 mg conjugate/mL. The solutions were filtered sterile and incubated at 37°C. At time points, aliquots were withdrawn and analysed by RP-HPLC and ESI-MS. The fraction of released PTH at a particular time point was calculated from the ratio of UV peak areas of liberated PTH and PEG conjugate. The % released PTH was plotted against incubation time. Curve-fitting software was applied to calculate the corresponding half times of release.

[0420] Results:

For conjugate **11b** a release half life time of 3.2 d was obtained.

For conjugate **12** a release half life time of 8.7 d was obtained.

For conjugate **13** a release half life time of 10.8 d was obtained.

For conjugate **14** a release half life time of 25.3 d was obtained.

For conjugate **15** a release half life time of 6.9 d was obtained.

Example 23**In vitro release kinetics of transient 2x20 kDa PEG conjugates**

[0421] Conjugates **18**, **19**, **20** and **21** were dissolved in pH 7.4 phosphate buffer (60 mM NaH_2PO_4 , 3 mM EDTA, 0.01 % Tween-20, adjusted to pH 7.4 by NaOH) containing 0.08 mg/mL pentafluorophenol as internal standard at a concentration of approximately 5 mg conjugate/mL. The solutions were filtered sterile and incubated at 37°C. At time points, aliquots were withdrawn and analysed by RP-HPLC. The fraction of released PTH at a particular time point was calculated from the ratio of UV peak areas of liberated PTH and PEG conjugate. The

% released PTH was plotted against incubation time. Curve-fitting software was applied to calculate the corresponding half times of release.

[0422] Results:

For conjugate **18** a release half life time of 2.8 d was obtained.

For conjugate **19** a release half life time of 13.4 d was obtained.

For conjugate **20** a release half life time of 1.3 d was obtained.

For conjugate **21** a release half life time of 7.1 d was obtained.

Example 24

PTH receptor activity of permanent 2x20 kDa PEG conjugates 16 and 17 in cell based assay

[0423] The residual PTH activity of permanently PEGylated conjugates **16** and **17** was quantified by measuring cAMP production from HEK293 cells over-expressing the PTH/PTHrP1 receptor (Hohenstein A, Hebell M, Zikry H, El Ghazaly M, Mueller F, Rohde, J. Development and validation of a novel cell-based assay for potency determination of human parathyroid hormone (PTH), Journal of Pharmaceutical and Biomedical Analysis September 2014, 98: 345-350). PTH(1-34) from NIBSC (National Institute for Biological Standards and Control, UK) was used as reference standard.

[0424] Results:

For conjugate **16** a receptor activity of 0.12 % was found relative to PTH(1-34) reference.

For conjugate **17** a receptor activity of 0.11 % was found relative to PTH(1-34) reference.

[0425] The results indicate an effective lowering of receptor activity in the permanent 2x20 kDa PEG conjugates **16** and **17**. It can be concluded that similar conjugates with transiently Ser1 or Lys26 linked PTH (like e.g. **18** and **21**) are suitable PTH prodrugs providing low residual receptor activity. Direct analysis of transient conjugates in the cell assay is not possible due to linker cleavage under the assay conditions. The released PTH would influence the assay result.

Example 25

Pharmacokinetic study of permanent 2x20 kDa PEG conjugates 16 and 17 in rats

[0426] Male Wistar rats (6 weeks, 230-260 g) received either a single intravenous (2 groups, n = 3 animals each) or a single subcutaneous (2 groups, n = 3 animals each) administration of **16** or **17** at doses of 29 µg/rat PTH_{eq} and 31 µg/rat PTH_{eq} respectively. Blood samples were collected up to 168 h post dose, and plasma was generated. Plasma PTH(1-34) concentrations were determined by quantification of the N-terminal signature peptide (sequence: IQLMHNLGK) and the C-terminal signature peptide (sequence: LQDVHNF) after LysC and GluC digestion as described in Materials and Methods.

[0427] Results: Dose administrations were well tolerated with no visible signs of discomfort during administration and following administration. No dose site reactions were observed any time throughout the study. After intravenous injection of **16** and **17** the total PTH(1-34) t_{max} was observed at 15 min (earliest time point analyzed), followed by a slow decay in total PTH(1-34) content with a half life time of approx. 13 h and 11 h respectively. After subcutaneous injection the total PTH(1-34) concentration peaked at a t_{max} of 24 h for both **16** and **17**, followed by a slow decay in total PTH(1-34) content with half life times of approx. 1.5 days for both conjugates. The bioavailability was approx. 40 % and 60 % respectively. Similar PK curves were obtained for the N- and the C-terminal signature peptide up to 168 h post dose, indicating the presence of intact PTH(1-34) in the conjugate.

[0428] The favourable long lasting PK and the stability of PTH in the conjugates indicate the suitability of the permanent 2x20 kDa PEG model compounds as slow releasing PTH prodrugs after subcutaneous injection. It can be concluded that similar conjugates with transiently Ser1 (like e.g. **18**) or Lys26 linked PTH are suitable PTH prodrugs providing long lasting levels of released bioactive PTH.

Example 26**Pharmacokinetic study of transient 2x20 kDa S1 PEG conjugate 19 in cynomolgus monkeys**

[0429] Male non naive cynomolgus monkeys (2-4years, 3.7-5.4 kg) received a single subcutaneous (n = 3 animals) administration of **19** at a dose of 70 µg/kg PTH_{eq}. Blood samples were collected up to 504 h post dose, and plasma was generated. Total plasma PTH(1-34) concentrations were determined by quantification of the N-terminal signature peptide (sequence: IQLMHNLGK) and the C-terminal signature peptide (sequence: LQDVHNF) after

LysC and GluC digestion as described in Materials and Methods. The PEG concentrations were determined using the method described in Materials and Methods.

[0430] Results: Dose administrations were well tolerated with no visible signs of discomfort during administration. One animal showed visible signs of discomfort 72 h post dose, but recovered the days after. No dose site reactions were observed any time throughout the study. The total PTH(1-34) concentration peaked at a $t_{\max}$ of 24 h, followed by a slow decay in total PTH(1-34) content with a half life time of approx. 2.5 d for the N-terminal signature peptide and 0.9 d for the C-terminal signature peptide. The PEG concentration peaked at $t_{\max}$ of 24 h, followed by a slow decay in PEG concentration with a half life time of 3.5 d.

[0431] It can be concluded that conjugate **19** is a suitable prodrug for sustained delivery of PTH.

Example 27

Pharmacokinetic study of transient 2x20 kDa S1 PEG conjugate **18** in cynomolgus monkeys

[0432] Non naive cynomolgus monkeys (2-3 years, 2.5-4 kg) received daily subcutaneous (n = 2 animals - 1 male / 1 female) administration of **18** at dose levels of 0.2, 0.5 and 1 $\mu\text{g/kg}$ PTH_{eq} for 28 days. Blood samples were collected up to 28 days (at days 1, 13 and 27 samples were collected at pre-dose, 2 h, 4 h, 8 h, 12 h and 24 h post-dose) and plasma was generated. Plasma PTH(1-34) concentrations were determined by quantification of the N-terminal signature peptide (sequence: IQLMHNLGK) and the C-terminal signature peptide (sequence: LQDVHNF) after LysC and GluC digestion as described in Materials and Methods.

[0433] Results: All dose administrations were performed without incident. No dose site reactions were observed any time throughout the study. Dose linearity was observed in the three groups. Dose stacking was observed from day 1 compared with day 13 and day 27. Total PTH(1-34) concentrations were quantified via the N-terminal signature peptide (sequence: IQLMHNLGK) at steady state (during day 27).

[0434] A low peak-to-trough ratio of total PTH(1-34) for all dose groups of below 3 was observed after daily subcutaneous application at steady state in cynomolgus monkeys. As free peptide concentrations at steady state are correlated to total PTH(1-34) concentration, the peak-to-trough ratio for the free peptide is below 4 in cynomolgus monkeys.

Example 28

Pharmacodynamic actions in thyroparathyroidectomised (TPTx) rats during a 28-days study with daily subcutaneous injections with conjugate 18 or PTH(1-84)

[0435] This study was performed in order to test and compare the effect of daily subcutaneous injection of compound **18** and PTH(1-84), the current standard of care, in an animal disease model relevant for investigating treatment of hypoparathyroidism (HP). Rats subjected to thyroparathyroidectomy (TPTx) by blunt dissection are unable to produce parathyroid hormone, PTH, the major regulator of calcium homeostasis. Hence, TPTx rats develop hypocalcemia and hyperphosphatemia characteristic of HP. 17 weeks old female SD TPTx rats (n = 9/group) were dosed subcutaneously for 28 days with compound **18** (5 µg PTH eq/kg/d; 1.2 nmol/kg/d, in 10 mM succinic acid, 46 g/L mannitol, pH 4.0), PTH(1-84) (70 µg PTH eq/kg/d; 7.3 nmol/kg/d; in 10 mM citrate, mannitol 39.0 g/L, pH 5.0) or vehicle. Additionally, one group of sham operated rats (n = 9) representing normophysiological background control were also given vehicle. Serum calcium (sCa) and phosphorous (sP) levels in the animals were measured pre- and post-dose on days 1, 6, 12 and 27. Moreover, bone turnover markers (P1NP and CTx) were measured and bone quality assessed by ex vivo pQCT.


[0436] Results: The average sCa in the TPTx rats pre-dosing at day 1 was 8.3 mg/dL compared to 10.9 mg/dL in the sham operated control rats. The sP values were 8.7 mg/dL and 5.9 mg/dL, respectively. Compound **18** given daily at 1.2 nmol/kg elevated sCa to near-normal levels while lowering sP within a few days of administration. At day 12 (day 5 at steady state with compound 18) sCa had stabilised at normal level (10.7 mg/dL) in this group of animals (compound 18/sham-control ratio = 1.01) as opposed to the hypocalcemic level (8.1 mg/dL) measured in the PTH(1-84) treated rats (PTH(1-84)/sham-control ratio = 0.76). Additionally, the 24-hour urinary Ca excretion at day 12 was comparable between the animals treated with compound **18** and sham-control. Bone mineral density (BMD) and bone mineral content (BMC) were increased in TPTx controls as seen in HP patients. Treatment with Compound **18** decreased BMD, BMC and area in parallel with an increase in CTx compared to sham and vehicle-treated TPTx animals. A significant increase in trabecular BMD was observed in animals dosed with PTH(1-84) compared to both control groups.


[0437] It was concluded that compound **18** at a dosage even as low as less than 20% of the molar equivalent of the here tested dose of PTH(1-84) was able to maintain sCa at a level comparable to the sCa level in sham-control animals (here representing normal level) over a 24 hour period. In contrast, PTH(1-84) at a dose of 7.3 nmol/kg/d did not lead to increase in sCa as compared to the levels in the vehicle-injected TPTx rats. However, a minimal decrease in sP was observed in the PTH(1-84) dosed animals confirming exposure and response to PTH(1-84) in the rats. Following the 28-days of treatment with compound **18**, trabecular and cortical BMD in vertebrae were within normal range, whereas an anabolic effect was observed for PTH(1-84) on trabecular and cortical bone in vertebrae.

Example 29

Synthesis of linker reagent 29h

[0438]





[0439] To a solution of compound **29a** (250 g, 294 mmol, 1 eq) in dichloromethane (1 L) was added a solution of Na_2CO_3 (187 g, 1.8 mol, 6 eq) in H_2O (1 L). The reaction solution was stirred at 15-30°C for 0.5 hour. TLC (DCM/MeOH = 10: 1, R_f = 0.5) showed the starting material was consumed completely. The organic layer was separated and the aqueous phase was extracted with dichloromethane (1 L). The organic layers were combined and washed with brine (800 mL), then dried with anhydrous Na_2SO_4 , filtered and concentrated in vacuum to give compound **29b** as a yellow oil.

Yield:	200 g, 272 mmol, 93 %
--------	-----------------------

Four reactions were carried out in parallel.

[0440] To a solution of compound **29b** (50 g, 68.1 mmol, 1 eq) and Fmoc-5-aminovaleric acid (25.4 g, 74.9 mmol, 1.1 eq), DIPEA (61.6 g, 477 mmol, 83.3 mL, 7 eq) in acetonitrile (500 mL) was added drop-wise T3P 50% [EtOAc] (130 g, 204 mmol, 122 mL, 3 eq) at 15-30°C for 1 hour. After addition, the reaction mixture was stirred at 15-30°C for 18 hours. TLC (Petroleum ether/Ethyl acetate = 1: 1, R_f = 0.5) showed the starting material was consumed completely. The four reactions were combined for workup. The mixture was diluted with water (3 L), then adjusted to pH= 3-4 with 0.5 N HCl solution. The mixture was extracted with EtOAc (3 L), then the aqueous phase was extracted with EtOAc (2 L). The organic layers were combined and washed with brine (1 L), then dried with anhydrous Na_2SO_4 , filtered and concentrated in vacuum to give the crude product as yellow oil. The crude product was purified by column chromatography on silica gel with petroleum ether/ethyl acetate to give compound **29c** as a yellow solid.

Yield:	220 g, 199 mmol, 73 %
--------	-----------------------

Four reactions were carried out in parallel.

[0441] To a solution of compound **29c** (55 g, 52 mmol, 1 eq) in dichloromethane (275 mL) was added piperidine (47.3 g, 555 mmol, 55 mL, 10.7 eq). The reaction solution was stirred for 3 hours at 15-30°C. TLC (Petroleum ether/Ethyl acetate = 1: 1, R_f = 0) showed the starting material was consumed completely. The four reactions were combined and the mixture was diluted with water (800 mL) and dichloromethane (800 mL), then adjusted to pH= 3-4 with 0.5 N

HCl solution. The organic layer was separated and the aqueous phase was extracted with dichloromethane (800 mL). The organic layers were combined and washed with brine (1 L), then dried with anhydrous Na_2SO_4 , filtered and concentrated in vacuum to give the crude product. The crude product was purified by column chromatography on silica gel with DCM/MeOH to give compound **29d** as a white solid.

Yield:	140 g, 168 mmol, 81 %
--------	-----------------------

Four reactions were carried out in parallel.

[0442] To a solution of compound **29d** (30 g, 36 mmol, 1 eq) in THF (300 mL) was added (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)acetaldehyde (6.8 g, 36 mmol, 1 eq) and $\text{NaBH}(\text{OAc})_3$ (15.3 g, 72 mmol, 2 eq) in one portion. After addition, the reaction mixture was stirred at 15-30°C for 18 hours. TLC (DCM/MeOH = 10: 1, R_f = 0.4) showed the starting material was consumed completely. The four reactions were combined and the mixture was diluted with water (2 L) and EtOAc (1.5 L). The organic layer was separated and the aqueous phase was extracted with EtOAc (1 L). The organic layers were combined and washed with brine (1 L), then dried with anhydrous Na_2SO_4 , filtered and concentrated in vacuum to give compound **29e** as yellow oil.

Yield:	164 g, crude
--------	--------------

Three reactions were carried out in parallel.

[0443] To a solution of compound **29e** (50 g, 49.7 mmol, 1 eq) in DCM (150 mL) was added Et_3N (25.1 g, 248 mmol, 34.4 mL, 5 eq) and Boc_2O (21.7 g, 99.4 mmol, 22.8 mL, 2 eq). After addition, the reaction mixture was stirred at 15-30°C for 12 hours. TLC (Petroleum ether/Ethyl acetate = 1: 1, R_f = 0.4) showed the starting material was consumed completely. The three reactions were combined and the mixture was diluted with water (800 mL), then adjusted to pH= 3-4 with 0.5 N HCl solution. The organic layer was separated and the aqueous phase was extracted with dichloromethane (800 mL). The organic layers were combined and washed with brine (800 mL), then dried with anhydrous Na_2SO_4 , filtered and concentrated in vacuum to give the crude product. The crude product was purified by column chromatography on silica gel with petroleum ether/ethyl acetate to give compound **29f** as yellow solid.

Yield:	80 g, 72.3 mmol, 48.5 %
--------	-------------------------

Three reactions were carried out in parallel.

[0444] To a solution of compound **29f** (25 g, 22.6 mmol, 1 eq) in DCM (125 mL) and EtOH (300 mL) was added $\text{NH}_2\text{NH}_2\cdot\text{H}_2\text{O}$ (28.9 g, 565 mmol, 28 mL, 98% purity, 25 eq) in one portion. After addition, the reaction mixture was stirred at 15-30°C for 18 hours. TLC (Petroleum ether/Ethyl acetate = 1: 1, R_f = 0.03) showed the starting material was consumed completely. The three reactions were combined and the mixture was diluted with water (1 L) and dichloromethane (800 mL), then adjusted to pH= 3-4 with 0.5 N HCl solution. The organic layer was separated and the aqueous phase was extracted with dichloromethane (500 mL). The organic layers were combined and washed with brine (800 mL), then dried with anhydrous Na_2SO_4 , filtered and concentrated in vacuum to give the crude product. The crude product was purified by column chromatography on silica gel with DCM/MeOH to give compound **29g** as yellow oil.

Yield:	45 g, 46.1 mmol, 68 %
--------	-----------------------

Four reactions were carried out in parallel.


[0445] To a solution of compound **29g** (11 g, 11.3 mmol, 1.0 eq) in THF (100 mL) was added Et_3N (3.4 g, 33.8 mmol, 4.7 mL, 3.0 eq) and 4-nitrophenyl carbonochloridate (2.5 g, 12.4 mmol, 1.1 eq). After addition, the reaction mixture was stirred at 15-30°C for 18 hours. TLC (Petroleum ether/Ethyl acetate = 1: 1, R_f = 0.4) showed the starting material was consumed completely. The four reactions were combined and the mixture was diluted with water (800 mL) and EtOAc (800 mL), then adjusted to pH= 3-4 with 0.5 N HCl solution. The organic layer was separated and the aqueous phase was extracted with EtOAc (500 mL). The organic layers were combined and washed with brine (800 mL), then dried with anhydrous Na_2SO_4 , filtered and concentrated in vacuum to give the crude product. The crude product was purified by column chromatography on silica gel with petroleum ether: ethyl acetate to give **29h** as pale yellow sticky oil.


Yield:	29 g, 25.4 mmol, 56 %
--------	-----------------------

Example 30

Synthesis of transient S1 PTH(1-34) conjugate 30

[0446]






[0447] Side chain protected PTH(1-34) on TCP resin having Fmoc protected N-terminus was Fmoc deprotected according to the procedure given in Materials and Methods. A solution of Fmoc-Ser(Trt)-OH (997 mg, 1.75 mmol), PyBOP (911 mg, 1.75 mmol) and DIPEA (305 μ L, 1.75 mmol) in DMF (5 mL) was added to 5.0 g (0.58 mmol) of the resin. The suspension was agitated overnight at rt. The resin was washed 10 x with DMF and Fmoc-deprotection was performed as described above. A solution of **29h** (2.66 g, 2.33 mmol) and DIPEA (611 μ L, 3.50 mmol) in DMF (5 mL) was added to the resin. The suspension was agitated overnight at rt. The resin was washed 10 x with DMF, 10 x with DCM and dried *in vacuo*. Cleavage of the peptide from the resin and removal of protecting groups was achieved by adding 30 mL cleavage cocktail 100/3/3/2/1 (v/w/v/v/v) TFA/EDT/TES/water/thioanisole and agitating the suspension for 1 h at rt. Crude **30** was precipitated in pre-cooled diethyl ether (-18 °C). The precipitate was dissolved in ACN/water and purified by RP-HPLC. The product fractions were freeze-dried.

Yield:	168 mg (5 %), 30 *9 TFA
MS:	m/z 1155.92 = $[M+4H]^{4+}$, (calculated monoisotopic mass for $[M+4H]^{4+}$ = 1155.85).

Example 31

Synthesis of transient 4x10 kDa S1 PEG conjugate **31**

[0448]



[0449] 2.3 mL of a solution containing **30** (13 mg/mL, 30 mg, 5.31 μ mol) in 8/2 (v/v) water/ethanol containing 0.1 % TFA (v/v) and 10 mM methionine were added to 3.4 mL of a solution containing PEG 2x10 kDa maleimide (Sunbright GL2-200MA, 342 mg, 15.9 μ mol) in the same solvent. 0.5 M NaH_2PO_4 buffer (0.8 mL, pH 7.0) was added and the mixture was stirred for 30 min at rt. 20 μ L of TFA was added and the mixture was stored at 4°C overnight.

Conjugate **31** was purified by IEX followed by RP-HPLC using a linear gradient of solvent system A (water containing 0.2 % AcOH v/v) and solvent system B (acetonitrile containing 0.2 % AcOH v/v). The product containing fractions were freeze-dried.

Yield:	161 mg (3.55 μ mol, 67 %) conjugate 31 *9 AcOH
--------	---

Example 32

In vitro release kinetics of transient 4x10 kDa PEG conjugate **31**

[0450] Conjugate **31** (11 mg) was dissolved in 1 vol% acetic acid in water (1.8 mL) at 0.5 mg PTHeq/mL. Buffer exchange to pH 7.4 phosphate buffer (100 mM NaH₂PO₄, 10 mM L-methionine, 3 mM EDTA, 0.05 % Tween-20, adjusted to pH 7.4 by NaOH) was performed by SEC chromatography. The eluate was further diluted with phosphate buffer to reach a concentration of 0.1 mg PTHeq/mL. The resulting solution was sterile filtered and incubated at 37 °C. At time points, aliquots were withdrawn and analysed by RP-HPLC. The fraction of released PTH at a particular time point was calculated from the ratio of UV peak areas of liberated PTH and PEG conjugate. The % released PTH was plotted against incubation time. Curve-fitting software was applied to calculate the corresponding half times of release.

[0451] Results:

For conjugate **31** a release half-life time of 14.5 d was obtained.

Example 33

Pharmacodynamic actions in cynomolgus monkeys during a single dose PK/PD study with compound **18**

[0452] Compound **18** was administered at 1 μ g/kg to male cynomolgus monkeys (N=3) in a single subcutaneous PK/PD study assessing serum calcium (sCa) levels and urinary calcium excretion for 96 hours post-dose.

[0453] Results: Following compound **18** administration at 1 μ g/kg to cynomolgus monkeys, sCa levels remained within the normal range for 96 hours post-dose and a clear trend for decreased urinary calcium levels over the first 24 hours was observed.

[0454] Conclusion: At a dose maintaining sCa in the normocalcemic range, a concurrent decrease in urinary Ca excretion was observed and compound **18** hereby addresses a key

unmet medical need in patients with HP.

Example 34

Pharmacokinetic study of transient 2x20 kDa S1 PEG conjugate 18 in cynomolgus monkeys

[0455] Naive cynomolgus monkeys (2-3.5 years, 2-5 kg) (3-5 males / 3-5 females) received daily subcutaneous administrations of **18** at dose levels of 0.2, 0.5 and 1.5 µg PTH/kg. Blood samples were collected at; Day 1: pre-dose, 4 h, 8 h, 12 h, 18 h and 24 h post-dose, at Day 8: pre-dose, at Day 14: predose, 8h, and 12 h and at Day 28: 3 h, 6 h, 8 h, 12 h, 18 h, 24 h, 72 h, 168 h and 336 h) and plasma was generated. Total PTH plasma concentrations were determined by quantification of the N-terminal signature peptide (sequence: IQLMHNLGK) after LysC and GluC digestion as presented earlier in Materials and Methods.

[0456] Results: Systemic exposure expressed as C_{max} and AUC increased in an approximately dose proportional manner. Systemic exposure of Total PTH expressed as AUC accumulated approximately 3-fold from Day 1 to Day 28.

[0457] A low mean peak-to-trough ratio of Total PTH for all dose groups was observed after daily subcutaneous administration in cynomolgus monkeys at Day 28 (steady state observed from Day 8).

Example 35

Pharmacokinetic study of transient 2x20 kDa S1 PEG conjugate 18 in Sprague-Dawley rats

[0458] Sprague-Dawley Crl:CD(SD) rats (initiation of dosing at 8 weeks of age) received daily subcutaneous administrations of **18** at dose levels of 10, 30 and 60 µg PTH/kg for 28 days. A TK group containing of 9 males and 9 females per dose group was divided into 3 subgroups with 3 rats per subgroup. Blood samples were collected up to 28 days with 3 rats per sex, per sampling time point. Samples were collected at Day 1: pre-dose, 4 h, 8 h, 12 h, 18 h and 24 h post-dose, and at Day 28: 3 h, 6 h, 8 h, 12 h, 18 h, 24 h and 336 h and plasma was generated. The total PTH plasma concentrations were determined by quantification of the N-terminal signature peptide (sequence: IQLMHNLGK) after LysC and GluC digestion as presented earlier in Materials and Methods.

[0459] Results: Systemic exposure expressed as mean $C_{\max}$ and AUC increased in an approximately dose proportional manner. Systemic exposure of Total PTH expressed as mean AUC accumulated 3-6-fold from Day 1 to Day 28. Systemic exposure in the female rat was approximately 2-fold higher than in males.

[0460] A low mean peak-to-trough ratio of Total PTH for all dose groups was observed after daily subcutaneous administration in Sprague-Dawley rats at Day 28 (steady state observed from Day 8).

Abbreviations:

[0461]

ACN	acetonitrile
AcOH	acetic acid
Aib	2-aminoisobutyric acid
BMD	bone mineral density
Bn	benzyl
Boc	tert-butyloxycarbonyl
COMU	(1-cyano-2-ethoxy-2-oxoethylidenaminoxy)dimethylamino-morpholino-carbenium hexafluorophosphate
cAMP	cyclic adenosine monophosphate
d	day
DBU	1,3-diazabicyclo[5.4.0]undecene
DCC	N,N'-dicyclohexylcarbodiimide
DCM	dichloromethane
DIPEA	N,N-diisopropylethylamine
DMAP	dimethylamino-pyridine
DMF	

N,N-dimethylformamide	
DMSO	dimethylsulfoxide
DTT	dithiothreitol
EDTA	ethylenediaminetetraacetic acid
eq	stoichiometric equivalent
ESI-MS	electrospray ionization mass spectrometry
Et	ethyl
Fmoc	9-fluorenylmethyloxycarbonyl
Glu-C	endoproteinase Glu-C
h	hour
HATU	O-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
HP	hypoparathyroidism
HPLC	high performance liquid chromatography
ivDde	4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl
LC	liquid chromatography
LTQ	linear trap quadrupole
Lys-C	endoproteinase Lys-C
LLOQ	lower limit of quantification
Mal	3-maleimido propyl
Me	methyl
MeOH	methanol
min	minutes
Mmt	

	monomethoxytrityl
MS	mass spectrum / mass spectrometry
m/z	mass-to-charge ratio
OtBu	tert-butyloxy
PEG	polyethylene glycol)
pH	<i>potentia Hydrogenii</i>
PK	pharmacokinetics
Pr	propyl
PTH	parathyroid hormone
PyBOP	benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate
Q-TOF	quadrupole time-of-flight
RP-HPLC	reversed-phase high performance liquid chromatography
rt	room temperature
sCa	serum calcium
SIM	single ion monitoring
SEC	size exclusion chromatography
sc	subcutaneous
sP	serum phosphate
t _{1/2}	half life
TCP	tritylchloride polystyrol
TES	triethylsilane
TFA	trifluoroacetic acid
THF	

	tetrahydrofuran
TK	
	toxicokinetic
Tmob	
	2,4,6-trimethoxybenzyl
TPTx	
	thyroparathyroidectomy
Trt	
	triphenylmethyl, trityl
ULOQ	
	upper limit of quantification
UPLC	
	ultra performance liquid chromatography
UV	
	ultraviolet
ZQ	
	single quadrupole

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [WO2005027978A2 \[0016\]](#)
- [WO2014033540A2 \[0017\]](#)
- [WO2005099768A2 \[0111\]](#)
- [WO2006136586A2 \[0111\]](#)
- [WO2011089216A1 \[0111\]](#)
- [WO2013024053A1 \[0111\]](#)
- [WO2011012722A1 \[0112\]](#)
- [WO2011089214A1 \[0112\]](#)


- [WO2011089215A1 \[0112\]](#)
- [WO2013024052A1 \[0112\]](#)
- [WO2013160340A1 \[0112\]](#)
- [WO2009095479A2 \[0113\]](#)
- [EP14180004A \[0205\]](#)
- [EP2015067929W \[0205\]](#)
- [EP1536334B1 \[0209\]](#)
- [WO2009009712A1 \[0209\]](#)
- [WO2008034122A1 \[0209\]](#)
- [WO2009143412A2 \[0209\]](#)
- [WO2011082368A2 \[0209\]](#)
- [US8618124B2 \[0209\]](#)
- [US8946405B2 \[0210\]](#)
- [US8754190B2 \[0210\]](#)
- [WO2013036857A1 \[0222\]](#)
- [US7585837B2 \[0226\]](#)
- [WO2002089789A1 \[0230\]](#)
- [WO29095479A2 \[0338\]](#)

Non-patent literature cited in the description

- **WINER et al.**J Pediatr, 2014, vol. 165, 3556-563 [\[0011\]](#)
- **KOSTENUK et al.**J Bone Miner Res, 2007, vol. 22, 101534-1547 [\[0013\]](#)
- **PONNAPAKKAM et al.**Drug Discov Today, 2014, vol. 19, 3204-208- [\[0013\]](#)
- **ARRIGHI et al.**Biomaterials, 2009, vol. 30, 91763-1771 [\[0015\]](#)
- **NA et al.**Analytical Biochemistry, 2004, vol. 331, 2323-328 [\[0018\]](#)
- **SMITHHANSEN**J. Am. Chem. Soc., 1998, vol. 120, 8910-8913 [\[0019\]](#)
- **BOWIE et al.**Science, 1990, vol. 247, 1306-1310 [\[0032\]](#)
- **HOHENSTEIN et al.**Journal of Pharmaceutical and Biomedical Analysis, 2014, vol. 98, 345-350 [\[0305\]](#)
- **HOHENSTEIN AHEBELL MZIKRY HEL GHAZALY MMUELLER FROHDE,**
JDevelopment and validation of a novel cell-based assay for potency determination of human parathyroid hormone (PTH)Journal of Pharmaceutical and Biomedical Analysis, 2014, vol. 98, 345-350 [\[0423\]](#)

Patentkrav

1. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf, hvor pro-druget har formelen (Ia)



5

hvor

- D er en PTH-enhed;

10

- L¹- er en reversibel pro-drug-linkerenhed, der er forbundet med den N-terminale aminfunktionelle gruppe af -D, og hvor bindingen mellem -D og -L¹- kan spaltes i fravær af enzymer under fysiologiske forhold med en halveringstid, der strækker sig fra én time til to måneder;

- L²- er en enkelt kemisk binding eller en afstandsenhed;

- Z er en vandopløselig PEG-baseret bærer-enhed; og

15

x er et heltal valgt fra gruppen bestående af 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 og 16.

2. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge krav 1, hvor -D har sekvensen SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114 eller SEQ ID NO:115.

20

25


3. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 eller 2, hvor -D har sekvensen SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:110, SEQ ID NO:111 eller SEQ ID NO:112.

30

4. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 3, hvor -D har sekvensen SEQ ID NO:51.

5. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 3, hvor -D har sekvensen SEQ ID NO:112.

5 6. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 5, hvor delen -L¹- har formelen (II)



hvor den stiplede linje angiver binding til den N-terminale aminfunktionelle gruppe af -D;

10 -X- er -C(R⁴R^{4a})-, -N(R⁴)-, -O-, -C(R⁴R^{4a})-C(R⁵R^{5a})-, -C(R⁵R^{5a})-C(R⁴R^{4a})-, -C(R⁴R^{4a})-N(R⁶)-, -N(R⁶)-C(R⁴R^{4a})-, -C(R⁴R^{4a})-O-, -O-C(R⁴R^{4a})- eller -C(R⁷R^{7a})-;

X¹ er C eller S(O);

-X²- er -C(R⁸R^{8a})- eller -C(R⁸R^{8a})-C(R⁹R^{9a})-;

15 =X³ er =O, =S eller =N-CN;

-R¹, -R^{1a}, -R², -R^{2a}, -R⁴, -R^{4a}, -R⁵, -R^{5a}, -R⁶, -R⁸, -R^{8a}, -R⁹ og -R^{9a} er uafhængigt udvalgt fra gruppen bestående af -H og C₁₋₆-alkyl,

-R³ og -R^{3a} er uafhængigt udvalgt fra gruppen bestående af -H og C₁₋₆-alkyl, forudsat at i tilfælde af, at en af -R³ og -R^{3a} eller begge er anderledes end -H,

20 er de forbundet til N, hvortil de er knyttet gennem en sp³-hybridiseret carbonatom;

-R⁷ er -N(R¹⁰R^{10a}) eller -NR¹⁰-(C=O)-R¹¹;

-R^{7a}, -R¹⁰, -R^{10a} og -R¹¹ er uafhængigt af hinanden valgt fra gruppen bestående af -H og C₁₋₆-alkyl;

25 eventuelt danner et eller flere af parrene -R^{1a}/-R^{4a}, -R^{1a}/-R^{5a}, -R^{1a}/-R^{7a}, -R^{4a}/-R^{5a} og -R^{8a}/-R^{9a} en kemisk binding;

eventuelt er et eller flere af parrene $-R^1/-R^{1a}$, $-R^2/-R^{2a}$, $-R^4/-R^{4a}$, $-R^5/-R^{5a}$, $-R^8/-R^{8a}$ og $-R^9/-R^{9a}$ forenet med de atomer, til hvilke de er bundet for at danne en C_{3-10} -cycloalkyl eller 3- til 10-leddet heterocyclyl;


eventuelt er et eller flere af parrene $-R^1/-R^4$, $-R^1/-R^5$, $-R^1/-R^6$, $-R^1/-R^{7a}$, $-R^4/-R^5$,
 5 $-R^4/-R^6$, $-R^8/-R^9$ og $-R^2/-R^3$ er forbundet med de atomer, som de er knyttet til, for at danne en ring A;

eventuelt er R^3/R^{3a} forbundet med det nitrogenatom, hvortil de er bundet, for at danne en 3- til 10-leddet heterocyklus;

A er phenyl, naphthyl, indenyl, indanyl, tetralinyl, C_{3-10} -cycloalkyl, 3- til 10-leddet heterocyclyl eller 8- til 11-leddet heterobicyclyl; og
 10

hvor $-L^1-$ er substitueret med $-L^2-Z$, og hvor $-L^1-$ eventuelt er yderligere substitueret, forudsat at det hydrogen, der er markeret med stjernen i formel (II) ikke er erstattet af $-L^2-Z$ eller en substituent.

15 **7.** PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 6, hvor enheden $-L^1-$ har formelen (IIb-i)



hvor

den stiplede linje indikerer binding til den N-terminale aminfunktionelle gruppe af -D ved dannelse af en amidbinding;


20 $-X^2-$ er $-C(R^8R^{8a})-$ eller $-C(R^8R^{8a})-C(R^9R^{9a})-$;

$-R^1$, $-R^{1a}$, $-R^2$, $-R^{2a}$, $-R^4$, $-R^8$, $-R^{8a}$, $-R^9$ og $-R^{9a}$ er uafhængigt valgt fra gruppen bestående af $-H$ og C_{1-6} -alkyl;

$-R^3$ og $-R^{3a}$ er uafhængigt udvalgt fra gruppen bestående af $-H$ og C_{1-6} -alkyl, forudsat at i tilfælde af, at en af $-R^3$ og $-R^{3a}$ eller begge er anderledes end $-H$, er de forbundet til N, hvortil de er knyttet gennem en sp^3 -hybridiseret carbonatom; og
 25

hvor $-L^1$ - er substitueret med $-L^2-Z$, og hvor $-L^1$ - eventuelt er yderligere substitueret, forudsat at hydrogenet markeret med stjernen i formen (IIb-i) ikke er erstattet af $-L^2-Z$ eller en substituent.

- 5 **8.** PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 7, hvor enheden $-L^1$ - har formen (IIb-ii)




hvor den stiplede linje indikerer binding til den N-terminale aminfunktionelle - X^2 - er $-C(R^8R^{8a})$ - eller $-C(R^8R^{8a})-C(R^9R^{9a})$ -;

- 10 $-R^2$, $-R^{2a}$, $-R^8$, $-R^{8a}$, $-R^9$ og $-R^{9a}$ er uafhængigt valgt fra gruppen bestående af - H og C_{1-6} -alkyl;

$-R^3$ og $-R^{3a}$ er uafhængigt udvalgt fra gruppen bestående af -H og C_{1-6} -alkyl, forudsat at i tilfælde af, at en af $-R^3$ og $-R^{3a}$ eller begge er anderledes end -H, er de forbundet til N, hvortil de er knyttet gennem en sp^3 -hybridiseret carbonatom; og

- 15 hvor $-L^1$ - er substitueret med $-L^2-Z$, og hvor $-L^1$ - eventuelt er yderligere substitueret, forudsat at hydrogenet markeret med stjernen i formen (IIb-ii) ikke er erstattet af $-L^2-Z$ eller en substituent.

- 20 **9.** PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 8, hvor enheden $-L^1$ - har formen (IIb-ii')



hvor

den stiplede linje indikerer binding til den N-terminale aminfunktionelle gruppe af -D ved dannelse af en amidbinding;


den stiplede linje, der er markeret med asterisken, angiver binding til $-L^2-$;

$-X^2-$ er $-C(R^8R^{8a})-$ eller $-C(R^8R^{8a})-C(R^9R^{9a})-$;

$-R^2$, $-R^{2a}$, $-R^8$, $-R^{8a}$, $-R^9$ og $-R^{9a}$ er uafhængigt valgt fra gruppen bestående af $-H$ og C_{1-6} -alkyl;

- 5 $-R^{3a}$ er $-H$ og C_{1-6} -alkyl, forudsat at i tilfælde $-R^{3a}$ er andet end $-H$, er den forbundet til N , hvortil den er bundet gennem et sp^3 -hybridiseret carbonatom; og hvor $-L^1-$ eventuelt er yderligere substitueret, forudsat at hydrogenet markeret med stjernen i formen (IIb-ii') ikke er erstattet af en substituent.

- 10 **10.** PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 8, hvor enheden $-L^1-$ har formen (IIb-iii)




hvor

den stiplede linje indikerer binding til den N-terminale aminfunktionelle gruppe

- 15 af $-D$ ved dannelse af en amidbinding; og

hvor $-L^1-$ er substitueret med $-L^2-Z$, og hvor $-L^1-$ eventuelt er yderligere substitueret, forudsat at det hydrogen, der er markeret med stjernen i formen (IIb-iii), ikke er erstattet af $-L^2-Z$ eller en substituent.

- 20 **11.** PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 10, hvor enheden $-L^1-$ har formen (IIb-iii'):



hvor

den stiplede linje indikerer binding til den N-terminale aminfunktionelle gruppe

- 25 af $-D$ ved dannelse af en amidbinding;

den stiplede linje markeret med asterisken angiver binding til $-L^2-$; og

hvor $-L^1$ - eventuelt er yderligere substitueret, forudsat at det hydrogen, der er markeret med stjernen i formelen (IIb-iii'), ikke er erstattet af en substituent.

12. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket


5 som helst af kravene 1 til 11, hvor $-L^2$ - er $-T$ -, $-C(O)O$ -, $-O$ -, $-C(O)$ -, $-C(O)N(R^{y1})$ -, $-S(O)_2N(R^{y1})$ -, $-S(O)N(R^{y1})$ -, $-S(O)_2$ -, $-S(O)$ -, $-N(R^{y1})S(O)_2N(R^{y1a})$ -, $-S$ -, $-N(R^{y1})$ -, $-OC(OR^{y1})(R^{y1a})$ -, $-N(R^{y1})C(O)N(R^{y1a})$ -, $-OC(O)N(R^{y1})$ -, C_{1-50} -alkyl, C_{2-50} -alkenyl eller C_{2-50} -alkynyl; hvor $-T$ -, C_{1-50} -alkyl, C_{2-50} -alkenyl og C_{2-50} -alkynyl eventuelt er substitueret med en eller flere $-R^{y2}$, som er ens eller forskellige, og hvor C_{1-50} -alkyl, C_{2-50} -alkenyl og C_{2-50} -alkynyl eventuelt er afbrudt af én eller flere grupper valgt blandt gruppen bestående af $-T$ -, $-C(O)O$ -, $-O$ -, $-C(O)$ -, $-C(O)N(R^{y3})$ -, $-S(O)_2N(R^{y3})$ -, $-S(O)N(R^{y3})$ -, $-S(O)_2$ -, $-S(O)$ -, $-N(R^{y3})S(O)_2N(R^{y3a})$ -, $-S$ -, $-N(R^{y3})$ -, $-OC(OR^{y3})(R^{y3a})$ -, $-N(R^{y3})C(O)N(R^{y3a})$ - og $-OC(O)N(R^{y3})$;
10 $-R^{y1}$ og $-R^{y1a}$ er uafhængigt af hinanden valgt fra gruppen bestående af $-H$ -, $-T$ -, C_{1-50} -alkyl, C_{2-50} -alkenyl og C_{2-50} -alkynyl; hvor $-T$ -, C_{1-50} -alkyl, C_{2-50} -alkenyl og C_{2-50} -alkynyl eventuelt er substitueret med en eller flere $-R^{y2}$, som er ens eller forskellige, og hvor C_{1-50} -alkyl, C_{2-50} -alkenyl og C_{2-50} -alkynyl eventuelt er afbrudt af en eller flere grupper gruppe bestående af $-T$ -, $-C(O)O$ -, $-O$ -, $-C(O)$ -, $-C(O)N(R^{y4})$ -, $-S(O)_2N(R^{y4})$ -, $-S(O)N(R^{y4})$ -, $-S(O)_2$ -, $-S(O)$ -, $-N(R^{y4})S(O)_2N(R^{y4a})$ -, $-S$ -, $-N(R^{y4})$ -, $-OC(OR^{y4})(R^{y4a})$ -, $-N(R^{y4})C(O)N(R^{y4a})$ - og $-OC(O)N(R^{y4})$;
15 $-R^{y1}$ og $-R^{y1a}$ er uafhængigt af hinanden valgt fra gruppen bestående af phenyl, naphthyl, indenyl, indanyl, tetralinyl, C_{3-10} -cycloalkyl, 3- til 10-leddet heterocyclyl, 8- til 11-leddet heterobicycyl, 8- til 30-leddet carbopolycyclyl og 8- til 10-leddet 30-leddet heteropolycyclyl; hvor hvert T uafhængigt er eventuelt substitueret med en eller flere $-R^{y2}$, som er ens eller forskellige;
20 hver $-R^{y2}$ er uafhængigt valgt fra gruppen bestående af halogen, $-CN$, oxo ($=O$), $-COOR^{y5}$, $-OR^{y5}$, $-C(O)R^{y5}$, $-C(O)N(R^{y5}R^{y5a})$, $-S(O)_2N(R^{y5}R^{y5a})$, $-S(O)N(R^{y5}R^{y5a})$, $-S(O)_2R^{y5}$, $-S(O)R^{y5}$, $-N(R^{y5})S(O)_2N(R^{y5a}R^{y5b})$, $-SR^{y5}$, $-N(R^{y5}R^{y5a})$, $-NO_2$, $-OC(O)R^{y5}$, $-N(R^{y5})C(O)R^{y5a}$, $-N(R^{y5})S(O)_2R^{y5a}$, $-$

30

$N(R^{y5})S(O)R^{y5a}$, $-N(R^{y5})C(O)OR^{y5a}$, $-N(R^{y5})C(O)N(R^{y5a}R^{y5b})$, $-OC(O)N(R^{y5}R^{y5a})$ og C_{1-6} -alkyl; hvor C_{1-6} -alkyl eventuelt er substitueret med et eller flere halogenatomer, som er ens eller forskellige; og

hver $-R^{y3}$, $-R^{y3a}$, $-R^{y4}$, $-R^{y4a}$, $-R^{y5}$, $-R^{y5a}$ og $-R^{y5b}$ er uafhængigt udvalgt fra gruppen bestående af $-H$ og C_{1-6} -alkyl, hvor C_{1-6} -alkyl eventuelt er substitueret med alkyl eller mere halogen, som er det samme eller anderledes.

13. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 12, hvor $-L^2-$ har formelen (i)



hvor



den stiplede linje, der er markeret med asterisken, angiver binding til $-L^1-$;


den umarkerede stiplede linje angiver binding til $-Z$; og

n er 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 eller 18; og hvor enheden med formelen (i) eventuelt er yderligere substitueret.

14. PTH-prodrug eller et farmaceutisk acceptabelt salt deraf ifølge krav 13, hvor n er 6.

15. PTH-prodrug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 13, hvor enheden $-L^1-L^2-$ is





hvor

den umarkerede stiplede linje indikerer binding til den N-terminale aminofunkti-
onelle gruppe af -D ved at danne en amidbinding; og


5 den stiplede linje markeret med asterisken angiver binding til -Z.

16. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket
som helst af kravene 1 til 15, hvor -Z er en forgrenet polymer.

10 **17.** PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket
som helst af kravene 1 til 16, hvor -Z er en forgrenet PEG-baseret polymer
med et, to, tre, fire, fem eller seks forgreningspunkter.

15 **18.** PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge krav 16
eller 17, hvor -Z har en molekylvægt på mindst 10 kDa.

19. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket
som helst af kravene 1 til 18, hvor -Z omfatter en enhed med formelen (a)



20 hvor

den stiplede linje angiver binding til -L²- eller til resten af -Z;

BP^a er et forgreningspunkt og er -N<, -CR< eller >C<;

-R er -H eller C₁₋₆-alkyl;

a er 0, hvis BP^a er -N< eller -CR<, og n er 1, hvis BP^a er >C<;

-S^a-, -S^{a'}-, -S^{a''}- og -S^{a'''}- er uafhængigt af hinanden en kemisk binding eller er valgt fra gruppen bestående af C₁₋₅₀-alkyl, C₂₋₅₀-alkenyl and C₂₋₅₀-alkynyl; hvor C₁₋₅₀-alkyl, C₂₋₅₀-alkenyl and C₂₋₅₀-alkynyl eventuelt er substitueret med en eller flere -R¹, som er ens eller forskellige, og hvor C₁₋₅₀-alkyl, C₂₋₅₀-alkenyl and C₂₋₅₀-alkynyl eventuelt består af en eller flere grupper, der er afbrudt fra gruppen

-T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R²)-, -S(O)₂N(R²)-, -S(O)N(R²)-, -S(O)₂-, -S(O)-, -N(R²)S(O)₂N(R^{2a})-, -S-, -N(R²)-, -OC(OR²)(R^{2a})-, -N(R²)C(O)N(R^{2a})- og -OC(O)N(R²)-;


hver -T- er uafhængigt valgt fra gruppen bestående af phenyl, naphthyl, indenyl, indanyl, tetralinyl, C₃₋₁₀-cycloalkyl, 3- til 10-leddet heterocyclyl, 8- til 11-leddet heterobicycyl, 8- til 30-leddet carbopolycyclyl og 8 - til 30-leddet heteropolycyclyl; hvor hver -T- uafhængigt eventuelt er substitueret med en eller flere -R¹, som er ens eller forskellige;

hver -R¹ er uafhængigt valgt fra gruppen bestående af halogen, -CN, oxo (=O), -COOR³, -OR³, -C(O)R³, -C(O)N(R³R^{3a}), -S(O)₂N(R³R^{3a}), -S(O)N(R³R^{3a}), -S(O)₂R³, -S(O)R³, -N(R³)S(O)₂N(R^{3a}R^{3b}), -SR³, -N(R³R^{3a}), -NO₂, -OC(O)R³, -N(R³)C(O)R^{3a}, -N(R³)S(O)₂R^{3a}, -N(R³)S(O)R^{3a}, -N(R³)C(O)OR^{3a}, -N(R³)C(O)N(R^{3a}R^{3b}), -OC(O)N(R³R^{3a}) og C₁₋₆-alkyl; hvor C₁₋₆-alkyl eventuelt er substitueret med et eller flere halogenatomer, som er ens eller forskellige;

hver -R², -R^{2a}, -R³, -R^{3a} og -R^{3b} er uafhængigt valgt fra gruppen bestående af -H og C₁₋₆-alkyl, hvor C₁₋₆-alkyl eventuelt er substitueret med en eller flere ens eller forskellige halogenatomer; og

-P^{a'}, -P^{a''} og -P^{a'''} er uafhængigt af hinanden en PEG-baseret enhed.

20. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 19, hvor Z omfatter en del med formlen (b)




hvor

den stiplede linje angiver tilknytning til $-L^2-$ eller til resten af $-Z$; og
m og p er uafhængigt af hinanden et heltal fra og med 150 til 1000.


5 **21.** PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge krav 20, hvori m og p uafhængigt af hinanden er et helt tal i intervallet fra og inklusive 400 til 500.

22. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 21, hvor PTH-pro-drug har formelen (If-i)



hvor

den umarkerede stiplede linje angiver bindingen til den N-terminale aminfunktionelle gruppe af $-D$ ved at danne en amidbinding; og
den stiplede linje markeret med asterisken angiver tilknytning til en enhed



hvor

m og p uafhængigt er et heltal, der går fra og inklusive 400 til 500.

20 **23.** Farmaceutisk sammensætning omfattende mindst ét PTH-prodrug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 22 og mindst én excipients.

24. Farmaceutisk sammensætning ifølge krav 23, hvor den farmaceutiske sammensætning har en pH i området fra og inklusive pH 4 til pH 6.

25. PTH-prodrug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 22 eller den farmaceutiske sammensætning ifølge krav 23 eller 24 til anvendelse som et medikament.

5 **26.** PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 22 eller den farmaceutiske sammensætning ifølge krav 23 eller 24 til anvendelse i behandlingen af en sygdom valgt fra gruppen
10 bestående af hypoparathyroidisme, hyperphosphatæmi, osteoporose, osteomalaci, arthritis, osteogenesis imperfecta, fibrøs dysplasi, Pagets sygdom, humoral hypercalcæmi forbundet med malignitet, osteopeni, periodontal sygdom, knoglebrud, alopeci og trombocytopeni.

15 **27.** PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf eller den farmaceutiske sammensætning til anvendelse ifølge krav 26, hvor sygdommen er hypoparathyroidisme.

20 **28.** PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf eller den farmaceutiske sammensætning til anvendelse ifølge krav 26 eller 27, hvor behandlingen er til en human patient.

29. PTH-pro-drug eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1 til 22 eller den farmaceutiske sammensætning ifølge krav 23 eller 24 til anvendelse i behandlingen af hypoparathyroidisme via subkutan injektion.

SEKVENSLISTE

Sekvenslisten er udeladt af skriftet og kan hentes fra det Europæiske Patent Register.

The Sequence Listing was omitted from the document and can be downloaded from the European Patent Register.

